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ABSTRACT
Chronic pain alters sensory responses and carries a strong emotional component.
Persistent pain can heighten pain experiences, resulting in hyperalgesia and allodynia.
Further, patients suffering from chronic pain are more prone to experience a range of
affective disorders including depression, sleep dysregulation, panic disorders, anxiety
abnormalities and stress-related disorders including post-traumatic stress disorder
(PTSD). Hence while pain serves a protective function to prevent additional
physiological harm by driving behavioral and cognitive responses, chronic or persistent
pain can lead to maladaptive nociceptive responses and exacerbate psychopathologies.
Among brain regions, the amygdala is centrally situated to integrate the many descending
and ascending signals to modulate the sensory and emotional components of pain. The
amygdala is well studied for its role in fear and stress-related behavioral processes. The
central nucleus of the amygdala (CeA), and in particular the lateral capsular subdivision
of the CeA (CeLC), receives prominent ascending pain neurotransmission via the spinoparabrachioamygdaloid tract. In this pathway, peripheral nociceptive signals carried via
primary sensory Aδ- and C-fibers terminate in the dorsal horn where second order
neurons send projections via the spino-parabrachial pathway to the lateral parabrachial
nucleus (LPBn). Thus, the LPBn collects cutaneous (mechanical and thermal), deep
(muscular and articular) and visceral nociceptive signals and relays the information in a
highly organized manner principally to the CeLC for nociceptive processing. In pain, the
CeA and the LPBn-CeLC projections have been shown to undergo plasticity in the forms
of enhanced synaptic transmission and alterations in neurotransmitter and receptor
expression. Accordingly, the neurocircuit intersections in the CeA can modulate the
sensory and emotional responses to pain. Yet despite these associations, the mediators
and mechanisms underlying the emotional consequences of pain are poorly understood.
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neural and
endocrine pleiotropic peptide important in the development and homeostatic regulation of
many physiological systems. Recently, the expression of PACAP and its cognate PAC1
receptor has been shown to be upregulated in specific limbic regions by chronic stress.
PACAP infusions into several limbic regions is anxiogenic, and altered blood PACAP
levels and PAC1 receptor polymorphism have been associated with PTSD and other
stress-related disorders. Here, we establish that CeLC PACAP originates from the LPBn
as part of the spino-parabrachoamygdaloid pathway. Chronic pain enhanced PACAP
expression along LPBn-CeLC projections, indicating it may be a component of painrelated plasticity. CeA PACAP signaling was sufficient to induce nociceptive
hypersensitivity and anxiety-like behaviors. In a chronic neuropathic pain model, CeA
PACAP signaling was found to contribute to heightened anxiety-like behaviors and
nociceptive responses. Further, we characterized one prominent intracellular signaling
mechanism through which CeA PACAP signaling influences these behaviors.
In these experiments we provide evidence that CeA PACAP signaling plays an
important role in the emotional components of pain and that alterations in CeA PACAP
signaling are part of pain-related plasticity. This work establishes novel molecular
mechanisms that underlie the emotional component of pain and may contribute to the
development of chronic pain and associated affective disorders.
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Chapter 1.
Literature Review

1.1. General Introduction
Chronic pain is one of the greatest medical health problems in the developed
world affecting approximately 19% of the adult population (Breivik et al., 2006). From
an economic standpoint, chronic pain presents an enormous burden. In 2010, the
estimated additional health care costs due to pain ranged from $261-300 billion within
the United States, and with the loss in productivity, the total costs increase to an
estimated $560-635 billion (Gaskin & Richard, 2012). In relative terms, the annual cost
of chronic pain is greater than that for heart disease ($309 billion), cancer ($243 billion),
and diabetes ($188 billion) (Gaskin & Richard, 2012). While readily available and
highly efficacious treatments for acute pain exist, successful treatment options for those
suffering chronic pain still remain elusive, with current medications reducing pain
severity by only 30-40% in fewer than 50% of patients treated (Turk, 2002).
Pain is an adverse sensory and emotional experience associated with real or
potential tissue damage. Under normal conditions, pain serves a protective function,
driving a set of responses that prevent the body from incurring additional harm. Pain is
multidimensional, acting both as an immediate sensory-discriminatory indicator and as an
emotional-affective drive that promotes defensive and vigilant behaviors. Poignantly
illustrative of this protective function are the accounts from case reports of individuals
with a congenital insensitivity to pain. Individuals with a set of rare nonsense mutations
1

in the SCN9A gene, encoding for the α-subunit of Nav1.7 channel, display normal
reactions to touch, warmth, cold, and pressure, but completely lack any kind of reaction
to painful stimuli. These individuals live in constant threat of injury, displaying frequent
bruises, cuts, damage to lips and tongue (from biting themselves during early years of
life), and are at risk for early mortality from accidental injury (Cox et al., 2006).
While acute pain serves a clear protective function, pain can outlast the injury and
the normal healing process and become chronic. In these cases, pain is detrimental to an
individual’s quality of life, without any physiological benefit. Clinically, chronic pain
has often been defined as pain that persists for at least 3 to 6 months; however, very often
chronic pain lasts much longer. One study reported that those seeking treatment at
chronic pain treatment facilities did so for 7 years on average (Flor et al., 1992). There is
a crucial need to determine both the mechanisms underlying the transition from acute to
chronic pain, and the mechanisms that maintain and reinforce chronic pain. One of the
key concepts to emerge from the efforts to understand the mechanisms of chronic pain is
that of central sensitization. Sustained noxious input can result in the prolonged increase
in excitability and synaptic efficacy in neurons along central nociceptive pathways. The
enhancement of nociceptive transmission is manifested as pain hypersensitivity, in which
pain can result from a normally non-painful stimulus (allodynia) or pain is enhanced from
a painful stimulus (hyperalgesia). Since central sensitization results from changes
occurring in central neurons, the increased responsiveness may become decoupled from
the peripheral noxious stimulus and could result in the persistence of pain in the absence
of injury (Latremoliere & Woolf, 2009). Thus, discovering the mechanisms underlying
2

the sensitization of nociceptive central circuits appears crucial to the understanding the
pathogenesis of chronic pain and will provide opportunities to develop treatments for
chronic pain.
Further increasing the burden of chronic pain sufferers is that pain often co-exists
with psychiatric illness. One study found that 59% of those being treated for chronic
back pain had at least one concurrent diagnosis of psychiatric illness compared to 15% in
the general population, and 77% had at least one lifetime psychiatric diagnosis compared
to 29-38% in the general population (Kroenke & Price, 1993). Epidemiological studies
have found a strong association between chronic pain and anxiety disorders. A nationally
representative sample (n=5877) of those who suffered chronic pain found that they were
2-3 times as likely to have an anxiety disorder compared to the general population. The
rate of posttraumatic stress disorder (PTSD) was present 3.7 times more often in those
with chronic pain than in the general population, and the rate of panic disorder (PD) was
4.3 times that of the general population (McWilliams et al., 2003). A large cross-national
mental health survey (n=85,088) found similar results, with chronic back or neck pain
being associated with PTSD, PD, and generalized anxiety disorder (GAD) 2-3 times the
rate in the general population (Demyttenaere et al., 2007). This relationship appears to
hold true across several different types of pain, as migraine, arthritis, and back pain
sufferers were found to have 2-4 times the rate of anxiety disorders compared to the
general population (McWilliams et al., 2004). Furthermore, pain may precipitate stressrelated disorders, as it has been shown that the level of peritraumatic pain in patients
admitted to a trauma center is highly predictive of the development of PTSD at 4 and 8
3

months following hospital admission (Norman et al., 2008). PTSD symptoms were
significantly positively correlated with pain ratings, with PTSD sufferers having higher
subjective pain and more pain-related disability (Phifer et al., 2011). Interestingly, PTSD
sufferers also have altered reactions to acute pain, with higher pain thresholds to acute
noxious stimulation, but greater intensity of pain with suprathreshold noxious stimulation
(Defrin et al., 2008; Geuze et al., 2007).
Theoretical models have been proposed to explain the relationship underlying the
concurrence of chronic pain and anxiety-related disorders. The mutual maintenance
model holds that both disorders interact in a way that reinforces the persistence of the
other (Asmundson & Katz, 2009). In the mutual maintenance model, the physiological,
affective, and behavioral components of anxiety disorders interact to maintain or
exacerbate symptoms of pain. Similarly, the various physiological and affective
components of pain interact to maintain or exacerbate symptoms of anxiety disorders.
For instance, pain sensations in a chronic pain sufferer could act as a persistent,
conditioned reminder of trauma, resulting in increased anxiety. Alternatively, the shared
vulnerability model posits that individual factors may predispose people to develop both
anxiety disorders and chronic pain. These factors, such as feelings of loss of control or
low threshold for alarm, may be genetically influenced (Asmundson & Katz, 2009).
While these models offer explanations for how pain and stress interact, the biological
mechanisms that underlie these relationships are still largely unknown.
In examining function of neuropeptide signaling within the nervous system, the
laboratories of Dr. Victor May and Dr. Sayamwong Hammack have recently identified
4

pituitary adenylate cyclase activating polypeptide (PACAP) and its cognate PAC1
receptor as a mediator of the stress response system. Increased PACAP expression is
found following a repeated variate stress (RVS) paradigm within the bed nucleus of the
stria terminalis (BNST) and the paraventricular nucleus of the hypothalamus (PVH)
(Hammack et al., 2009). Infusion of PACAP into the BNST is anxiogenic, increasing
anxiety-like behaviors and hypothalamic pituitary axis (HPA) activation, and producing
an anorexic response (Hammack et al., 2009; Kocho-Schellenberg et al., 2014; Lezak et
al., 2014). Blocking BNST PACAP signaling during RVS can significantly attenuate
heightened anxiety-like behaviors and stress-induced anorexia (Roman et al., 2014).
PACAP signaling may be relevant to human anxiety-disorders, as a single nucleotide
polymorphism (SNP) in the PAC1 receptor gene, ADCYAP1R1, has been correlated with
PTSD symptoms in women, and PAC1 receptor methylation has been found to be
associated with PTSD symptoms in both sexes (Ressler et al., 2011). In aggregate, these
findings implicate limbic PACAP signaling as a central mediator of the stress response
system. In the course of our investigation, we noted dense PACAP immunoreactivity in
the nerve terminals within the central amygdala (CeA). Subsequently, we found that
CeA PACAP corresponded to nociceptive input originating from the parabrachial nucleus
(PBn). Thus, PBn PACAP released in the CeA could serve as a mechanism linking
nociceptive input to amygdala-mediated emotional responses.
To further understand the pathways described above, we investigated whether
CeA PACAP signaling mediates the emotional components of pain, first, by establishing
PACAP in the PBn-CeA projections, and next by examining whether CeA PACAP was
5

involved in pain-related emotional responses. Further, we characterized the potential
molecular pathways through which CeA PACAP signaling may be acting. These
investigations were aimed at understanding the molecular and anatomical substrates
underlying the relationship of pain and emotional behaviors. The coexistence of pain
with affective disorders may not only result in substantial disease burden, but also lead to
the amplification and perpetuation of pain. The mechanisms linking these two systems
may be particularly effective targets for the development of treatments for affective
disorders comorbid with chronic pain.
In interest of clarity, the background and introduction are divided into three main
sections: 1) mechanisms of nociception - reviewing the detection and transmission of
nociceptive information; 2) amygdala and its functions in pain; and 3) PACAP signaling
in pain. The subsequent two chapters are primary research studies in manuscript form,
which is then concluded with a comprehensive discussion.

1.2. Neurobiology of Pain
Detection of painful stimuli
The detection of stimuli of a thermal, mechanical, or chemical nature is performed
by a set of sensory afferent fibers in the body containing a set of specialized receptors
that transduce sensory stimuli into electrical currents. For thermal stimuli, a clear
demarcation between innocuous warmth and noxious heat exists and typically rests
around 42.5 C. At this temperature lies the approximate thermal activation threshold for
the transient receptor potential cation channel subfamily vanilloid member 1 (TRPV1)
6

receptor. A member of the transient receptor potential (TRP) ion channel family, TRPV1
receptor activation results in the perception of a burning sensation. Capsaicin, the
pungent ingredient in “hot” chili peppers, is a TRPV1 agonist. On the other end of the
thermal spectrum, TRPM8 and possibly TRPA1 receptors are sensitive to noxious cold
stimuli and display an affinity to natural cooling agents such as menthol (Basbaum et al.,
2009). Mechanical stimuli are detected through multiple mechanisms including highthreshold mechanoreceptors that terminate in free nerve-endings in the skin, lowthreshold mechanoreceptors that terminate on hair fibers, as well as Merkel cells and
Pacinian corpuscles, which detect texture, vibration, and light pressure. It is predicted
that these structures contain ion channels that are activated directly by force underlie
mechanotransduction; however the identity of these channels has been difficult to
determine. Recently, piezo channels, piezo 1 and piezo 2, have been shown to be
potential candidates for mechanotransduction (Coste et al., 2010). Piezo channels are
extremely large proteins comprised of more than 2000 amino acids with 30 to 40
transmembrane segments, and exist in an even larger structural complex, as the functional
channels appear to be tetramers. Initial evidence suggests that piezo1 might be
particularly important in vascular architecture as a shear-stress-evoked ionic current (Li
et al., 2014). Piezo 2 has been shown to be important in low-threshold
mechanotransduction, mediating innocuous touch sensation (Ranade et al., 2014). The
channels mediating high-threshold, noxious mechanosensation are still unknown.
Noxious chemical stimuli can consist of environmental agents such as capsaicin,
menthol, and isothiocyanates that bind to receptors that transduce noxious stimuli,
7

including TRPV1, TRPM8, and TRPA1 respectively. Additionally, noxious chemical
stimuli can be substances that are endogenously released after tissue damage or
physiological stress. These include signaling molecules, such as calcitonin gene related
peptide (CGRP) and substance P, and factors released from mast cells and macrophages,
such as bradykinin, prostaglandin E2, interleukin-6 (IL-6) and tumor necrosis factor – α
(TNFα). These molecules bind to receptors on the cell surface to activate or sensitize
nociceptors directly, thereby inducing pain or lowering the threshold for pain perception
(Basbaum et al., 2009).

Nociceptive pathways
After detection of noxious stimuli and transduction into electrical currents, two
main classes of fibers convey nociceptive information, medium diameter, lightly
myleinated Aδ fibers and small diameter, unmyleinated C-fibers. Aδ-fibers range in
diameter from 2-6 µm with a conduction velocity of 12-30 m/s, while C-fibers have a
diameter of 0.4 to 1.2 µm with a conduction velocity between 0.5-2 m/s. Whereas Aδ
afferents convey acute, well-localized pain, C-fibers are responsible for more diffuse,
slow onset pain. Each fiber type can be further divided into subpopulations. Aδ-fibers
can be divided into type I fibers that respond to mechanical stimuli but have a high heat
threshold, and type II fibers that have a low heat threshold but high threshold for
mechanical stimuli. Many C-fibers are polymodal, responding to both mechanical and
thermal stimuli; however subsets of these fibers may have modality specificity. Based on
molecular characterization, C-fibers consist of a peptidergic population that expresses
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substance P and calcitonin-gene related peptide (CGRP), and a nonpeptidergic population
that binds IB4 isolectin and express G protein-coupled receptors of the Mrg family
(Basbaum et al., 2009). Although still a matter of debate, there might be modality
specificity as it was recently found that selective ablation of these peptidergic fibers
reduced sensation to noxious heat and capsaicin, without impairing mechanosensation
(McCoy et al., 2013). Nociceptive fibers originate from pseudo-unipolar somatosensory
neurons that have cell bodies residing in the dorsal root ganglion (DRG) or the trigeminal
ganglion. The peripheral terminals of these neurons transduce nociceptive information
and convey it to the central terminals that synapse in the outer layers of the dorsal horn of
the spinal cord, specifically Rexed laminae regions I, II, and V. Subtypes of afferents
synapse with regional specificity creating a distinct laminar organization. Projections
from dorsal horn neurons within laminae I and III-VI form the main connections to
brainstem and brain (Todd, 2010).
Within the dorsal horn, second order neuronal projections form multiple parallel
pathways to convey nociceptive information to higher order central nervous system
(CNS) regions. The afferent pain pathways can be separated on a phylogenetic basis into
two different systems, ancient and more evolutionarily recent pathways. The
evolutionarily ancient pathways run through the medial brainstem consisting of the
paleospinothalamic, spinoreticular, spinomesencephalic, spinoparabrachio-amygdaloid,
and spinohypothalamic tracts. In contrast, evolutionarily recent pathways traverse the
lateral region of the brainstem and consist of the neospinothalamic and spinocervical
tracts (Almeida et al., 2004). These tracts form the main projections from the superficial
9

dorsal horn to brainstem and brain. The main targets of dorsal horn projection neurons
within the brainstem include the caudal ventrolateral medulla (CVLM), which is an
integrative center of cardiovascular response and nociception, and a site of origin for
many of the descending projections back to the dorsal horn. The nucleus of the solitary
tract (NTS) is a second major target involved in cardio-respiratory integration, as well as
a major target for visceral nociceptive information arriving via the vagus nerve. The
periaqueductal grey (PAG) in the medulla is involved in the descending modulation of
dorsal horn circuits, one of the key regions for the actions of analgesics, and critical in
stress-induced analgesia through descending output from the amygdala (Butler & Finn,
2009). The lateral PBn (LPBn) is a major target of lamina I input, and LPBn neurons
have axonal projections to the amygdala, hypothalamus, and BNST; these projections
will be discussed further in the next section. Another major target of nociceptive lamina I
projections neurons is the thalamus. In particular, several regions in the thalamus receive
nociceptive information, including the ventral posterolateral nucleus (VPL), which
receives nociceptive information from the body, and the ventral posteromedial nucleus
(VPM), which receives nociception information from the face via the trigeminal nerve.
The VPL and VPM have direct projections to the primary somatosensory cortex, and are
involved in the sensory-discriminative aspects of pain. Another set of thalamic nuclei the
posterior group and posterior triangular nucleus of the thalamus (PoT) also receive
nociceptive information and project primarily to the insular cortex, secondary
somatosensory cortex, and amygdala. These regions are thought to be involved the
aversive emotional aspects of pain (Gauriau & Bernard, 2004). Studies in rodents have
10

examined the anatomical distribution for each spinal pathway by injecting retrograde
tracers into each brain region and quantifying the number of lamina I neurons labeled
(Spike et al., 2003; Todd, 2010). Upon examination, lamina I of the L4 segment of the
rat spinal cord contains approximately 400 projection neurons, which is about 5% of the
total number of neurons in lamina I. A majority of the neurons project to the
contralateral side of the brain; however about 25% have bilateral projections. The vast
majority of lamina I neurons exhibit extensive collateralization projecting to multiple
regions. Hence, of all L4 lamina I projections neurons, an estimated 85% project to the
LPBn, 85% project to the CVLM, 30% project to the PAG, 25% project to the NTS, and
less than 5% project to the thalamus (Spike et al., 2003). The very small proportion of
projections to the thalamus may be unique to the lumbar region, because the cervical
spinal cord contains a greater number of spinothalamic projection neurons and fewer
spinoparabrachial projection neurons (Al-Khater & Todd, 2009).

Parabrachial nucleus (PBn) anatomy and connectivity
The PBn is an anatomical area surrounding the superior cerebellar peduncle
(SCP), or brachium conjunctivum, located in the dorsolateral rostral pons and caudal
midbrain. The PBn can be divided into medial (MPBn) and lateral (LPBn) nuclei, with a
third ventrolateral extension called the Kölliker-Fuse nucleus. The PBn can be further
divided into 10 distinct subnuclei based on cytoarchitecture (Figure 1.1). Immediately
ventromedial to the SCP is the MPBn subnucleus containing a heterogenous cell
population. In contrast, the external MPBn subnucleus contains larger multipolar
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neurons and is interposed between the MPBn and Kölliker-Fuse nucleus. The LPBn is
made up of several homogeneous groups of cells, including the superior lateral, internal
lateral, central lateral, ventral lateral, dorsal lateral, external lateral, and extreme lateral
nuclei, which are delineated by morphology and spatial distribution (Fulwiler & Saper,
1984). Individual subdivisions can also be differentiated based on connectivity. The
primary projections of the PBn include several hypothalamic regions (the medial preoptic
hypothalamus (MPO), ventromedial hypothalamus (VMH), lateral hypothalamus, and
paraventricular hypothalamus (PVH)), the nucleus of the solitary tract (NTS), several
thalamic regions including the intralaminar nuclei and paraventricular nucleus of
thalamus (PVT), and the extended amygdaloid complex including the BNST and CeA
(Fulwiler & Saper, 1984). Within the amygdaloid complex, the central medial amygdala
(CeM) receives projections mainly from the MPBn and ventral lateral subnucleus. The
central lateral amygdala (CeL) and the BNST receives projections from the central LPBn
and the outer portion of the external LPBn subnucleus. The central laterocapsular
amygdala (CeLC) receives projections primarily from the external and dorsal LPBn
(Bernard et al., 1993). Reconstruction of axonal branching patterns have found that,
while the LPBn has projections that travel exclusively to either the BNST or CeA, the
LPBn projections in passage to the CeA can also send collaterals to the BNST (Sarhan et
al., 2005). After leaving the LPBn, the efferent fibers can travel through the dorsal and
central tegmental tracts, and then join the medial forebrain bundle and ansa lenticularis.
Here, the fibers can branch and course via dorsal or ventral pathways. In the ventral
pathway, the fibers immediately turn laterally to reach the CeLC and CeL. In the dorsal
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pathway, the fibers can continue to travel rostrally sending collaterals to the lateral BNST
and traveling back around through the stria terminalis to reach the CeL and CeLC (Figure
1.2).

Spino-parabrachio-amygdaloid tract
The LPBn is a key site of convergence for nociceptive input. It is one of the
largest targets of nociceptive dorsal horn projection neurons, relayed primarily through
the dorsal lateral funiculus, and receives nociceptive information broadly from the body.
Besides the substantial input from lamina I, the PBn also receives input from the
trigeminal nucleus, carrying nociceptive information from the face, and from the NTS
relaying visceral nociceptive inputs. Thus, the LPBn may integrate both peripheral and
visceral nociceptive signals.
To examine the role of the parabrachio-amygdaloid projections in nociception,
PBn neurons from anesthetized rats were examined using extracellular
electrophysiological recordings (Bernard et al., 1996). Antidromic stimulation of the
CeA was used to identify PBn-CeA projecting neurons and to examine the
responsiveness of these neurons to mechanical thermal or visceral stimuli.
Approximately 70% of PBn-CeA neurons were exclusively excited by noxious stimuli,
whereas innocuous somatic or gustatory stimuli did not alter firing of these neurons.
These neurons tended to have large excitatory receptive fields, often covering several
areas of the body, suggesting that these neurons are likely not encoding specific spatial
information to allow for sensory discrimination. A subpopulation (30%) of PBn-CeA
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neurons had a smaller receptive field and were only excited when noxious stimuli were
applied to a specific part of the body. Subthreshold or non-noxious stimuli were found to
inhibit responses in the nociceptive-responsive PBn-CeA neurons. Noxious thermal
stimuli tended to induce a stronger excitatory response than noxious mechanical stimuli.
Morphine was found to have multiple effects blocking the excitatory response to thermal
stimuli in PBn-CeA neurons and reducing c-fos expression in a subset of lamina I spinoparabrachial neurons following noxious stimulation (Huang et al., 1993; Jasmin, Wang,
Tarczy-Hornoch et al., 1994).

Central pain processing
While this review primarily focuses on the role of the amygdala in pain processes,
the experience of pain is multifactorial and utilizes a large distributed brain network
commonly referred to as the pain matrix (Tracey & Mantyh, 2007). It can be divided into
two main systems, one lateral sensory-discriminatory and the other medial affectivecognitive. The majority of the research on these systems has been based on
neuroimaging studies to determine which brain regions are more or less active depending
on the interplay of particular conditions and factors, including the type of injury, mood,
and cognitive components. As such, the pain matrix is not precisely defined, nor is it
always consistent as to which regions are included or excluded. Rather, the pain matrix
may be more a pain signature, reflective of individual and subjective experiential
differences (Tracey & Mantyh, 2007). During acute pain, the most common regions
involved are the thalamus, primary and secondary somatosensory cortices, insular cortex,
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anterior cingulate cortex, and prefrontal cortex (Apkarian et al., 2005). Within the pain
matrix, the regions responsible for emotional components of pain, including those related
to anxiety and depression, may act to further amplify the pain experience. Commonly
associated regions in the processing of the emotional aspects of pain regions include the
anterior cingulate cortex, insular cortex, hippocampus, and amygdala (Yalcin et al.,
2014). Thus, in the context of the larger pain matrix, the amygdala might serve to impart
an emotional context to pain.

1.3. Amygdala in Pain Processes
Anatomy
The amygdala refers to a group of nuclei deep within the temporal lobe, vital in
the processing of emotion-related responses. The amygdala can be divided on the basis
anatomy and function into several major divisions; the basolateral nuclei, cortical-like
nuclei, and centromedial nuclei. The basolateral nuclei (BLA) consist of the lateral
nucleus (LA) and the basal nucleus (BA). The BLA is bordered laterally by the external
capsule and medially by the central amygdala (CeA). The cortical-like nuclei are the
most superficial group consisting of the nucleus of the lateral olfactory tract, bed nucleus
of the accessory olfactory tract, periamygdaloid cortex, anterior cortical nucleus, and
posterior cortical nucleus. The centromedial group consists of the CeA and medial
nucleus (MeA). The CeA can be further divided into central medial (CeM), central
lateral (CeL), and central lateral capsular (CeLC) (Sah et al., 2003). Further, it has been
argued on the basis of structural and functional homology that the centromedial group
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should be extended rostrally and medially to include the bed nucleus of the stria
terminalis (BNST) and the caudodorsal regions of the substantia innominata to form what
is referred to as the extended amygdala complex (Alheid, 2003). This distinction is on
the basis of similarities between efferent and afferent connections and histochemical
architecture in these regions. Another amygdala group, the intercalated neurons, does not
form a distinct nucleus but occurs as numerous dense clusters found in the external
capsule on the lateral border of the BLA, and two clusters in the intermediate capsule
between the BLA and CeA.

Intrinsic and extrinsic connectivity
The amygdala has fairly extensive intrinsic connections. In general, information
in the amygdala tends to flow in a lateral to medial direction, with sensory and
multimodal input from cortical association areas arriving in the LA. The main output is
from the CeM, where the amygdala is strongly connected to autonomic and modulatory
centers of the hypothalamus and brainstem, including the paraventricular hypothalamus
(PVH), lateral hypothalamus (LH), the periaqueductal grey (PAG), PBn, NTS and dorsal
vagal complex. Between the LA and CeM are few to no direct connections, instead
projections to the CeL, CeLC and intercalated cells are thought to function to gate
sensory input to modulate fear behavior under particular environmental conditions
(Duvarci & Paré, 2014). The BLA is primarily composed (~80%) of large glutamatergic
projection neurons with the remaining neurons belonging to a diverse set of GABAergic
interneurons that form local circuits. These glutamatergic projections neurons synapse
16

primarily onto CeL, CeLC and intercalated neurons. The CeA is composed primarily of
GABAergic neurons, with the CeM neurons having large soma and sparsely branching
dendrites, and the CeL and CeLC neurons having smaller soma and dendritic trees that
branch profusely (Ehrlich et al., 2009). Neurons within the CeL and CeLC project to the
CeM, with few to no reciprocal projections (Petrovich & Swanson, 1997). Within the
CeL and CeLC are microcircuits with GABAergic interneurons synapssing on a second
GABAergic interneuron. In turn, these interneurons then project to the CeM and can
result in the activation of the CeM through disinhibition. These two populations of
interneurons have been defined genetically by the presence of protein kinase Cδ. During
a fear-evoking stimulus, one CeL/CeLC interneuron population is selectively activated
(CeL-On), whereas a second population is inhibited (CeL-Off). The CeL-Off population
projects to the CeM, and the inhibition of CeL-Off neuron during fear results in
disinhibition of the CeM and evokes fear-related behaviors (Ciocchi et al., 2010;
Haubensak et al., 2010). In aggregate, this suggests that the CeL and CeLC form a
complex inhibitory gate on the CeM, allowing for multiple points of modulation. One
input to the CeLC and CeL is through the previously described projection from the LPBn
to CeL and CeLC. These nociceptive inputs bypass the BLA completely. Additionally,
while the CeM is the source of the largest output from the amygdala, projecting to
multiple regions in the brainstem and hypothalamus, the CeL and CeLC also modulate
behavior through a set of direct projections to the BNST (Dong et al., 2001).
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Amygdalar neuronal circuits for fear and anxiety
Fear and and anxiety serve a protective function driving behavioral responses
aimed at avoiding potential harm. The amygdala has been long held to be a key mediator
of emotional behaviors. The pioneering studies in this area were of macaques with a
temporal lobe lesion wherein the amygdala was ablated. Following the lesions, there
were behavioral alterations including amnesia, inability to recognize familiar objects,
docility and a striking lack of emotional responses. This was most apparent by the
complete absence of fear responses in these macaques (Klüver & Bucy, 1937). Since
then, the role of the amygdala in fear has become a focus of a substantial body of
research. Due to relative simplicity and robustness of response, fear conditioning
paradigms remain on the forefront of our ability to understand the brain at the level of
neural circuits. The fundamental framework of the amygdalar fear conditioning network
posits that information about both the unconditioned stimulus (US) and conditioned
stimulus (CS) converge onto neurons in the LA. The LA then projects to the CeA, the
main output, which then has projections to various brainstem regions that generate fear
responses (Ledoux, 2000). In this model, the LA receives information related to the CS,
such as context cues from the hippocampus or tone information from the auditory cortex.
Concurrently, the LA is also receiving information related to the US, such as the aversive
information from electrical shock via the thalamus. Hence, in this model there is a
convergence of the US and CS in the LA, and synaptic plasticity within this region is
thought to be critical for the formation of the association between the US and CS, or fear
acquisition. The fundamentals of this model are still valid; however, numerous updates
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and clarifications have been made surrounding the basic circuitry. Between LA neurons,
which receive sensory input, and the CeA output neurons in the CeM, there are little to no
direct connections. Rather, the LA projects to three intermediaries including the CeLC
and CeL, ITC cells and the BLA, where each one in turn projects to the CeM (Duvarci &
Paré, 2014; Tovote et al., 2015) (Figure 1.3). Additionally, while there is significant
synaptic plasticity occurring in the LA following fear conditioning, synaptic plasticity in
the CeA also appears important in the acquisition of fear (Paré et al., 2004). The
infralimbic (IL) and prelimbic (PL) regions of the medial prefrontal cortex appear critical
in the suppression of fear responses via projections of the IL to the ITC cells, and the PL
to the BLA. These circuits appear particularily important in learned suppression of fear
response, as occurs during fear extinction (Tovote et. al. 2015). Of particular relevance
to the current work, is the recognition of direct nociceptive projections from the LPBn to
the CeLC and CeL, which completely bypass the BLA and thalamus (Veinante et al.,
2013). Further, it has emerged that the amygdala may play a central role in the response
to short, phasic fear-evoking stimuli. However, in response to sustained sustained fearevoking stimuli, more akin to anxiety, it is thought that the BNST becomes the primary
mediator (Davis et al., 2010; Walker et al., 2009). The current work involving the
amygdala in fear has begun to utilize novel genetic manipulations to dissect
subpopulations of neurons that may represent circuits with specific functions. One of the
ideas to emerge from this work is that within the BLA specific circuits might encode
either a positive or negative valence, that either heightens or dampens the overall fear
response (Namburi et al., 2015; Redondo et al., 2014).
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Nociceptive input
Due to its integration of a wide range of emotionally salient sensory stimuli,
extensive nociceptive input, and its prominent role in the production of emotional
behaviors, the amygdala is thought to be a key region in the processing and production of
the emotional components of pain. As a whole, the amygdala is thought to attach an
emotional valence to sensory stimuli and initiate behavioral and affective responses. In
the context of the pain matrix, the amygdala would likely function to attach a negative
emotional valence to nociceptive stimuli, resulting in compensatory behavioral changes.
Within the amygdala, the CeA is situated at the interface of two nociceptive pathways
(Figure 1.3). The first pathway carries nociceptive information originating from the
cerebral cortex and thalamus and relayed by the BLA. The BLA receives nociceptive
information from the ventroposterior, posterior, triangular, and posterior intralaminar
thalamic nuclei, the secondary somatosensory area, and the insular cortex (Sah et al.,
2003; Shi & Davis, 1999). The BLA then projects to the CeLC and CeL or to the
intercalated cell masses, which, in turn, project to the CeM. This nociceptive information
has gone through the thalamus and cerebral cortex, where it can be integrated with other
sensory, affective, and cognitive influences to become a highly polymodal and processed
form of information. While the BLA receives a majority of its input from the cortex and
thalamus, there is, however, a small projection from these cortical and thalamic areas that
directly innervates the CeA (Shi & Davis, 1999). The second main nociceptive input is
the spinoparabrachio-amygdaloid pathway that sends direct and less processed
nociceptive information to the CeLC and CeL. Additionally, there is also a sparse
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projection directly from lamina I in the dorsal horn to the CeA. Nociceptive information
both directly through the PBn-CeA pathway and indirectly through the BLA-Ce A
pathway converges in the CeLC and CeL (Neugebauer et al., 2004).
There is substantial evidence that neurons in CeA respond to nociceptive
information. Using in vivo electrophysiology, CeA neurons of anesthetized rats were
examined for their responsiveness to noxious stimuli, defined as stimuli that would be
painful in an awake subject. The majority of responsive neurons were located in the
CeLC with approximately 80% of neurons displaying responses exclusively or
predominantly to noxious stimulation of superficial or deep body tissue (Bernard et al.,
1992; Neugebauer & Li, 2002). Of the approximately 80% of nociceptive responsive
neurons, 46% were excited by noxious stimulation and the remaining 34% of CeA
neurons were inhibited in the presence of noxious stimulation (Bernard et al., 1992). The
excited neurons tended to be located in the CeLC, and inhibited neurons tended to be
located in the CeL and CeM. In light of recent understanding of CeA microcircuitry, in
which a population of CeLC and CeL neurons have inhibitory projections onto neurons in
the CeL and CeM, increased excitatory drive on these GABAergic CeLC neurons could
be directly inhibiting CeM and CeL neurons and explain the heterogeneity of response.
Three main types of neurons were described based on their responses to nociceptive
stimulation. Nociceptive-specific neurons are activated exclusively by noxious
stimulation. Multireceptive neurons respond to both nociceptive and innocuous stimuli,
and nonresponsive neurons do not respond to noxious stimulation at all. The majority of
responsive neurons have large, often bilateral, receptive fields that include large portions
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of the body. In response to differing intensities of mechanical and nociceptive stimuli,
responsive neurons display a sigmoidal response curve rather than increasing
monotonically, suggesting poor resolution of intensity. Similar to the PBn, this suggests
that CeA neurons are unlikely to encode a sensory-discriminative component of pain
(Bernard et al., 1992; Neugebauer & Li, 2002; Neugebauer et al., 2004).
Human brain imaging supports involvement of the amygdala in pain. In
experimental settings, application of an infrared laser thermal stimulus or colorectal
distention leads to increased amygdala activity (Bonaz et al., 2002; Bornhovd, 2002).
Although a few studies have reported either reduced activation or no change in the
amygdala with noxious stimuli, a meta-analysis found that the majority of experiments
applying noxious stimulation supported increased amygdala activation (Simons et al.,
2012).

Pain-related plasticity
In states of persistent pain, the amygdala undergoes considerable synaptic,
neurochemical, and transcriptional plasticity. Increases in the immediate early gene c-fos
have been repeatedly found across different models of pain. Amygdala c-fos mRNA was
increased one hour following intra-plantar injection with formalin or following
intraperitoneal injection with acetic acid (Nakagawa et al., 2003). c-fos
immunoreactivity increased in the amygdala with esophageal acid exposure, and
increased c-fos immunoreactivity was found in the CeLC 4 hours following
cyclophosphamide-induced cystitis (Bon et al., 1998; Suwanprathes et al., 2003).
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Glutamatergic signaling is increased in the CeA, as demonstrated in models of arthritic
pain or neuropathic pain where increased expression of the metabotropic glutamate
receptors mGluR1 and mGluR5 were found, as well as increased phosphorylation of the
NR1 subunit of the NMDA receptor (Bird et al., 2005; Neugebauer et al., 2003). A
model of neuropathic pain was associated with increases in glucocorticoid receptor
mRNA expression, and higher levels of corticotropin-releasing hormone (CRH) mRNA
and peptide immunoreactivity in the CeA, suggesting involvement of several of these key
mediators of the stress response system (Rouwette et al., 2012; Ulrich-Lai et al., 2006).
Interestingly, one study raised the possibility that neurogenesis may be a component of
pain-related plasticity in the amygdala. Two months following induction of neuropathic
pain, bromodeoxyuridine (BrdU) incorporation was found in both BLA and CeA cells.
While BrdU+ cells were found in astrocytes in both control and neuropathic pain
conditions, the increase in BrdU+ cells under pain conditions also included cells that
colocalized with neuronal markers, evidence suggesting that either enhanced
neurogenesis or increased neuronal migration contributes to pain-related plasticity in the
amygdala (Goncalves et al., 2008).
Electrophysiological recordings from rodent brain slices from models of
persistent pain have demonstrated synaptic alterations. One of the most prominent
changes is an enhancement of evoked PBn-CeA and BLA-CeA transmission. Using
patch-clamp recordings of CeLC neurons, the regions of PBn or BLA afferents were
electrically stimulated to characterize PBn-CeA or BLA-CeA transmission. An increase
in PBn-CeA transmission was identified following neuropathic pain, arthritic pain, acid23

induced muscle pain, and visceral pain (Cheng et al., 2011; Han & Neugebauer, 2004;
Ikeda et al., 2007; Neugebauer et al., 2003). The potentiation of these synapses
heightened nociceptive input via the PBn and emotional-salience input via the BLA,
leading to the amygdala being more reactive with chronic pain. This hypothesis has also
been supported by human brain imaging studies, where changes in amygdala activity
were identified in people suffering from arthritis, neuropathy, or irritable bowel
syndrome (Bonaz et al., 2002; Kulkarni et al., 2007; Petrovic et al., 1999).

1.4. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
PACAP and its receptors
PACAP is a neuropeptide with diverse roles in neurotransmission, development,
trophic support, and homeostatic function. This important neuropeptide was first
identified in 1989 by Akira Arimura and colleagues, who were searching for
undiscovered hypothalamic peptides capable of stimulating adenylate cyclase activity and
cyclic AMP production in anterior pituitary cells (Miyata et al., 1989). In humans, the
PACAP, ADCYAP1, gene is at chromosomal locus 18p11 and is comprised of five exons.
The cDNA encodes for a 176-amino-acid prepro-protein, which is then
endoproteolytically cleaved by prohormone convertases into either a 38-amino-acid or a
27-amino-acid form. Subsequently, peptidylglycine α-amidating monooxygenase
converts the protein into a bioactive peptide. Within the central nervous system,
PACAP38 peptide is approximately 10- to 100-fold more abundant than PACAP27
(Vaudry et al., 2009). The highest expression of PACAP transcript within the central
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nervous system is within several hypothalamic nuclei, habenular nuclei, the pontine
nucleus, the LPBn and the vagal complex (Hannibal, 2002).
PACAP is the most conserved member of the VIP/secretin/glucagon superfamily
of peptides across animal species. Its amino acid sequence is well conserved across the
mammals that have been studied. Among chicken and frogs, PACAP differs by only a
single amino acid, and PACAP cDNA cloned from tunicates has 96% nucleotide identity
with human cDNA. The closest related peptide, vasoactive intestinal peptide (VIP)
shares 68% amino acid homology. It is thought that PACAP is the ancestral precursor to
the VIP/secretin/glucagon family. The highly conserved nature of PACAP suggests that
it might have functions essential for survival (Sherwood et al., 2000).
PACAP signals through three G-protein coupled receptor subtypes; PAC1,
VPAC1 and VPAC2 receptors. Both the VPAC1 and VPAC2 receptors bind to PACAP
and VIP with near equal affinity; however the PAC1 receptor has a much higher affinity
for PACAP than VIP. The alternative splicing of the PAC1 receptor results in multiple
variants to allow greater signaling diversity. Alterations in the N-terminal extracellular
regions result in short receptor isoforms that can affect ligand-binding specificity.
Alternative splicing also results in the presence or absence of two 84 base pair cassettes
termed “hip” and “hop” within the PAC1 receptor corresponding to the third cytoplasmic
loop resulting in the generation of at least 4 variants; PAC1-null (neither hip nor hop),
PAC1-hip, PAC1-hop, and PAC1-hiphop. PAC1 receptor signaling can activate
adenylate cyclase (AC) through Gs activation and phospholipase C (PLC) through Gq
activation; variants in the third cytoplasmic loop of PAC1 receptors can result in the
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differential engagement of AC and PLC signaling (Blechman & Levkowitz, 2013).

PACAP expression in nociceptive pathways
A variety of bioactive neuropeptides participate in the formation, transmission,
modulation, and perception of pain. Substance P and neurokinin A of the tachykinin
family of peptides and CGRP, for example, have expression patterns along nociceptive
pathways and the ability to initiate and modulate nociceptive transmission (Basbaum et
al., 2009). Although appreciated as a sensory peptide within a few years after discovery,
the recent accumulation of evidence has generated renewed interest in PACAP as a
nociceptive peptide critical in mediating the development of chronic pain and painrelated behavioral responses.
The initial evidence that PACAP plays a role in nociception stemmed from its
distribution and expression patterns within the peripheral nervous system.
Complementing other sensory peptides, PACAP expression has been identified in both
DRG and trigeminal ganglion neurons through immunocytochemical and in situ
hybridization histochemical studies (Moller et al., 1993; Mulder et al., 1994). Under
normal physiological conditions, PACAP immunoreactivity in DRG neuronal soma and
peripheral axons has been identified in small to medium-sized unmyelinated capsaicinsensitive C-fiber nociceptor afferents, along with other sensory peptides, including CGRP
and substance P. In addition, PACAP expression within a defined subset of peptidergic
DRG neurons has been confirmed using single-cell RNA sequencing (Usoskin et al.,
2015). In the spinal cord, the central axons of PACAPergic DRG neurons are largely
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confined to lamina I and II of the dorsal horn, corresponding to projections important for
nociceptive transmission (Jongsma et al., 2000; Moller et al., 1993; Zhang et al., 1996).
In addition to DRG, there is also a population of PACAP-expressing neurons in lamina I
and II of the spinal cord dorsal horn, raising the possibility that PACAP may be
expressed in second order neurons in the nociceptive pathway (Beaudet et al., 1998;
Pettersson et al., 2004). Based on in vitro receptor autoradiography and in situ
hybridization, PAC1 receptors have been shown to be densely expressed in laminae I and
II of the dorsal horn in correspondence with PACAP DRG central axon projections.
While the distribution of PACAP fibers, PACAP neurons and PAC1 receptors in the
superficial layers of the dorsal horn is suggestive, the potential functional ‘PACAP to
PACAP’ connectivity between DRG and second order dorsal horn PACAPergic neurons
is still unclear. Based on ultrastructural studies, PACAP signaling on PACAP
expressing neurons has been suggested in the enteric nervous systems (Nagahama et al.,
1998). Only a few isolated neurons in the ventral horn appear to express PAC1 receptors
(Pettersson et al., 2004). PAC1 receptors are not apparent in DRG neurons implying that
PACAP does not act in an autocrine or paracrine manner in the ganglion or
presynaptically in the dorsal horn (Jongsma et al., 2000).

Plasticity following injury
Among several sensory peptides, PACAP demonstrates phenotypic plasticity in
various peripheral models of injury- and inflammation-induced pain. Across different
experimental paradigms, including axotomy, nerve compression and adjuvant treatments,
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DRG PACAP transcripts, peptide levels and cell numbers can be dramatically induced
(Jongsma et al., 2000; Jongsma Wallin et al., 2003; Mabuchi et al., 2004; Pettersson, et.
al., 2004; Zhang et al., 1995; Zhang et al., 1998; Zhang et al., 1996). Notably, depending
on the nature of insult, there appears to be an induction of PACAP within select DRG
neuronal populations with concurrent changes in central and peripheral axon peptide
immunoreactivity. PACAP is normally identified in a subpopulation of small and
medium-sized nociceptive cells and following inflammatory insult, the induction of
PACAP appears to be confined to the same small-sized neuronal population (Jongsma
Wallin et al., 2003). Accordingly, inflammatory cyclophosphamide-induced cystitis
augments DRG PACAP neuronal numbers and immunoreactive fiber density in the
superficial layers of the dorsal horn, consistent with projections from DRG small neuron
induction of PACAP (Vizzard, 2000). By contrast, axotomy shifts PACAP expression in
different DRG populations, resulting in decreased peptide expression in small DRG
neurons and increased peptide expression in the medium and large-sized DRG neurons
(Jongsma et al., 2000; Zhang et al., 1996). Large DRG neurons project to deeper layers
of the dorsal horn and in coherence with axotomy-mediated induction patterns, PACAPimmunoreactivity in fibers appear reduced in the superficial layers of the dorsal horn but
enhanced in the deeper laminae. However, whether or not the decrease in PACAP fiber
immunoreactivity in the superficial dorsal horn laminae reflects heightened C-fiber
PACAP secretion has not been determined. Nerve compression increases PACAP levels
in both small and large neuronal populations (Pettersson et al., 2004). The mechanisms
underlying the various PACAP induction patterns to different injuries and the
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consequences of the dynamics in fiber projections in pain remain unclear but are
supported in recent transgenic animal studies (see below). Whether the second order
PACAP neurons in laminae I and II of the dorsal horn also demonstrate plasticity under
the different injury models is unknown, although no overt changes were observed
following axotomy (Pettersson et al., 2004). In contrast to DRG PACAP inductions,
PACAP binding in the dorsal horn after injury was diminished without apparent changes
in PAC1 receptor transcript levels (Jongsma et al., 2000). Although the expression
patterns for PACAP and PAC1 receptors exhibit an inverse relationship in some studies,
the loss of PACAP binding may reflect higher PAC1 receptor internalization and
turnover following heightened signaling (May et al., 2014; Merriam et al., 2013).
Likewise, VPAC1 receptor expression is decreased but VPAC2 receptors are increased
following neuropathic pain (Dickinson & Fleetwood-Walker, 1999). While the changes
in PACAP expression in the multiple experimental models may be related to enhanced
nociceptive neurotransmission, the interpretations are complicated by cellular stressinduced plasticity responses to the various injury challenges. PACAP/PAC1 receptor
activation can engage neurotrophic pro-survival signals to promote regeneration (Vaudry
et al., 2009); hence induction in DRG PACAP expression in the neuropathic and
inflammatory pain paradigms may have distinct, dual or overlapping activities in
nociception and trophic support.
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PACAP and PAC1 receptors in nociceptive signaling
Based on PACAP and PAC1 receptor expression, distribution and plasticity
observed in experimental injury models, the PACAPergic system was implicated in the
facilitation of nociceptive responses. While seemingly straightforward, the results of
PACAP infusion studies were equivocal as to whether PACAP was pro- or antinociceptive. At peripheral nerve terminals, the actions of PACAP appeared largely antinociceptive. While intraplantar PACAP injections alone had no effect on thermal or
mechanical sensitivity in naïve animals, intraplantar PACAP injections proved antiallodynic, anti-nociceptive and anti-hyperalgesic in experimental models of somatic and
visceral inflammatory pain (Sándor et al., 2009). However, PACAP at knee joint
afferents resulted in increased mechanical sensitivity (Sándor et al., 2009). Intrathecal
PACAP injections was reported to inhibit spinal and inflammatory nociceptive responses
(Yamamoto & Tatsuno, 1995; Zhang et al., 1996; Zhang et al., 1993), whereas PACAP
administration was reported by others to be anti-nociceptive in the early phase of
formalin induced pain, but transitioned to pro-nociception in the late phase of the
inflammatory response (Shimizu et al., 2004).
The pro-nociceptive actions of PACAP, however, are compelling. Intrathecal
PACAP infusions to naïve rats produced hyperalgesia in thermal hypersensitivity and tail
flick latency tests, and amplified pain neurotransmission to the dorsal horn via NMDA
mechanisms (Narita et al., 1996; Ohsawa et al., 2002). The intrathecal nociceptive
effects of PACAP were gradual but long lasting, which were in contradistinction to the
rapid and transient effects of substance P (Shimizu et al., 2004). Demonstrating a direct
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effect of PACAP signaling, PACAP application to spinal cord neurons increased
excitability of multireceptive cells in lamina III-V of the dorsal horn (Dickinson et al.,
1997). Importantly, in comparable studies, blockade of PACAP signaling with the
PAC1/VPAC2 receptor antagonist PACAP(6-38) or neutralizing PACAP antibodies
attenuated the thermal hypersensitivity and nocifensive responses in a variety of
neuropathic and inflammatory pain models (Davis-Taber et al., 2008; Ohsawa et al.,
2002). Further, while PACAP(6-38) had no effects alone or upon non-noxious
stimulation, the receptor antagonist blocked the increased excitation of dorsal horn
neurons to noxious stimuli (Dickinson & Fleetwood-Walker, 1999). The effects of Cfiber stimulation on spinal nociceptive reflex responses were facilitated by PACAP
administration and inhibited with a specific PAC1 receptor antagonist (Sakashita et al.,
2001; Xu & Wiesenfeld-Hallin, 1996). The causes for the observed discrepancies in the
PACAP nociceptive effects in the various experimental models are not well understood
but may be related to dose and temporal parameters, and route or site of PACAP
administration, especially after pain initiation. Under specific circumstances, PACAP
may have activated autoregulatory or descending inhibitory pathways or stimulated antiinflammatory responses by blocking immune cell cytokine release into the peripheral
milieu of pain mediators to produce anti-nociceptive effects. Based on PACAP and
PAC1 receptor expression and distribution in the sensory pathways, and the
preponderance of electrophysiological and behavioral data, however, the central effects
of PACAP in injury appear to result in system sensitization and are pro-nociceptive.

31

Nociception studies in PACAP/PAC1 receptor knockout mice
The most convincing evidence for PACAP involvement in pain stems from
studies using transgenic PACAP (PACAP -/-) and PAC1 receptor (PAC1R -/-) knockout
mice, which have been coherent in demonstrating the facilitatory roles of PACAP
signaling in chronic pain (Table 1.1). PACAP-/- mice display a range of physiological
and neuropsychiatric phenotypes, including decreased locomotor activities, decreased
feeding behaviors, altered memory performance, and attenuated stress responses,
reflecting the multifaceted roles of PACAP (Girard et al., 2006; Hitoshi Hashimoto et al.,
2001; Hattori et al., 2012). In several experimental models, PACAP-/- mice exhibited
important deficits in neuropathic pain development. Under control conditions, naïve
PACAP-/- mice showed unaltered or slightly decreased sensitivity responses to thermal
or mechanical stimuli (Mabuchi et al., 2004; May & Vizzard, 2010; Sándor et al., 2010).
However, following chronic pain with intraplantar noxious stimulus, PACAP-/- mice
displayed a marked loss in the induction of mechanical or thermal hypersensitivity, and
nocifensive behaviors (Mabuchi et al., 2004; Sándor et al., 2010). Similarly, PACAP-/mice failed to develop thermal or mechanical hypersensitivity in response to spinal nerve
transection or sciatic nerve ligation, and demonstrated substantially attenuated writhing
responses in response to intraperitoneal acetic acid injection (Botz et al., 2013; Mabuchi
et al., 2004; Sándor et al., 2010). The diminished nociceptive responses in the PACAP-/mice to either formalin or acetic acid treatments were accompanied by decreased c-fos
expression in the somatosensory cortex and periaqueductal grey (PAG), indicating a
tangible decrease in nociceptive transmission rather than an absence of behavioral
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responses (Sándor et al., 2010). Interestingly, following intraplantar TRPV1 agonist
resiniferatoxin injection into PACAP-/- mice, a reduction in mechanical sensitivity but an
immediate enhancement of thermal nociception was observed, which suggests differential
roles for PACAP in central versus peripheral nociceptive signaling.
PACAP activation of multiple different receptor subtypes and PAC1 receptormediated intracellular signaling appear central to nociceptive mechanisms. This was
supported by studies where PACAP nociceptive responses were recapitulated with the
PAC1 receptor selective agonist maxadilan and blocked by the specific receptor
antagonist max.d.4 (Sakashita et al., 2001). Accordingly, as in PACAP -/- animals, mice
with PAC1 receptor deficiency (PAC1R -/-) under naïve conditions also exhibited normal
responses to acute thermal or mechanical stimuli, but demonstrated reduced nocifensive
responses to intraplantar formalin administration and decreased abdominal responses to
intraperitoneal acetic acid injection (Jongsma et al., 2001; Martin et al., 2003). The
knockout studies conducted to date have not addressed the different potential sites of
PACAP/PAC1 receptor action mediating the nociceptive responses; however,
PAC1CamKCre2 mice with forebrain-specific deletions of the PAC1 receptor (PAC1
receptor deletions in the forebrain cortical areas, hippocampus and olfactory bulb) did not
demonstrate diminished chemical and visceral pain responses (Martin et al., 2003). Thus,
the nociceptive actions of PACAP likely reside within the peripheral pathways, spinal
cord and brainstem, or possibly in combinations these regions. The PACAP knockout
studies do not exclude possible roles for VIP, or PACAP on VPAC1/VPAC2 receptor
signaling in pain responses, as VIP is an important mediator of inflammatory processes,
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and VIP administration is often potently anti-inflammatory (Delgado, Pozo, & Ganea,
2004). Nevertheless, these studies in aggregate implicated PACAP and PAC1 receptor
involvement in the development of nociceptive hypersensitivity across several models of
chronic pain.

PACAP and PAC1 receptors in emotional behaviors
In the peripheral and central nervous systems, PACAP and the PAC1 receptor are
expressed in structures that orchestrate a diverse set of responses following stressor
exposure. In autonomic pathways, PACAP appears to be one of the principal regulators
of sympathetic function (Braas et al., 2007; May et al., 1998). In the brain, some of the
highest levels of PACAP expression have been identified in hypothalamic and related
F
i

limbic structures, and PACAP has been shown to regulate classical stress mediators
(Piggins et al., 1996). PACAP stimulates hypothalamic CRH transcription, c-fos
expression, and CREB phosphorylation, and can augment plasma corticosterone levels
(Agarwal et al., 2005; Tsukiyama et al., 2011). Although previous work has shown that a
variety of acute stress paradigms do not alter hypothalamic PACAP transcript levels,
more recent studies have shown that chronic stress can increase PACAP and the PAC1
receptor transcript levels in the paraventricular nucleus (PVN) of the hypothalamus and
the BNST (Hammack et al., 2009; Hannibal et al., 1995). Further, PACAP infusions into
the BNST can mimic chronic stress-related responses by increasing startle and anxietylike behavior on the elevated plus maze, decreasing weight gain and feeding (anorexia),
and elevating circulating corticosterone levels (Hammack et al., 2009; Roman et al.,
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2014; Kocho-Schellenberg et al., 2014; Lezak et al., 2014). A role for PACAP signaling
in mediating these chronic stress responses was supported by the demonstration that
PACAP receptor antagonists can attenuate all of these responses. To complement these
observations, PACAP and PAC1 knockout mice exhibit decreased anxiety- like
behaviors, have attenuated corticosterone responses, and show impairments in
hypothalamus CRH regulation in response to stress (Girard et al., 2006; Hashimoto,
2006; Hattori et al., 2012). Evidence has also been found linking PACAP to disease. In
humans, altered blood PACAP levels and PAC1 receptor polymorphism was associated
with PTSD and other stress-related disorders (Ressler et al., 2011). In sum, these
observations implicate PACAP/PAC1 receptor signaling in anxiety-related behaviors.

Signaling through extracellular signaling regulated kinase (ERK) activation
A signature of nociceptive signaling is extracellular signaling-regulated kinase
(ERK) activation, which participates in the neuroplasticity that promotes the
manifestation of chronic pain and stress-related disorders (Ji et al., 2009). Both
inflammation and axotomy injury have been shown to increase pERK+ neurons in the
DRG; following inflammatory or neuropathic pain, increased pERK levels are found in
lamina I and II neurons of the spinal cord, and the ensuing development of
hypersensitivity can be abrogated upon blockade of ERK phosphorylation by intrathecal
application of a mitogen-activated protein kinase kinase (MEK) inhibitor (Ji et al., 1999;
Obata et al., 2003). ERK signaling has been shown to contribute to pain-related
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enhancement of PBn-CeLC synaptic neurotransmission and inhibition of CeA ERK
activation attenuates pain-related behavioral hypersensitivity (Carrasquillo & Gereau,
2007; Cheng et al., 2011; Ji et al., 2009). PACAP and PAC1 receptor signaling can
stimulate and sustain ERK activation potently and efficaciously (May et al., 2014; May et
al., 2010). There are multiple intracellular PAC1 receptor effector mechanisms that
activate ERK, including PKA and PKC (Barrie et al., 1997; Bouschet et al., 2003; May et
al., 2014), but, more recently, it has been suggested that PAC1 receptor internalization
and endosomal signaling provide a means to sustain cellular ERK levels (May et al.,
2014; Merriam et al., 2013).

PACAP and glutamate signaling
In addition to stimulation of ERK-mediated neuroplasticity, PACAP signaling
may also regulate postsynaptic neuronal function by modulating glutamatergic
neurotransmission. PACAP is coexpressed with glutamate in a variety of systems,
including retinal ganglion cells and the suprachiasmatic nucleus (Engelund et al., 2010;
Hannibal et al., 2000). Furthermore, in the developing dorsal horn of the spinal cord, the
same transcription factors that determine glutamatergic cell fate also appear to control
PACAP expression (Guo et al., 2012). The co-release of PACAP with glutamate may
function to modulate excitatory neurotransmission, since NMDA receptor blockade in the
ventromedial hypothalamus (VMH) leads to diminished PACAP-induced hypophagia
(Resch et al., 2014). The attenuation of fear conditioning by intra-BLA PACAP(6-38)
administration was mediated through altered NMDA signaling (Schmidt et al., 2015).
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Intrathecal PACAP-mediated pain resulted in a dose-dependent enhancement of NMDAinduced aversive behaviors and potentiated NMDA currents in dorsal horn neurons
(Ohsawa et al., 2002). In addition, transgenic PACAP-/- mice failed to develop
mechanical allodynia to NMDA, but allodynia could be restored by co-infusion of
PACAP with NMDA (Mabuchi et al., 2004). There are multiple mechanisms by which
PACAP could potentially modulate glutamatergic signaling. In the dorsal horn, there is
evidence that PACAP may promote the functional coupling of nitric oxide synthase to
NMDA receptors (Mabuchi et al., 2004). In the hippocampus, PACAP has been found to
enhance synaptic NMDA trafficking and surface expression through Gq, PKC and Src
signaling mechanisms (Chowdhury et al., 2013; Macdonald et al., 2005; Trepanier et al.,
2012). In the amygdala, PACAP resulted in potentiation of BLA-CeA transmission
through a postsynaptic mechanism involving synaptic targeting of GluR1 subunitcontaining AMPA receptors. Alternatively, PACAP may enhance glutamate signaling by
regulating mGluR function (Kammermeier, 2008).

1.5. Summary
Pain is a multidimensional experience comprised of both sensory-discriminative
and emotional homeostatic components. Despite the high comorbidity between chronic
pain and stress-related behavioral disorders, the neurocircuits, neurochemical mediators,
and mechanisms underlying these responses are not well understood. The current work
tests the hypothesis that PACAP expression, plasticity and signaling in nociceptive
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pathways intersect with those in the amygdala and related limbic systems to drive the
maladaptive behavioral responses.
The detection of noxious stimuli is performed by sensory nerve afferents that
transduce noxious stimuli into electrical currents which are then relayed centrally. The
second order projection neurons then relay the information via sets of spinal tracts to a
wide range of brainstem and subcortical regions. The diffuse network of regions that
process pain information is thought to result in the diverse sensory and emotional
experiential components of pain. Maladaptive neurochemical and neuroplastic processes
can produce central nociceptive network sensitization leading to the potentiation of
nociceptive transmission and the amplification and persistence of pain.
In these studies, we identified PACAP expression in the spinoparabrachioamygdaloid nociceptive tract. As the amygdala is a critical structure for fear
and anxiety-like behavior, the convergence of nociceptive input in the amygdala allows
for the integration of pain with emotional information. We found that PACAP signaling
in the amygdala produced both pain and anxiety-like behaviors. In a model of
neuropathic pain, PACAP expression was found to be upregulated at multiple locations
along the spinoparabrachio-amygdaloid tract. The increase in CeA PACAP signaling in
neuropathic pain contributed to both heightened anxiety-like and hypersensitivity
behaviors as the PAC1/VPAC2 receptor antagonist PACAP(6-38) attenuated the chronic
pain-induced responses. Further, we demonstrated that PACAP signaling may modulate
nociceptive hypersensitivity through ERK via the internalization of PACAP receptors.
The adverse emotional consequences of chronic pain may result in the exacerbation and
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perpetuation of both pain and anxio-depressive disorders. Understanding the
mechanisms that link pain to its emotional consequences may offer novel approaches for
the rational development of therapeutics to alleviate suffering.
The studies in this dissertation were divided into four main aims. The experiments
in Aim 1 examined if PACAP is expressed in the PBn-CeA projections, as components of
the spino-parabrachioamygdaloid tract. Aim 2 examined if CeA PACAP signaling is
capable of altering pain or emotion-related behaviors. Aim 3 evaluated whether chronic
pain heightened PACAP expression in the spino-parabrachioamygdaloid and whether
these plasticity responses in CeA PACAP signaling contribute to heightened pain and
anxiety-related behaviors. Lastly Aim 4, examined the potential downstream mechanism
of CeA PACAP signaling. The results of these studies are presented in manuscript form
in the following sections.
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1.6. Figures

Figure 1.1. Subnuclear organization of the parabrachial nucleus (PBn). The PBn can
be divided into the lateral PBn (LPBn, blue), medial PBn (MPBn, pink), and the Köllikerfuse nucleus (kf, green). The MPBn consists of the medial (m) and external medial (em)
subnuclei. The LPBn can be divided into the external (eL), ventral (vL), central (cL),
dorsal (dL), internal (iL) lateral subnuclei, as well as the superior lateral subnucleus (not
shown). scp: superior cerebellar peduncle, D: dorsal, V: ventral, M: medial, L: lateral.
Nomenclature adapted from (Fulweir et. al., 1985).
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Figure 1.2. Diagram of the spino-parabrachioamygdaloid tract. Convergences and
divergences of the spinoparabrachio-amygdaloid pathway are illustrated. In red is one
particular pathway that nociceptive information travels, beginning at the detection of
noxious stimulus and ending at the CeLC. The pathways in black show known
alternative or variations on the pathway to the CeLC, including ipsilateral projections
from the spinal cord, the convergence of projections multiple spinal cord segments in the
LPBn, and an alternative LPBn-CeLC pathway that gives off collaterals to the
anterolateral BNST (BNSTal) before returning to the CeLC. Dotted line illustrates
contralateral projections. DRG: dorsal root ganglion.

42

Thalamus
Cortex
polymodal

BNST
Substantia Innominata
Thalamus
Periaqueductal gray
Lateral Hypothalamus
PBn

CeL
!!!
CeLC

LA

CeM

C
IT

BA
PACAP Immunoreactivity

nociceptive

PBn

43

Figure 1.3. Afferent pathways and connections involved in pain processes in the
amygdala. The CeA (blue region) receives direct, highly processed, polymodal pain
information from thalamus via the basolateral amygdala (green region) consisting of the
basal (B) and lateral (LA) nuclei of the amygdala. Circuits from the LA known to
enhance fear expression are shown, including BA to centromedial subdivision (CeM), via
the inhibitory cells of the intercalated cell mass (ITC), and through interneurons in the
centrolateral capsular (CeLC) and centrolateral (CeL) amygdala subdivisions. Direct, and
less processed nociceptive information arrives in the CeLC and CeL as part of a spinal
tract from the PBn. The main output is CeM, in a addition to some direct projections
from the CeL/CeLC to a number of brain regions including the bed nucleus of the stria
terminalis (BNST), periaqueductal gray (PAG) and a reciprocal projection back to the
PBn.
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Gene
Deleted
PACAP

Phenotype
n.c. Baseline

thermal or mechanical sensitivity (Mabuchi et al., 2004)

Early and late nocifensive behaviors to formalin (Sandor et al., 2010)
Somatic sensitivity (May & Vizzard 2010)
Mechanical hypersensitivity following neuropathic pain (Mabuchi et
al., 2004)
Acetic acid induced writhing (Sandor et al., 2010)
NMDA induced allodynia (Mabuchi et al., 2004)
c-fos expression in somatosensory cortex and brainstem following
formalin or acetic acid pain (Sandor et al., 2010)
Thermal hypersensitivity to resiniferatoxin (immediate) (Sandor et al.,
2010)
Mechanical hypersensitivity to resinferatoxin (delayed) (Sandor et al.,
2010)
PAC1 R n.c. Baseline thermal sensitivity (Jongsma et al. 2001)
Acetic acid induced writhing (no change in forebrain specific deletion)
(Martin et al., 2003)
Morphine withdrawal symptoms (Martin et al., 2003)
Late phase of formalin induced nocifensive behaviors (Jongsma et al.,
2001)
Galanin expression in DRG following nerve crush (Jongsma et al.,
2001)
n.c.:no change
Table 1.1. Summary of pain-related behaviors in PACAP or PAC1 receptor gene
knockout studies
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Chapter 2.
Parabrachial nucleus (PBn) pituitary adenylate cyclase activating polpeptide
(PACAP) signaling in the amygdala: Implication for the sensory and behavioral
effects of pain

Missig G., Roman C. W., Vizzard M. A., Braas, K. M., Hammack S. E., May V..
(2014). Neuropharmacology, 86, 38-48.
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2.1. Abstract
The intricate relationships that associate pain, stress responses and emotional
behavior have been well established. Acute stressful situations can decrease nociceptive
sensations and conversely, chronic pain can enhance other pain experiences and heighten
the emotional and behavioral consequences of stress. Accordingly, chronic pain is
comorbid with a number of behavioral disorders including depression, anxiety
abnormalities and associated stress-related disorders including posttraumatic stress
disorder (PTSD). The central nucleus of the amygdala (CeA) represents a convergence
of pathways for pain, stress and emotion, and we have identified pituitary adenylate
cyclase activating polypeptide (PACAP) immunoreactivity in fiber elements in the lateral
capsular division of the CeA (CeLC). The PACAP staining patterns colocalized in part
with those for calcitonin gene related peptide (CGRP); anterograde fiber tracing and
excitotoxic lesion studies demonstrated that the CeLC PACAP/CGRP immunoreactivities
represented sensory fiber projections from the lateral parabrachial nucleus (LPBn) along
the spino-parabrachioamygdaloid tract. The same PBn PACAP/CGRP fiber system also
projected to the BNST. As in the BNST, CeA PACAP signaling increased anxiety-like
behaviors accompanied by weight loss and decreased feeding. But in addition to
heightened anxiety-like responses, CeA PACAP signaling also altered nociception as
reflected by decreased latency and threshold responses in thermal and mechanical
sensitivity tests, respectively. From PACAP expression in major pain pathways, the
current observations are novel and suggest that CeA PACAP nociceptive signaling and
resulting neuroplasticity via the spino-parabrachio- amygdaloid tract may represent
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mechanisms that associate chronic pain with sensory hypersensitivity, fear memory
consolidation and severe behavioral disorders.

2.2. Introduction
Chronic neuropathic pain alters sensory responses and carries an emotional
subtext that can have severe effects on behavior. Persistent pain can heighten pain
experiences from hyperalgesia and allodynia (Rouwette et al., 2012; Veinante et al.,
2013). Further, patients suffering from chronic pain are more prone to experience
depression, sleep dysregulation, panic disorders, obsessive compulsive behavior, anxiety
abnormalities and stress-related disorders including post-traumatic stress disorder (PTSD)
(Asmundson and Katz, 2009). The intricate relationship between pain and behavior has
been well studied and among brain regions, the amygdala is centrally situated to integrate
the many descending and ascending signals to modulate the sensory and emotional
components of pain. Highly processed descending polymodal nociceptive information is
conveyed from the somatosensory cortex and thalamus to the basolateral amygdala
(BLA) which in turn projects to the central nucleus of the amygdala (CeA). The resulting
CeA efferents signals are relayed to other central nuclei, including those traveling with
hypothalamic e periaqueductal grey projections for autonomic control and antinociception to dampen pain stimuli (Veinante et al., 2013). Among several ascending
pathways carrying pain transmission to the CeA, the most prominent is the spinoparabrachioamygdaloid tract (Bernard et al., 1996; Gauriau and Bernard, 2002; Rouwette
et al., 2012; Veinante et al., 2013). Peripheral nociceptive signals carried via primary
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sensory Aδ- and C-fibers terminate in the dorsal horn where second order neurons send
projections via the spino-parabrachial pathway to pontine lateral and external medial
parabrachial nuclei (PBn) (Todd, 2010). Hence the PBn collects cutaneuous (mechanical
and thermal), deep (muscular and articular) and visceral nociceptive signals and relays
the information in a highly organized topographical manner principally to lateral capsular
division of the CeA (CeLC). The roles of the CeA/CeLC in nociceptive processing have
been examined from a number of vantages. In vivo electrophysiological studies have
shown that noxious stimuli and chronic pain paradigms increase spontaneous and evoked
CeA neuronal activity (Bernard et al., 1992; Ji and Neugebauer, 2009; Neugebauer and
Li, 2003), and synaptic transmission at PBn-CeA and BLA-CeA synapses (Ikeda et al.,
2007; Neugebauer et al., 2003). Visceral, inflammatory and chronic neuropathic pain can
induce CeA neuron stress peptide and c-fos expression (Bon et al., 1998; Nakagawa et
al., 2003; Suwanprathes et al., 2003; Ulrich-Lai et al., 2006; Rouwette et al., 2011) and
increase glutaminergic NR1 receptor phosphorylation in CeA neurons (Bird et al., 2005).
Further, human brain imaging studies have implicated the amygdala in pain (Simons et
al., 2014). Hence the neurocircuit intersections in the CeA can modulate the sensory,
emotional and affective responses to pain.
Pituitary adenylate cyclase activating polypeptide (PACAP) is a well studied
neural and endocrine pleiotropic peptide important in the development and homeostatic
regulation of many physiological systems (reviewed in Vaudry et al., 2009). In the
central and peripheral nervous systems, PACAP is neurotrophic to promote neuronal
survival, proliferation and differentiation in development and regeneration, participates in
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sensory and autonomic signaling, is important in hippocampal learning and memory
processes and regulates a variety of hypothalamic/limbic stress-related behavioral
responses. PACAP binds to several G protein-couple receptor subtypes (Braas and May,
1999; Harmar et al., 2012; Spengler et al., 1993). PACAP binds selectively at the PAC1
receptor; both PACAP and VIP bind the VPAC receptors with equal high affinity.
Recently, the expression of PACAP and its cognate PAC1 receptor has been shown to be
upregulated in specific limbic regions by chronic stress (Hammack et al., 2009). PACAP
infusions into the bed nucleus of the stria terminalis (BNST) is anxiogenic, and altered
blood PACAP levels and PAC1 receptor polymorphism have been associated with PTSD
and other stress-related disorders (Almli et al., 2013; Chen et al., 2013; Ressler et al.,
2011; Uddin et al., 2013; Wang et al., 2013). In sum, these observations have implicated
limbic PACAP/PAC1 receptor signaling in stress- and anxiety-related behaviors.
In evaluating PACAP expression in other limbic structures, we noted high levels
of PACAP immunoreactivity in fiber terminals and varicosities within the CeLC,
suggesting that the CeLC may be a target of distant PACAP projections. The CeLC is
heavily innervated by the lateral PBn (LPBn) and PACAP has been localized to many
sensory pathways. From these observations, we have hypothesized that LPBn PACAP
signaling to the CeLC has both sensory and behavioral consequences. In examining the
localization and roles of PACAP to the CeLC, our current work demonstrates that
PACAP is a component of the parabrachioamygdaloid pathway and that PACAP/PAC1
receptor signaling in the CeA elicits nociceptive and behavioral responses. The
integration of these nociceptive and
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emotion pathways may represent a set of neural circuits that mediate the adverse sensory
and emotional consequences of chronic pain.

2.3. Methods
Animals
Adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA)
were habituated to the animal facility for 1 week before experimentation. Rats were
single-housed and maintained on a 12 h light/dark cycle (lights on at 0700 h). Food and
water were available ad libitum. All procedures were approved by the Institutional
Animal Care and Use Committee at the University of Vermont.

Chronic variate stress
Following acclimation, each animal was randomly assigned to either a control or
chronically stressed group. Control group animals were handled and remained in their
home cages until euthanasia. The chronically stressed group of animals underwent a
chronic variate stress paradigm in which rats were exposed to one of 5 different stressors
(oscillation, forced swim, restraint, pedestal standing and foot- shock) each day for 7
days, as described previously (Hammack et al., 2009; Roman et al., 2012, 2014). All
animals within the group were exposed to the same order of stressors for the same
duration.
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Immunocytochemistry
The brains from perfusion fixed animals were postfixed in 4% paraformaldehyde
at 4C for 24 h, washed and equilibrated in 30% surcrose before embedding in Tissue-Tek
OCT compound for cryosectioning. The sections (30 µm) were mounted onto subbed
slides, permeabilized with 0.3% Triton X-100, blocked with 1% BSA and incubated in
primary antibody for 48 h at 4C. CRH immunoreactivity was localized using an affinity
purified rabbit antibody (1:100, No. G-019-06, Phoenix Pharmaceuticals, Burlingame,
CA). CGRP immunoreactivity was examined using a polyclonal antibody raised against
the full length CGRP(1-37) peptide (1:1500, Ian Dickerson, Univ Rochester) for
visualization with AlexaFluor 488 conjugated donkey anti-rabbit IgG (1:200, Jackson
Immunoresearch). PACAP immunoreactivity was detected using a mouse PACAP
monoclonal antibody (1:10, Jens Hannibal, Bisperg Hospital, Copenhagen, Denmark)
followed by tyramide signal amplification (Hannibal, 2002). Following primary PACAP
antibody incubation, the tissues were incubated in biotinylated horse anti-mouse antibody
(1:200, 2 h; Vector Laboratories, Burlingame, CA) and treated with streptavidin-HRP
(1:200, 30 min) before application of tyramide-biotin reagent (1:100, 10 min; Perkin
Elmer, Waltham, MA). After extensive washing, the PACAP immunoreactivity was
localized with Cy3-conjugated streptavidin (1:200, 2 h; Jackson Immunoresearch, West
Grove, PA). In dual localization studies, the sections were incubated in PACAP and
CGRP or CRH antisera concurrently. Tissue sections from BDA anterograde tracing and
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excitotoxic lesion studies were also processed for immunocytochemistry using the same
procedures. Images from immunocytochemistry, excitotoxic lesion and anterograde
tracing experiments were acquired sequentially with appropriate filter sets using a Nikon
E800 point scanning confocal microscope. Image analyses were performed using NIH
ImageJ (Schneider et al., 2012) to threshold, determine signal area (pixel number in
staining area) and calculate Pearson's and Mander's correlation coefficients. In within
subject excitotoxic lesion studies, the area of immunoreactivity on the side of the lesion
was compared to the vehicle control contralateral side.

Transcript analyses
Quantitative PCR (QPCR) was performed exactly as described previously (Girard
et al., 2002, 2006; Hammack et al., 2009). Briefly, after euthanasia by rapid decapitation,
the coronal rat brain sections were prepared using a rodent brain matrix (Ted Pella, Inc.
Redding, CA) and the micropunched amygdala tissues were quickly frozen on dry ice for
total RNA extraction using STAT-60 RNA/mRNA isolation reagent (Tel-Test “B”,
Friendswood, TX). All RNA were reverse transcribed simultaneously using random
hexamer primers with the SuperScript II Preamplification System (Invitrogen, Carlsbad,
CA) to obviate variability. Real-time QPCR was performed as described using SYBR
Green I detection (Girard et al., 2002, 2006; Hammack et al., 2009). Briefly, cDNA
templates were diluted 5-fold to minimize the inhibitory effects of the reverse
transcription reaction components and assayed on an ABI Prism 7500 Fast Real-Time
PCR System (Applied Biosystems, Foster City, CA) using SYBR Green I JumpStartTM
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Taq ReadyMix (Sigma, St. Louis, MO) containing 3.5 mM MgCl2, 200 µM dATP,
dGTP, dCTP and dTTP, 0.64 U Taq DNA polymerase and 300 nM of each primer in a
final 25 µl reaction volume. Oligonucleotide primer sequences were: PACAP (S) 5'CATGTGTAGCGGAGCAAGGTT-3' (AS) 5'- GTCTTGCAGCGGGTTTCC-3'; CRH
(S) 5'-TGGATCTCACCTTCCACCTTCTG-3' (AS) 5'CCGATAATCTCCATCAGTTTCCTG-3'. The melting profiles for amplified DNA
fragments were performed to verify unique product amplification in the quantitative PCR
assays. For data analyses, a standard curve was constructed by amplification of serially
diluted plasmids containing the target sequence (Girard et al., 2002, 2006). The increase
in SYBR Green I fluorescence intensity (DRn) was plotted as a function of cycle number
and the threshold cycle (CT) was determined by the software as the amplification cycle at
which the DRn first intersects the established baseline. The transcript levels in each
sample were calculated from the CT by interpolation from the standard curve to yield the
relative changes in expression. For each target sequence, all samples from the same brain
region were amplified together in the same assay to minimize variability. All data were
normalized to 18S RNA.

Surgical procedures
Anterograde tracing
Rats were anesthetized with isoflurane (1.5-3.5%), and secured into a stereotactic apparatus (David Kopf Instruments, Tunjunga, CA). The skull was exposed from a
midline incision and a micropipette (30-50 µm tip diameter) filled with 10% biotinylated
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dextran amine (BDA; 10 kDa) was lowered into the LPBn using coordinates (from
bregma in mm) AP: -9.3, ML: ±2.3, DV: -8.0, for iontophoretic tracer application (5 µA,
7 s on and 7 s off, 20 min total). The process was repeated on the contralateral LPBn.
After 14 days, the 4% paraformaldehyde perfusion-fixed rat brains were processed and
the cryosections incubated in 1:200 streptavidin-Cy2 (Jackson Immunoresearch) for BDA
tracer localization. The anterograde tracing studies were sometimes performed in
conjunction with peptide immunocytochemistry for concurrent localizations (Section
2.3). As for most peptide antisera, the PACAP antibody preferentially labeled fibers than
soma which precluded immunocytochemistry of retrogradely labeled LPBn neurons from
the CeLC.

Excitotoxic lesion
Adult male rats were surgically prepared as above and a microsyringe (1 µl,
Hamilton Co., Reno, NV) was unilaterally placed into the LPBn (from bregma in mm,
AP: -9.3, ML: ±2.3, DV: -7.9) for automated pump infusion of 2 mg NMDA in 200 nl
over 4 min. The syringe was left in place for an additional 4 min and following
postsurgical recovery the rats were returned to their home cages and for 7 days. NMDA
excitotoxic lesion at the targeted site was verified by processing the brain cryosections
for neuron specific nuclear protein (anti-NeuN, 1:1500) immunoreactivity as visualized
using Cy3-coupled secondary antisera (Roman et al., 2012). Only brains that displayed
LPBn neuronal loss were used for further analyses.
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Intra-amygdalar PACAP infusion
Rats were anesthetized and secured in a stereotactic apparatus as described above.
Four screws were secured into the exposed skull and two stainless steel cannulae (22 GA,
PlasticsOne, Roanoke, VA) were targeted to the CeA bilaterally using coordinates (from
bregma in mm) AP: -2.6, ML: ±4.5, DV: -7.2. A dental cement skullcap was formed to
secure the cannula and during the 7 day postsurgical recovery the rats were routinely
wrapped in a towel to habituate handling. For treatments, the rats were similarly
restrained in a towel and PACAP or vehicle (0.05% BSA in saline) was slowly infused (1
µg/0.5 µl each side) at 0.25 µl/min (Harvard Apparatus, Holliston, MA) through an
internal cannula that projected 1 mm from the guide cannulae; the PAC1 receptor specific
agonist maxadilan (from Ethan Lerner, Harvard/Massachusetts General Hospital) was
similarly infused in some studies. The peptide concentrations and treatment procedures
were similar to those described in previous work (Hammack et al., 2009; KochoSchellenberg et al., 2014; Roman et al., 2014). The infusion cannula were left in place
for an additional minute before removal. Animal body weights were determined before
and 24 h after infusions for all experiments (Kocho-Schellenberg et al., 2014). At the end
of each study, the rats were perfused with 4% paraformaldehyde and the brains
cryosectioned for cresyl violet staining to confirm cannulae placement. Only data from
correct CeA cannulae placements are described in Results. PACAP infusions into
misplaced targets outside of the CeA, including the basolateral amygdala, had no effects
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on stress-related behavior, body weight, food consumption and water intake.

Behavioral assessments
Elevated plus maze
The plus maze was elevated 75 cm from the floor and consisted of two opposing
open and two opposing closed arms (each arm 50 cm long and 10 cm wide) that extended
perpendicularly from a central square platform (10 x 10 cm). The length of the closed
arms were walled with black opaque plastic panels 30 cm in height. Illumination using a
red bulb was 6 lux at the center of the maze. The rats were first room habituated for 10
min and then individually placed in the center of the maze facing a closed arm for free
exploration for 5 min. A ceiling mounted camera digitally captured all movements
during each session for analyses.

Mechanical sensitivity testing
Mechanical sensitivity assessment was performed using von Frey monofilaments (Stoelting, Wood Dale, IL). All rats were first habituated in the clear acrylic
testing chamber 20 min/day for 4 days with a fan to generate ambient noise. On day of
testing, the rats were placed in the acrylic testing chamber on top of a metal mesh floor
(IITC Life Science Inc., Woodland Hills, CA) and habituated again for 10 min before the
application of von Frey filaments to the lateral plantar surface of the hindpaw. In
ascending diameter thickness, each filament was applied until bent at 30° for 5-7 s. The
smallest filament that evoked a paw withdrawal in at least 3 of 5 trials was used as the
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mechanical threshold for that trial. Thresholds from both the left and the right hindpaws
were measured.

Thermal sensitivity testing
Responses to thermal stimuli were tested using a Hargreave's apparatus (Plantar
Analgesia Meter, IITC Life Science Inc., Woodland Hills, CA). Prior to behavioral
testing, the rats were first habituated in the acrylic testing chamber for 4 days. On day of
testing, the rats were placed in an elevated clear acrylic testing chamber on top of a glass
floor with an internal heating element that heated the glass to a consistent 30 °C. Using a
guide light to target the hindpaw, a beam of focused radiant light (4-6 mm, set to 25% of
active intensity) from the apparatus beneath the glass floor was delivered to the plantar
surface of the paw. Upon rat awareness of the heat stimuli, as indicated by withdrawal or
licking of the hindpaw, the heat source was immediately terminated and the reaction time
automatically recorded. An automatic cut-off timer set at 30 s was built into the system
to prevent tissue damage. Each time point represented the latency average of 3 trials
from both the left and right hindpaw separated by 5 min inter-trial intervals. The
PACAP, maxadilan and vehicle treatment groups exhibited comparable average baseline
latency scores (PACAP, 12.9 s; maxadilan, 12.5 s; vehicle, 12.3 s).
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Experimental treatment and testing procedures

Experiment 1 - behavioral effects of amygdala PACAP infusions on elevated plus maze
Adult male rats were cannulated for amygdala infusions as described in Surgical
procedures. The rats were handled daily for habituation and after 7 day postsurgery
recovery, the rats were randomly assigned to vehicle or PACAP groups (n = 10 per
group). On experimental day, the rats were weighed for baseline measures and bilaterally
injected with vehicle or PACAP38 as described in random order. The injection needle
was left in place for 1 min after which the rats were returned to their home cages for 30
min and habituated in the testing room (10 min) before evaluation on the elevated plus
maze. The rats were allowed to freely roam the maze for 5 min and all data were
captured digitally. At the same time the following day, the vehicle and PACAP-treated
rats were re-weighed to assess weight change over 24 h; food and water consumption
were also measured. All weight change measures in this and subsequent experiments
were performed between 0900 and 1000 h. All behavioral tests were completed between
0900 and 1500 h; behavioral testing was randomized and counter balanced for order and
time of testing.

Experiment 2 - nociceptive effects of PACAP after amygdala infusions
Adult male rats were surgically prepared and handled as described in Experiment
1 above. The rats received 2 days of baseline thermal and mechanical sensitivity testing,
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and on experiment day, the rats were weighed and received either vehicle or PACAP38
amygdala infusions (n = 6 per group) as described in random order. After 30 min, the
rats were tested for mechanical sensitivity using von Frey filaments and evaluated for
thermal sensitivity on a Hargreave's apparatus at subsequent time points (1 h, 4 h and 24
h). As before, weight change in the vehicle and PACAP-infused rats was assessed after
24 h; food and water consumption was also determined. As robust PACAP-induced
thermal sensitivity was noted at 1 h, a separate study was prepared to better establish
amygdala PACAP thermal nociception onset and persistence (30 min and 72 h time
points) using exactly the same procedures (n = 7-8 per group). The thermal sensitivity
data at the different time points from the two cohorts were combined for analyses in a
linear mixed model using an autoregressive covariate structure as described in statistical
methods.

Experiment 3 - the nociceptive effects of amygdala maxadilan infusions
Adult male rats were surgically prepared, handled and treated exactly as described
for the first study in Experiment 2 except for the application of maxadilan (n = 7 - 8 per
group). Thirty min after amygdala maxadilan infusion, the rats were tested for
mechanical sensitivity using von Frey monofilaments; at subsequent time points the rats
were evaluated on a Hargreave's apparatus for thermal sensitivity.

Statistics
Statistical Student's t-tests were performed using GraphPad PRISM v.6. For
74

analyses of thermal withdrawal thresholds, a linear mixed model using an autoregressive covariate structure was employed to allow combined analysis of two cohorts
with differing timepoints, followed by pairwise comparisons between groups using
Sidak-Holmes correction for multiple comparisons (MIXED procedure of the SAS
System for Windows version 9.2; SAS Institute Inc, Cary, NC). All values represent the
mean change ± SEM. P < 0.05 was considered significant.

2.4. Results
PACAP and CGRP are expressed in the CeA and BNST
Our previous studies identified regulated PACAP expression in the BNST
(Hammack et al., 2009). In evaluating PACAP expression in other limbic structures, we
observed significant levels of PACAP immunoreactivity restricted to the lateral capsular
division of the CeA (CeLC; Fig. 2.1). A number of neuropeptides have been identified in
the CeA including corticotropin releasing hormone (CRH) which has been shown to
regulated by psychological stressors (Makino et al., 1999). However, unlike PACAP in
the CeLC, CRH immunoreactivity in the amydala was prominent in the adjacent lateral
(CeL) and medial (CeM) subdivisions of the CeA, recapitulating the apparent dichotomy
of PACAP and CRH peptidergic pathways in the limbic system (Roman et al., 2014).
Further, the pattern of PACAP and CRH expression following repeated stress appeared
converse of that in the BNST. Whereas BNST PACAP was augmented after stress
(Hammack et al., 2009; Roman et al., 2014), chronic stress increased CRH
immunoreactivity levels in the CeA approximately 2-fold without altering CeA PACAP
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expression (Fig. 2.1A-C). The stress-mediated changes PACAP and CRH staining in the
CeA mirrored transcript expression patterns (Fig. 2.1D) and in aggregate were suggestive
of their distinct but complementary roles in stress pathways and behaviors.
A number of neuropeptides exhibit distinct expression patterns within the CeA
(Cassell et al., 1986). From staining patterns the immunoreactivity for PACAP in the
CeLC was largely punctate which appeared characteristic of terminals and varicosities of
neuronal PACAP fiber projections from distal nuclei. As the CeLC is heavily innervated
by the PBn in the spino-parabrachioamygdaloid tract (Bernard et al., 1996; Gauriau and
Bernard, 2002; Rouwette et al., 2012; Veinante et al., 2013) and PACAP is highly
expressed in sensory neurons in many pathways (Beaudet et al., 1998; Mulder et al.,
1994; Pettersson et al., 2004b; Zhang et al., 1995), we examined whether the PACAP
immunoreactivity in the CeLC reflected parabrachioamygdaloid projections. Further, as
fibers in the CeLC have been described to contain CGRP immunoreactivity (Dobolyi et
al., 2005), we also compared the relative distribution of PACAP and CGRP in the
parabrachioamygdaloid tract.
In these studies, PACAP and CGRP immunoreactivities displayed considerable
overlap in fiber elements (Fig. 2.2A-C) that appeared to form basket-like networks
suggestive of axosomatic innervation of CeLC neurons. Given the heavy density of the
peptide immunoreactivites, both Pearson's and Mander's correlation coefficients were
determined for the acquired images to assess the extent of CeLC PACAP and CGRP
colocalization. For both measures, scores closer to 1 represent greater degrees of overlap
and from 4 independent studies, Pearson's r was >0.7 and Mander's coefficient was >0.6
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(Mander's CGRP/PACAP ratio = 0.625; PACAP/CGRP ratio = 0.631).
Since the bed nucleus of the stria terminalis (BNST) is part of the central extended
amygdala and has been described to display both PACAP and CGRP expression and
function (Hammack et al., 2009; Sink et al., 2011), the relationship between PACAP and
CGRP within the BNST was also investigated. BNST PACAP and CGRP expression
was highest within the oval nucleus (BNSTov) and as in the CeLC, PACAP and CGRP
immunoreactivities were coexpressed in a majority of the fiber elements (Fig. 2.2D-F).
Image analyses were performed as before and from 3 independent experiments, Pearson's
coefficient for PACAP and CGRP colocalization was approximately 0.7, and Mander's
coefficient was approximately 0.6 (Mander's CGRP/PACAP ratio = 0.57; PACAP/CGRP
ratio 1= 0.56). Hence the two statistical measures were in good agreement and suggested
that more than half of the PACAP or CGRP neuronal fibers projecting to the CeLC and
BNSTov expressed both peptides.

PACAP and CGRP immunoreactives in the CeLC and BNST are localized to projection
fibers from pontine parabrachial nucleus (PBn)
From several considerations, our evaluations for the potential origins of the
PACAP- and CGRP-expressing neurons projecting to the CeLC and BNSTov narrowed
to the LPBn. The external LPBn contains a large population of PACAPergic neurons that
may transmit signals to the amygdala (Das et al., 2007; Hannibal, 2002; Resch et al.,
2013). Further, CGRP expression in the CeLC and BNSTov has been suggested
previously to originate from PBn neurons (Dobolyi et al., 2005). Hence from these
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observations, we examined whether PACAP- and CGRP-expressing fibers to the CeLC
and BNSTov were components of the parabrachioamygdaloid tract.
For these studies, we first evaluated whether anterograde fibers from the LPBn to
the amygdala and BNST expressed PACAP. From injection site analyses, the BDA
infusions into the LPBn was confined to a small area (Fig. 2.3A). In the amygdala, the
neuroanatomical tracer was confined to the CeLC and upon immunocytochemical
processing, a subset of the BDA-labeled fibers in the CeLC expressed PACAPimmunoreactivity (Fig. 2.3B). Although these results provided evidence for CeLC
PACAP immuonoreactivity originating from the LPBn, the small focal size of the PBn
BDA injection resulted in a modest number of labeled fibers in the CeLC. Hence the
number of BDA labeled fibers was not as extensive as that observed for PACAPimmunoreactivity which precluded estimations of the relative contribution of CeLC
PACAP immunoreactive fibers originating from the PBn. From the same limitations, the
BDA-labeled fibers from the PBn to the BNST appeared low (data not shown).
As an independent means of assessing peptide expression in LPBn projection
fibers and to facilitate dual PACAP and CGRP immunocytochemistry in the same tissues,
the LPBn was lesioned before amygdala and BNST immunocytochemistry (Fig. 2.4). As
the BDA anterograde fiber labeling studies demonstrated that the external lateral PBn
projected only to the ipsilateral amygdala, only one side of the PBn was lesioned so that
the contralateral LPBn and limbic structures could remain intact and serve as vehicle
controls. Accordingly, one side the LPBn was lesioned by excitotoxic NMDA injection
(2 µg NMDA in 0.2 µl) and after postsurgery recovery for 7 days, coronal brain
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cryosections were prepared to assess the extent of PBn lesion and altered peptide
immunocytochemistry in the ipsilateral CeLC/BNST compared to staining patterns on the
contralateral side. Only brain lesions with neuronal loss in the external LPBn as
identified by diminished neu-N staining (Fig. 2.4A and B) were used in subsequent
analyses.
Following external LPBn lesion, PACAP and CGRP immunoreactivities in both
the CeLC and BNSTov were greatly reduced. The tissue sections were simultaneously
processed for PACAP and CGRP immunoreactivities and within subjects, CeLC PACAP
immunoreactivity was diminished 70% ± 5% on the side ipsilateral to the PBn lesion
compared to staining levels in the contralateral CeLC in which the corresponding PBn
received vehicle injection (t(2) = 4.41, p = 0.048; Fig. 2.4C-D and 2.5A). The same
changes were observed in the BNSTov. PACAP staining levels in the BNSTov ipsilateral to the PBn lesion were diminished 59% ± 11% compared to the contralateral
BNSTov with PBn vehicle injections (t(2) = 5.77, p = 0.029; Fig. 2.4G-H and 2.5B). As
PACAP and CGRP demonstrated significant colocalization in these structures (Fig. 2.2),
a similar change in CGRP staining was therefore anticipated. From analyses, LPBn
lesions resulted in a 64% ± 8% loss in CGRP immunoreactivity in the CeLC (t(2) = 7.49,
p = 0.017) and 72% ± 6% in the BNSTov (t(2) = 8.90, p = 0.012) compared to contralateral structures with vehicle injections into the PBn (Fig. 2.4E-F, 2.4I-J, 2.5A and 5B).
Hence the anterograde labeling/lesion studies complement immunocytochemical data to
demonstrate that PACAP and CGRP can be colocalized in the LPBn and that their
projections are substantial components in the fibers innervating the CeLC and BNSTov.
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PACAP signaling in the amygdala alters emotional behaviors and pain responses
Our previous work demonstrated that PACAP signaling in the BNST enhances
anxiety-related responses including increased baseline startle responses, decreased open
arm entries on the elevated plus maze, decreased open field crossings, decreased
exploratory behavior in novelty tests and decreased weight gain (Hammack et al., 2009;
Kocho-Schellenberg et al., 2014; Roman et al., 2014). To examine whether PACAP
expression and signaling in the central amygdala produced similar stress-related
behavioral responses, we implanted bilaterally cannulae targeting the CeA for PACAP
infusions (1 µg/0.5 µl) following previous treatment protocols (Hammack et al., 2009;
Kocho-Schellenberg et al., 2014; Roman et al., 2014; Experiment 1). Similar to PACAPelicited responses in the BNST, amygdala PACAP infusions induced anxiety-like
responses as shown by decreased open arm time (54.2 vs 88.3 s, t(18) = 2.71; p = 0.01)
and open arm entries (5.9 vs 13.8; t(18) = 4.39, p = 0.0003) compared to vehicle-treated
animals on the elevated plus maze (Fig. 2.6A). Unlike the BNST where PACAP had no
apparent effects on locomotor activity, PACAP injections into the CeA appeared to
produce a small but significant decrease in total distance traveled during the test period
not attributed to spontaneous freezing behavior. To mitigate this potential confound,
open arm preference (open : total arm entries) was calculated for each animal as this
measure is less prone to locomotor vagaries. Whereas vehicle control animals had no
preference for either open or closed arms (open : total arm entries = 0.51 ± 0.03), CeA
PACAP- infused animals demonstrated diminished open arm preference (Fig. 2.6B, open
: total arm entries = 0.32 ± 0.04; t(18) = 3.70, p = 0.0015). These PACAP-mediated
80

changes were comparable to those observed following BNST PACAP injections
suggesting that PACAP signaling in the BNST and CeA can contribute to stress- related
behaviors.
Similar to stress-mediated behaviors, BNST PACAP infusions were also capable
of inducing anorexia-like responses resulting dramatic animal weight loss over the next
24 h which approximated 5-8% of body weight and was reflected by decreased food
consumption. Accordingly, animal weight changes were also monitored during the CeA
PACAP infusion studies (Experiments 1 and 2). After 24 h, animals with CeA PACAP
injections demonstrated a small (~1%) but significant decrease in body weight compared
vehicle treated animals (t(45) = 2.63, p = 0.012). Given the small weight changes, we
sought to establish these observations using the PAC1 receptor selective agonist
maxadilan (Experiment 3). CeA maxadilan infusions again produced a small decrease in
body weight (1.5% decrease; t(13) = 2.81, p = 0.014) which was accompanied by
diminished food intake (17.5% decrease; t(13) = 2.66, p = 0.018) without apparent
changes in water consumption (t(13) = 1.47, p = 0.163). These changes largely reflected
the propensity for vehicle treated animals to gain a small amount of weight during the 24
h period while the PACAP treated animals experienced a slight weight loss. Hence, in
apparent contrast to the BNST, the effects of CeA PACAP signaling on stress related
anxiety-like responses did not appear to be strongly associated with weight and feeding
changes.
The fiber projections from the LPBn to the CeLC are part of the spinoparabrachial amygdaloid pathway conveying nociceptive information from the dorsal
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horn to the amygdala. PACAP has been identified at many sensory pathway intersections
including the dorsal root ganglion, layers 1 and 2 of the dorsal horn, and from previous
and current work, the LPBn. The CeLC responds to noxious stimuli and in modulating
pain perception may contribute to the affective component of the pain experience. Hence
from its attributes as a sensory peptide and its localization in the CeLC, we examined
whether PACAP signaling in the amygdala also altered spinal pain-associated reflexes.
As before, cannulae were placed into the amygdala bilaterally and following recovery,
the rats were habituated for Hargreave's thermal nociception tests (Experiment 2). A
baseline latency for hindpaw thermal withdrawal was first determined for each rat;
PACAP was subsequently infused into the CeA and the temporal changes in hindpaw
withdrawal to the same thermal stimuli were examined over the next 72 h. Following
PACAP infusion, there was a significant reduction in paw withdrawal latency at 30 min
(35% decrease in latency; veh, 13.0 ± 1.0s vs PACAP 9.1 ± 0.9s, p = 0.002; Fig. 2.7A)
and at 1h (31% decrease in latency; veh, 11.8 ± 0.9 s vs PACAP, 7.9 ± 0.6 s, p = 0.011).
The PACAP-induced responses persisted at 4 h (21% decrease in latency; veh, 11.3 ± 0.8
s vs PACAP 8.9 ± 0.7 s; p = 0.015) and returned to baseline by 24 h. There was a small
but significant decrease in latency at 72 h post injection compared to the corresponding
vehicle control group (p = 0.021); whether this reflected any PACAP-mediated plasticity
in the CeA remains to be examined. Again, the thermal sensitivity responses were
recapitulated with the PAC1 receptor-specific agonist maxadilan (Experiment 3). CeA
maxadilan infusions decreased paw withdrawal latency approximately 24% (veh, 11.7 ±
0.9 s vs maxadilan, 8.9 ± 0.6 s; p = 0.002; Fig. 2.7B) at 1 h which returned to baseline by
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24 h. Overall, the PACAP and maxadilan results were robust and well reproducible
across trials suggesting that intra-amygdalar PACAP signaling can facilitate thermal
hyperalgesia.
To assess whether CeA PACAP infusion would elicit similar changes on
mechanical threshold, the same animals were also evaluated using von Frey hair
stimulation tests (Experiment 2). From baseline tests, all animals demonstrated decreases
in mechanical threshold after repeated trials over time. Although mechanical threshold in
the PACAP-and maxadilan-treated rats appeared decreased compared to vehicle control
animals after 30 min, analyses revealed a trend rather than statistical difference (PACAP,
t(10) = 1.7, p = 0.11; maxadilan, t(13) = 1.65, p = 0.12) which reflected in part the high
variability within the assay. These apparent PACAP changes in mechanical threshold
dissipated by 2 h post-peptide infusion. As thermal and mechanical pain are transduced
by separate mechanisms, these differences may have contributed to the observed efficacy
of PACAP between the two measures. Nevertheless, the ability for PACAP to modulate
pain responses via amygdala signaling appears novel and suggests that it may carry
nociceptive information to impact the behavioral and emotional aspects of pain.

2.5. Discussion
The central nucleus of the amygdala integrates nociceptive and stress-related
signals that may be important for behavioral responses and the formation of emotional
memory. In examining PACAP/PAC1 receptor expression and function in the limbic
system, we identified high levels of fiber PACAP immunoreactivity in the CeLC. The
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CeLC is innervated by LPBn neurons that form part of the spino-parabrachioamygdaloid
pathway and although PBn PACAP expression was previously described, the targets of
these PBn PACAP neurons were not identified. Our current work identified PACAP
immunoreactivity in anterogradely labeled LPBn projection fibers to the CeLC, and
importantly, LPBn lesions significantly abolished PACAP immunoreactivity in the CeLC
and BNST. These studies were also revealing in demonstrating the relationships between
PACAP and other CeA peptides. Both CRH and CGRP share functional similarities with
PACAP in mediating pain, stress and anxiety-like behaviors (Hammack et al., 2002;
Koob and Heinrichs, 1999; Lee and Davis, 1997; Sink et al., 2011). Yet the dual
localization studies demonstrated a dichotomy in PACAP and CRH expression pattern;
the localization of PACAP predominantly to the CeLC was distinct from CRH in the CeL
which suggested separate but coordinate functions in intra-amygdalar neurocircuits. By
contrast, PACAP and CGRP immunoreactivities in CeLC and BNST fibers were well
colocalized from image analyses, and PBn lesions abolished much of the staining for both
peptides in the CeLC and BNST to a comparable extent. Limbic PACAP and CGRP
signaling share similarities in feeding and anxiety-like behaviors (Carter et al., 2013;
Hammack et al., 2009; Kocho-Schellenberg et al., 2014; Sink et al., 2011); how their
coordinate signaling modulates CeA and BNST functions however, remains to be
evaluated.
Despite the extensive PACAP and CGRP colocalizations (60-70%), PACAP and
CGRP may also exhibit independent CeLC and BNST functions. After LPBn lesions the
remaining PACAP and CGRP immunoreactivities appeared largely dissociate (Pearson's
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coefficient 0.3-0.4) which may have represented endogenous CeLC/BNST peptide
expression or PBn subpopulations expressing one of the peptides not affected by the
lesion procedures. The former may be consistent with the upregulation of BNST PACAP
transcripts by chronic stress (Hammack et al., 2009). PACAP and CGRP
immunoreactivities in subpopulations of dorsal root ganglion (DRG) neurons for example
can be separate and overlapping (Mulder et al., 1994), and comparable expression
patterns may be present in the PBn and limbic structures.
The presence of PACAP in the parabrachioamygdaloid pathway has prominent
implications in its roles modulating the sensory and emotional consequences of pain. The
ability for the amygdala to integrate pain processes and the emotional aspects of behavior
has been well appreciated (Bernard et al., 1992; Gauriau and Bernard, 2002; Ulrich-Lai et
al., 2006; Morano et al., 2008; Rouwette et al., 2011, 2012; Veinante et al., 2013) and
among its many functions, the roles of PACAP as a sensory peptide are well recognized.
PACAP and its PAC1/VPAC receptor subtypes are expressed in central and peripheral
nervous system regions that mediate nociception. PACAP is found in small-diameter
nociceptive DRG and in lamina I/II of the spinal cord neurons (Beaudet et al., 1998;
Mulder et al., 1994; Pettersson et al., 2004a, 2004b), and neuropathic pain through
axotomy, chemical induced cystitis or related models of nerve injury, can induce longlasting upregulation of PACAP or PACAP receptor expression in these tissues
(Dickinson et al., 1999; Mulder et al., 1994; Pettersson et al., 2004a; Vizzard, 2001). In
the central nervous system, PACAP can be found in many regions such as the
hypothalamus, limbic system, hippocampus, various brainstem nuclei including the PBn,
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and a number of thalamic and cortical regions implicated in pain processing (Das et al.,
2007; Hannibal, 2002; Resch et al., 2013).
However, the early investigations on PACAP in mediating pain were equivocal
resulting in hyperalgesia in some experimental paradigms and hypoalgesia in others.
These divergent responses likely reflected differences in the time course used in pain
assessments in the different experimental models, and the peripheral vs central actions of
PACAP. Peripheral intraplantar PACAP injections, for example, appeared to produce
mechanical hypoalgesia in both the early and late stages of inflammatory pain (Sandor et
al., 2009) whereas intrathecal injections were hyperalgesic (Ohsawa et al., 2002). In
detailed studies, intrathecal PACAP administration resulted in an immediate analgesic
response as measured by tail flick latencies, but transitioned into a long lasting
hyperalgesia as demonstrated by increased aversive responses (Shimizu et al., 2004). By
contrast, the studies using PACAP and PAC1 receptor knockout mice demonstrated
unequivocally a role for PACAP signaling in the development of persistent pain. Mice
deficient in PACAP or PAC1 receptor do not develop normal pain responses after
arthritic pain or neuropathic pain (Jongsma et al., 2001; Mabuchi et al., 2004). PACAP
knockout mice do not display thermal hyperalgesia or mechanical allodynia after
intraplantar carrageenan injection or spinal nerve transection, but show normal acute
nociceptive processes compared to wildtype mice (Mabuchi et al., 2004). In congruence,
PAC1 receptor null mice exhibit dramatic decreases in thermal and mechanical
nociceptive responses in the late phase of the formalin test, but preserve acute nociceptive
processes in unchallenged states (Jongsma et al., 2001). Hence PACAP/PAC1 receptor
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signaling and resulting neuroplasticity appear critical in the central sensitization and
development of persistent pain states.
Fibers from the lamina I spinal cord neurons carry thermal and mechanical
noxious stimuli and project heavily via the spino-parabrachioamygdaloid tract to the
lateral and external medial PBn (Gauriau and Bernard, 2002; Todd, 2010). From the
convergence of these projections onto the PBn, the sensory representations on the PBn
neurons are therefore necessarily large, covering several areas of the body. The majority
of PBn neurons then project onto the lateral division of the BNST, the ventral medial
hypothalamus (VMH), and the CeA; interestingly, as in the dorsal horn, high levels of
PACAP expression are found within all of these regions. The LPBn prominently
innervates the CeLC and consistent with the modalities conveyed by the tract, in vivo
electrophysiological studies demonstrate that these CeLC neurons are selectively
activated by thermal and mechanical nociceptive stimuli with receptive fields that can
encompass the entire body. Hence from the broad body areas capable of stimulating the
PBn and CeLC, the stimulus-response profiles, and the demonstration that spinoparabrachioamygdaloid tract lesions in the dorsolateral funiculus does not modify
noxious stimuli response latency/threshold, the amygdala does not appear to mediate
sensory discrimination but the affective-emotional and behavioral consequences of pain.
Many models of visceral, inflammatory and neuropathic pain have been shown to
increase not only CeA neuronal excitability and PBn-CeA transmission, but also CeA cfos expression and ERK activation (Veinante et al., 2013) which may play roles in painrelated neuroplasticity. Among bioactive peptides, CeA infusions with oxytocin,
87

neurotensin and galanin have produced anti-nociceptive responses (Dobner, 2006; Jin et
al., 2010; Robinson et al., 2002); interestingly, CRH and CGRP have been described to
produce either nociceptive or antinociceptive processes which may have been related to
dose and temporal parameters (Cui et al., 2004; Han et al., 2010; Ji et al., 2013; Xu et al.,
2003). To facilitate understandings of PACAP roles in the CeLC, our current studies
demonstrated that PACAP infusions into the CeA heightened noxious stimuli responses,
especially in thermal reactivity tests. The effects of PACAP can be mediated by
PAC1/VPAC receptors and notably, the PACAP-elicited CeA stress and nociceptive
effects were recapitulated using maxadilan to implicate specific activation of the PAC1
receptor in these responses. Although the studies did not discriminate hyperalgesia from
allodynia or spontaneous pain, the decrease in hindpaw withdrawal latency after CeA
PACAP treatment was robust to clearly demonstrate altered sensory responses. The CeA
PACAP effects in mechanical sensitivity assessments, however, appeared smaller which
may have reflected assay variability in the testing protocol or neuronal responses to
specific sensory modalities. The PBn responses to thermal stimuli are greater than those
from mechanical stimuli (Bernard et al., 1996) and whether these mechanistic signals to
the CeLC resulted in smaller PACAP-mediated mechanical responses remain to be
established. The CeLC has major projections to the BNST, the dorsal substantia
innominata and the medial CeA (CeM) which represents the major output of the CeA.
The CeM has reciprocal projections to other nociceptive effector centers including
thalamic nuclei, periaqueductal gray, lateral hypothalamus, ventromedial reticular
formation, substantia nigra, rostral tegmental area, locus coeruleus, and dorsal raphe
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complex; hence in aggregate, the CeA is well integrated within ascending and descending
pathways to influence nociceptive signal processing and responses.
The amygdala assigns emotional valence to extrinsic challenges and has been well
studied with respect to fear. The prominent nociceptive inputs to the CeLC and in
particular the high levels of PACAP expression carrying nociceptive information in the
spino-parabrachioamygdaloid tract provide important mechanistic insights on how
chronic pain can initiate and/or amplify stress- related behavioral abnormalities,
including depression and anxiety disorders. As in the BNST, PACAP signaling in the
amygdala promoted anxiety-like responses. CeA PACAP infusions decreased open arm
time, entries and preference on the elevated plus maze which appeared comparable in
efficacy compared to that observed from BNST signaling. Although CeA PACAP
infusions may have induced nociceptive sensitivity to decrease locomotion and affect
behavior, mitigating the potential confound by open arm preference analyses still
demonstrated PACAP-mediated increases in anxiety-like behaviors. Conversely, there is
also a small possibility that CeA PACAP-induced stress- and anxiety-related behaviors
may have contributed to the heightened nociceptive responses described above; this
consideration is being pursued in ongoing studies. However, unlike the overt BNST
PACAP-elicited anorexia that accompanied the stress-related behavioral responses, CeA
PACAP signaling had modest effects on feeding and weight change. These observations
suggested that the PACAP effects on stress-related behaviors and feeding may be not be
strongly associated mechanisms or circuits; the small changes in weight, for example,
may have reflected PACAP effects on thermogenesis (Hawke et al., 2009). Interestingly,
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the PBn PACAP projections to the BNST also implicate direct nociceptive transmission
to the BNST and in agreement, the anterolateral BNST has been shown to participate in
pain and stress-induced nociceptive hypersensitivity (Morano et al., 2008; Rouwette et
al., 2011; Tran et al., 2012). As in the BNST (Roman et al., 2014), preliminary
experiments have shown that PACAP6-38, a PAC1/VPAC2 receptor antagonist, is
capable of attenuating the effects of CeA PACAP signaling (data not shown). Although
the neurocircuits and mechanisms underlying the CeA PACAP effects have not been
examined extensively, one PACAP function has been suggested to potentiate excitatory
transmission at the BLA-CeL synapse by enhancing post-synaptic AMPA receptor levels
(Cho et al., 2012). The identities of PACAP targets in the CeLC, the functional
mechanisms and consequences of PACAP CeLC signaling, and the functional
relationships between PACAP and CGRP and CRH activities all remain to be
investigated.
In summary, our results suggest that PACAP signaling via nociceptive fibers in
the spino-parabrachioamygdaloid and associated tracts to the CeA and BNST may
represent mechanisms that associate chronic pain with hypersensitivity and behavioral
abnormalities including depression and anxiety-related disorders. Previous studies have
shown that PACAP is a pleiotropic peptide with neurotransmitter, hormonal and
neurotrophic functions which can facilitate neuroplasticity in development and
regeneration after injury. PACAP signaling in chronic stress, fear and pain may facilitate
the neuronal remodeling and plasticity in the limbic system that promote the maladaptive
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behavioral responses, and transition short-term memory to long term forms that appear
necessary for fear memory consolidation associated with PTSD.
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2.6. Figures
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Figure 2.1. PACAP and CRH immunoreactivities are differentially distributed and
regulated in the CeA. Tissue sections from control (A) and chronically stressed (B) rats
were examined for CeA PACAP (Cy2, green) and CRH (Cy3, red) staining patterns. In
both groups, CeA fiber PACAP immunoreactivity was predominantly in the lateral
capsular region (CeLC) with diffuse staining extending into the lateral division (CeL);
CRH immunoreactivity was localized predominantly to the CeL. From quantitative
image analyses, only CRH immunoreactivity was augmented by chronic variate stress (C,
n = 3). These results complemented quantitative PCR measurements which also
demonstrated increased CRH transcript expression after stress (D, n = 6). Data represent
mean ± SEM. Asterisk, significantly different from control at p < 0.05. Scale bar, 250
µm.
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Figure 2.2. PACAP and CGRP immunoreactivities can be colocalized in the CeLC
and BNST. Tissue sections for the amygdala (A-C) and BNST (D-F) were processed
for dual PACAP (Cy3, red) and CGRP (Alexa488, green) immunocytochemical
localization. The merged micrographs demonstrate that in both regions, PACAP and
CGRP immunoreactivities were largely colocalized (yellow) in the same fiber
structures. Amygdala, representative micrograph from 4 independent experiments;
BNST, representative micrograph from 3 experiments. LV, lateral ventricle; CPu,
caudate-putamen. Correlation coefficients described in text. Scale bar, 200 µm for
corresponding tissues.
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Figure 2.3. PBn projection fibers to the CeLC demonstrate PACAP
immunoreactivity. Biotinylated dextran amine (BDA, 10 kD; 10%) was injected
iontophoretically into the LPBn for anterograde transport into the CeLC over 14 days.
BDA at the LPBn injection site (A) and in the projection fibers to the CeLC (B) were
detected using streptavidin- conjugated Cy2 (green). Processing of the same CeLC
sections for PACAP immunoreactivity (Cy3, red) demonstrated that the LPBn projection
fibers can contain PACAP (B, merge in yellow). Representative data from 3 separate
preparations. scp, superior cerebellar peduncle. Scale bar, 200 µm for corresponding
tissues.
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Figure 2.4. Excitotoxic LPBn lesions diminish PACAP and CGRP fiber
immunoreactivities in the CeLC and BNST. The LPBn was unilaterally lesioned with
NMDA as described in Methods; the contralateral LPBn received vehicle. After 7 days,
the PBn sections were processed for neuron-specific nuclear NeuN immunoreactivity
(Cy3, red) to assess the specificity and extent of the lesion. Whereas vehicle injections
had no apparent effects (A), NMDA injections produced substantial LPBn neuronal loss
(B, dashed circled area). Representative vehicle treated and contralateral NMDA
excitotoxic lesioned PBn in the same animal are shown; the lesioned image was flipped
to facilitate comparison. CeA and BNST tissue sections from the NMDA excitotoxic
lesioned animals were processed for dual PACAP and CGRP immunocytochemical
localizations. Similar to Fig. 2.2, tissue sections ipsilateral to LPBn - vehicle injections
(left panels) demonstrated substantial PACAP (Cy3, red) and CGRP (AlexaFluor 488,
green) colocalization in the CeLC (C and E) and BNST (G and I); colocalization in
merged micrographs illustrated in yellow. By contrast, the same CeLC and BNST
regions in the contralateral half that received LPBn NMDA excitotoxic lesion (PBn lesion) demonstrated marked decreases in both PACAP and CGRP immunoreactivities.
Again, micrographs from the stained CeLC and BNST regions from the PBn - lesioned
side were flipped for comparisons with the control vehicle e injected side from the same
animals to facilitate comparisons. These data were consistent with the colocalization of
PACAP and CGRP in Fig. 2.2 scp, superior cerebellar peduncle; CPu, caudate putamen.
Representative figures from 3 separate animals. Scale bar, 200 µm.
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Figure 2.5. CeA and BNST peptide immunoreactivities are diminished after PBn
lesions. PACAP and CGRP immunoreactivities in the CeA (A) and BNST (B) from
studies described in Fig. 2.4 were subjected to image analyses as described in Methods.
The PBn lesions decreased PACAP and CGRP immunoreactivities in the limbic regions
to a comparable extent compared to levels on the contralateral hemisphere with PBn vehicle injections. n = 3, data represent mean ± SEM. *, different from vehicle control at
p < 0.05.
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Figure 2.6. PACAP infusions into the CeA decrease open arm entries on the elevated
plus maze. Adult rats were cannulated as described in Methods for CeA PACAP
infusions. Thirty minutes after PACAP injection, the animals were placed in the center
square of the elevated plus maze, facing a closed arm, for behavior testing during a 5 min
period. All movements were tracked digitally for data analyses. Total open arm entries
(A) and open arm preference (B, open arm entries/total arm entries) were calculated.
CeA PACAP signaling significantly increased anxiety-like behavior reflected by
decreased number of open arm entries and open arm preference. There were no changes
in the number of closed arm entries and there were no indications of freezing behaviors.
n = 10 per group, data represent mean ± SEM, *, different from vehicle control p < 0.05.

99

Figure 2.7. CeA PACAP/PAC1 receptor signaling increases thermal sensitivity.
A, Rats were habituated in Hargreave's thermal sensitivity apparatus with 2 days of
baseline assessments (24 and 48 h). PACAP was subsequently infused into the CeA
(single injection) for thermal testing at the indicated time (shaded area). Whereas vehicle
injection produced no apparent responses changes compared to baseline (white bars),
CeA PACAP infusions consistently decreased thermal latency responses (black bars) up
to 4 h post treatment. The responses dissipated by 24 h; the small but significant
decrease in thermal latency at 72 h may reflect latent plasticity events. n = 6 - 8 per
group, data represent mean response ± SEM, *, different from corresponding vehicle
control, p < 0.025. B, the PACAP-induced decrease in thermal latency was mirrored in
CeA infusions with the PAC1 receptor specific agonist maxadilan. The maxadilan
responses observed at 1 h was again dissipated by 24 h n = 7 - 8 per group, data represent
mean response ± SEM, *, different from corresponding vehicle control, p = 0.002.
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Chapter 3.
Parabrachial PACAP activation of amygdala endosomal ERK signaling regulates
the emotional component of pain

Missig G., Mei L., Vizzard, M.A., Braas, K.M., Waschek, J.A., Hammack S.E., May V.
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3.1. Abstract
The high coincidence of chronic pain and stress-related psychopathologies, such
as depression, anxiety-associated abnormalities and posttraumatic stress disorder (PTSD)
can aggravate the debilitating conditions of both disorders through neurocircuit
intersections and mechanisms that are still not well understood. Pituitary adenylate
cyclase activating polypeptide (PACAP; Adcyap1) and its cognate PAC1 receptor
(Adcyap1r1) are expressed in peripheral nociceptive pathways, participate in anxietyrelated responses and have been associated with stress-related disorders including PTSD.
In a partial sciatic nerve ligation chronic constriction injury (CCI) model, we show that
chronic neuropathic pain increases PACAP expression at multiple levels along the spinoparabrachioamygdaloid tract and bilaterally augments nociceptive amygdala (CeA)
PACAP immunoreactivity, ERK phosphorylation and c-fos activation in parallel with
heightened anxiety-like behavior and nociceptive hypersensitivity. Acute CeA infusions
with the PACAP receptor antagonist PACAP(6-38) blocked CCI-induced behavioral
responses; further, pretreatments with MEK or endocytosis inhibitors to block endosomal
PACAP receptor ERK signaling attenuated PACAP-induced CeA neuronal activation and
nociceptive responses. Accordingly, chronic pain-induced PACAP neuroplasticity and
signaling in spino-parabrachioamygdaloid projections can impact CeA stress- and
nociception-associated maladaptive responses, which can be ameliorated upon receptor
antagonism even during disorder progression.
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3.2. Introduction
Pain carries an aversive emotional component that can severely impact
physiological and behavioral responses. Accordingly, chronic pain has been well
associated with a number of stress-related psychopathologies, including depression, sleep
dysregulation, panic disorders, obsessive compulsive behavior, anxiety abnormalities and
post-traumatic stress disorder (PTSD) 1. The high comorbidity between pain and stressrelated behavioral disorders suggests that the two may be interrelated maladaptive
processes 2. Among brain regions, the amygdala is centrally situated to integrate the
many descending and ascending signals to modulate the sensory and emotional
components of pain. Among several direct ascending pathways carrying nociceptive
transmission to the CeA, the most prominent is the spino-parabrachioamygdaloid tract 3-6.
Peripheral nociceptive signals carried via primary sensory Aδ- and C-fibers terminate on
spinal projection neurons in lamina I/II and IV of the dorsal horn where the second order
neurons send projections via the spino-parabrachial pathway to pontine lateral
parabrachial nuclei (LPBn) 7. In turn, the third-order LPBn neurons relay sensory
information to the lateral (CeL) and lateral capsular (CeLC) subdivisions of the CeA.
Hence the PBn collects cutaneous (mechanical and thermal), deep (muscular and
articular) and visceral nociceptive signals and relays the information in a highly
organized topographical manner principally to the nociceptive amygdala.
Although the integration of these inputs with amygdala circuits is a key
mechanism underlying the emotional aspects of pain, the neurochemistry, neuroplasticity
and regulatory events that drive the maladaptive responses are still not completely
110

understood. In the CeA, chronic pain upregulates mGluR1/mGluR5 levels and function,
increases NMDA NR1 phosphorylation, enhances extracellular-regulated kinase (ERK)
signaling and c-fos expression, and facilitates LPBn and basolateral amygdala (BLA)
synaptic transmission to the CeLC8-12 . Relatedly, the pathophysiology of pain and
stress-related disorders has been attributed to the decrease or dysregulation of antinociceptive neuropeptide Y (NPY), opioid, endocannabinoid or neuroactive steroid
actions on GABA signaling 2. But in addition to diminished inhibitory neurocircuit
function, persistent pain may also augment stimulatory CeA nociceptive neuropeptide
levels including corticotropin releasing hormone (CRH) and calcitonin gene-related
peptide (CGRP) as complementary means to facilitate the stress- and pain-induced
changes in neural function 6,11,13.
Among brain peptides, there is accumulating evidence implicating pituitary
adenylate cyclase activating polypeptide (PACAP) and its cognate PAC1 receptor in
mediating the behavioral and physiological responses to a variety of homeostatic
challenges 14. Altered PACAP levels and a PAC1 receptor polymorphism have been
associated with PTSD 15-19. Mice that lack PACAP or the PAC1 receptor exhibit blunted
anxiety-like behavior, show hypothalamic-pituitary-adrenal (HPA) axis and autonomic
system dysregulation, and fail to develop hypersensitivity to nociceptive stimuli in
inflammatory pain paradigms 20-27. Furthermore, chronic but not acute stress leads to an
upregulation of PACAP and PAC1 receptor transcript expression in the bed nucleus of
the stria terminalis (BNST) 28-30. BNST PACAP signaling increases anxiety-like
behaviors and HPA axis activation, and mediates many of the behavioral consequences of
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chronic stress 28-30. The BNST and the CeA share similar circuit connectivity, architecture
neurochemistry, and physiology, and may play complementary roles in emotional
behavior processes. As in the BNST, dense PACAP immunoreactivity has been
identified in the neuronal fibers of the CeLC/CeL which from previous work has shown
to reflect LPBn PACAP projections in the spino-parabrachioamygdaloid tract 31.
Importantly, infusions of PACAP or a specific PAC1 receptor agonist directly into the
CeA of naive rats produced both anxiety-like behaviors and nociceptive hypersensitivity,
suggesting that LPBn PACAP activity via the spino-parabrachioamygdaloid circuit
carries signals that may in part alter the emotional responses to pain. Using a partial
sciatic nerve ligation chronic constriction injury (CCI) model, we examined whether
persistent neuropathic pain alters PACAP transcript expression in the spinoparabrachioamygdaloid tract and whether PAC1 receptor antagonism can mitigate CCIinduced nociceptive hypersensitivity and anxiety-like behaviors. As PACAP signaling
potently and efficaciously activates MAPK/ERK, a central mechanism in synaptic
plasticity and CeA-dependent behaviors and pain hypersensitivity, we also assessed CeA
PAC1 receptor mechanisms in vivo. The studies in aggregate suggest that endogenous
PACAP signaling in the spino-parabrachioamygdaloid pathway and the resulting
endosomal PAC1 receptor-stimulated activation of ERK in the CeA mediate the adverse
emotional consequences of chronic pain, and may also explain comorbidities between
chronic pain and other stress-related pathologies.
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3.3. Results
Neuropathic pain augments PACAP expression in the spino-parabrachioamygdaloid
pathway.
Our previous studies identified PACAP in neuronal projections from the LPBn to
CeLC and demonstrated that CeA PACAP infusions resulted in heightened nociceptive
sensitivity and anxiety-like behaviors 31. As previous studies implicated PACAP
phenotypic plasticity in sensory systems 32,33 we examined whether chronic neuropathic
pain in a unilateral sciatic nerve CCI model regulated endogenous PACAP expression
along the spino-parabrachioamygdaloid pathway. The partial sciatic nerve ligation
procedure reliably heightened nociceptive sensitivity as reflected by decreased thermal
latency responses and also induced anxiety-like behavior in open field tests 14 days postsurgery compared to sham controls without compromising locomotor activity (see
below). Quantitative PCR analyses of micropunched PBn tissues demonstrated that CCI
specifically elevated PBn PACAP transcript levels approximately 1.5 fold compared to
tissues from sham animals (t(12)=2.36, p=0.036); CCI did not augment PACAP
transcript levels in the CeA, anterolateral BNST, or the solitary nucleus (NTS)(figure
S3.1). Additionally, no significant change was found for the PAC1 receptor transcripts in
the LPBn or CeA (figure S3.1). As in other peptidergic systems, the
immunocytochemical localization for PACAP in the nervous system preferentially
identified bioactive peptides in fibers rather than soma to preclude corresponding
analyses of neuronal LPBn PACAP peptide changes after CCI. But as an alternative
means of evaluating injury-induced PACAP expression in the LPBn, the same unilateral
113

CCI was performed on PACAP-EGFP mice. LPBn PACAP-EGFP+ cells were identified
under basal conditions and CCI induced the number of PACAP neurons almost 2-fold
compared to sham operated animals, main effect of CCI, F(1,22)=7.99, p = 0.01) (Figure
1A - 1C). The CCI-induced PACAP-EGFP+ neurons appeared throughout the LPBn, with
the majority confined to the external lateral and central lateral regions. Notably, the
LPBn PACAP induction was observed both ipsilateral and contralateral to the injury,
which reflected bilateral dorsal horn neuronal projections to LPBn (Figure 3.1C), no main
effect of side main effect (F(1,28) = 0.32, p = 0.6).
In good correspondence to the increase LPBn PACAP transcripts and neurons,
CCI also augmented CeLC fiber PACAP staining from parabrachioamygdaloid
projections (Figure 3.1D - 1F). Consistent with previous studies, dense punctate
PACAP-immunoreactivity characteristic of PACAP fiber terminals and varicosities was
found primarily in the CeLC that extended into the CeL; image analyses after
thresholding fluorescence intensity revealed a 1.4-fold increase in PACAP staining
density in the CeLC of CCI animals compared to that in sham animals F(1,28)=14.74,
p=0.0006). As anticipated from bilateral dorsal horn neuronal projections to the LPBn,
the increase in CeLC PACAP immunoreactivity was also bilateral after unilateral CCI;
however, there was a notable bias toward greater PACAP immunoreactivity in the right
CeLC irrespective of the side of the CCI which appeared consistent with CeA
lateralization described in previous studies 34,35 (Suppl Figure 3.2).
Given the role of PACAP in neuroplasticity, we also evaluated whether
neuropathic pain from CCI similarly affected other PACAPergic neurons within the
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spino-parabrachioamygdaloid tract in the PACAP-EGFP mice. While the sciatic nerve in
sham operated and the contralateral leg of CCI animals demonstrated minimal PACAPEGFP fluorescence, the sciatic nerve segment proximal to CCI ligation demonstrated
pronounced fiber PACAP expression (condition*side F(1,10)=57.22, p<0.0001, post-hoc
Sham-ipsilateral vs. CCI-ipsilateral, p<0.0001) (Figure 3.2D - 2F). In mouse, the
sensory fibers in the sciatic nerve are predominantly peripheral axons from L3 - L5 dorsal
root ganglia (DRG) with the largest contributions from L4 sensory neurons. In
correspondence, CCI increased the number of PACAP-EGFP+ L3 - L5 DRG neurons
ipsilateral to the injury with the greatest increase in L4 DRGs compared to neurons from
the same levels under all control conditions (L4 DRG condition*side F(1,8)=93.12,
p<0.0001, post-hoc Sham-ipsilateral vs. CCI-ipsilateral, p<0.0001). (Figure 3.2A - 2C,
L3, and L5 Suppl Figure 3.2). The CCI-induced increase in DRG PACAP expression
was also reflected by a dramatic increase in DRG central axon EGFP fluorescence in
laminae III-V of the ipsilateral dorsal horn and in the gracile fasciculus (Figure 3.2G)
projecting to higher order central nuclei. There were no apparent changes in the number
of second order PACAP-EGFP+ dorsal horn neurons in CCI (data not shown).
Interestingly, CCI also induced PACAP-EGFP in some ipsilateral ventral horn motor
neurons which appeared consistent with previous nerve transection studies (Pettersson et
al., 2004). Accordingly, these demonstrate that chronic neuropathic pain elevates
PACAP expression levels along multiple neuronal elements in the spinoparabrachioamygdaloid pathway.
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CeA PACAP signaling facilitates neuropathic pain-related anxiety-like behaviors and
thermal hypersensitivity
We next examined if elevated CeA PACAP signaling in CCI contributes to
heightened anxiety-like behaviors and nociceptive sensitivity. Our previous work
demonstrated that CeA administration of PACAP or the PAC1 receptor specific agonist
maxadilan was capable of producing both anxiety-like behaviors and thermal
hypersensitivity31. But to evaluate the contribution of sustained endogenous CeA
PACAP signaling in chronic neuropathic pain, the PAC1 receptor antagonist PACAP(638) was infused bilaterally into the CeA of CCI rats before assessing anxiety-like
behavior in the open field and thermal nociception testing with the Hargreave’s test
(Figure 3.3A). Similar to chronic stress models, CCI attenuated weight gain over the
course of observation; (Figure 3.3B, main effect of CCI, F(10,280) = 80.80, p < 0.0001).
In open field tests 14 days post-surgery, CeA PACAP(6-38) infusions into the sham
control group did not significantly change the number of center field entries compared to
those receiving vehicle bonferroni’s m.c. t(22)=0.47, p = 0.9) suggesting that the
antagonist alone had no apparent behavior effects. Animals with CCI had fewer center
field entries and these pain-associated stress responses were completely blocked upon
CeA PACAP(6-38) administration (Figure 3.3C - 3D, bonferroni’s m.c. t(22)=3.12, p =
0.03). These responses were paralleled by a trend for PACAP(6-38) to increase center
field durations times in CCI (bonferroni’s m.c. t(22)=2.22, p = 0.07). The CCI procedure
did not impair locomotion or affect the total distance traveled (F(1,20)=0.46, p = 0.6),
similarly PACAP(6-38) did not alter total distance travelled (F(1,20)=1.22, p = 0.3).
116

Concurrent with anxiety-related behaviors, CeA PACAP infusions also reliably
facilitated nociceptive hypersensitivity in Hargreave’s thermal assays that persisted for
several hours31. CCI of the sciatic nerve has been well used to produce thermal
nociceptive responses and comparable to previous work, CCI 14 days post-surgery
typically decreased thermal latency 40 - 50% in the ipsilateral hindpaw compared to
sham control groups or to the contralateral hindpaw (Figure 3.3E - 3G, F(1,21)=14.13, p
= 0.001). In the same experimental paradigm, all of the CCI animal groups demonstrated
ipsilateral hindpaw thermal sensitivity prior to treatments; however, 1 h following
bilateral CeA PACAP(6-38) administration, the PAC1 receptor antagonist attenuated the
heightened thermal nociceptive responses compared to baseline measures prior to
antagonist treatments in the ipsilateral hindpaw in the CCI condition (Figure 3.3E,
interaction of condition*treatment*day (F(1,21) = 7.83, p = 0.009). The effects were
more marked when the responses in each animal were normalized to their own latency
baseline immediately prior to the injections (Figure 3.3H, F(1,21)=16.40, p = 0.001,
interaction of condition*treatment F(1,21) = 15.49, p = 0.001). There were no significant
effects of CeA PACAP(6-38) on the uninjured contralateral hindpaw or in the sham
operated condition (Figure 3.3F). Accordingly, these results mirrored previous PAC1
receptor antagonist studies, demonstrating that PACAP has no apparent behavioral
effects under control sham handling conditions, but contributes to heightened anxiety-like
behavior and nociceptive sensitivity in chronic neuropathic pain.
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CeLC PACAP-mediated ERK signaling in chronic neuropathic pain
One of the most consistent amygdala responses to persistent pain is an increase in
ERK activation in a subset of CeLC neurons. Enhanced amygdala ERK signaling can
increase behavioral sensitivity in normal conditions and ERK signaling contributes to
PBn - CeLC neurotransmission in persistent pain10,36,37. Conversely, MEK/ERK
inhibition in inflammatory pain can decrease behavioral hypersensitivity10. Comparable
to previous work and PACAP transcript/immunocytochemistry data above, unilateral CCI
on either the right or left hind limb increased bilaterally the number of CeLC pERK+ cells
compared to sham (Figure 3.4A - 4C, main effect of CCI F(1,26)=7.62, p = 0.01); there
was no apparent difference in response relative to the side of injury ((IL vs CL) no main
effect of side F(1,26) = 0.01, p = 0.9). However, for all CCI (left or right hind limb),
there was an apparent trend towards a greater number of pERK+ cells in the right CeLC
((left vs right) F(1,26) = 3.15, p = 0.09) (Suppl Figure 3.2). These results signify that
similar to other pain models, chronic neuropathic pain enhances ERK signaling in the
CeLC.
But to evaluate whether CeA PACAP fibers can affect amygdala ERK activation
in CCI, dual pERK and PACAP localization was performed (Figure 3.4D - 4E). Notably,
the majority of the CCI pERK+ cells (84.5 ± 5.0%) were in immediate apposition (< 2
µm) with CeLC PACAPergic fibers with a high occurrence of PACAP fibers forming
perisomatic contacts. The fraction of pERK+ cells with PACAP contacts is likely an
underestimate given the limitations of section thickness and antibody penetration. Thus,
PACAP is optimally situated to activate ERK in the CeLC. In good correspondence with
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previous characterizations of PACAP neurons, the CeLC PACAP fibers are mainly
glutamatergic from PACAP colocalization with vGlut2 immunoreactivity; there was little
overlap with vGlut1 or glutamic acid decarboxylase (GAD) staining (Suppl Figures 3.3
and 3.5).
As the BNST displays structural and functional homology with the CeA and also
receives LPBn PACAP projections31, the effects of CCI on neuronal pERK were also
examined in the BNST. As in the CeLC, CCI induced a robust increase in the number of
pERK+ cells in the anterolateral BNST, with almost no cellular pERK labeling under
sham conditions (main effect of CCI, F(1,8) = 15.04, p = 0.005) (Suppl Figure 3.5).
Similar to the CeLC, the majority of BNST pERK neurons (83.1 ± 0.5%) were in close
contact with glutamatergic PACAP fibers (Suppl Figures 3.3 and 3.5). These results
implied that BNST PACAP signaling may also have roles in the behavioral consequences
of persistent pain, which complements previous work 38.
To establish whether CeA PACAP signaling via ERK can evoke thermal
hypersensitivity, the MEK inhibitor PD98059 (20 µM) was infused into the CeA prior to
PACAP38 injection. While infusions of PACAP38 alone resulted in marked increases in
CeA c-fos and pERK immunoreactivity in the same neurons (Figure 3.5; co-incidence =
87%), pretreatment with the MEK inhibitor abolished the PACAP-stimulated responses,
demonstrating that ERK activation is an essential component of PACAP signaling to
instigate CeA neuronal activity (Figure 3.5A - 5L). CeA PACAP infusion and signaling
within the same study heightened nociception sensitivity as shown by the decreases in
thermal latency times; the PACAP responses were completely abolished by MEK
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inhibition, corroborating that PACAP/PAC1 receptor signaling via ERK pathways is
central to CeA nociception processes (Figure 3.5M - 5N, bonferroni m.c. t(41)=3.59, p =
0.002).
There are several potential mechanisms for PAC1 receptors to engage MEK/ERK
pathways including PKA and/or PKC activation39-42; however, PAC1 receptor
internalization into signaling endosomes has also been shown to be an alternative and
efficacious means of ERK phosphorylation to potentially sustain cell stimulation 41,42.
Blocking PAC1 receptor internalization at ambient temperature conditions or with
endocytosis inhibitors substantially attenuated ERK phosphorylation. Contiguous with
the previous experiment, a separate experimental group was pretreated with Pitstop 2 (30
µM), an inhibitor of clathrin-mediated endocytosis, prior to PACAP infusion. Consistent
with cell culture data 42, Pitstop 2 pretreatments markedly block PACAP-mediated c-fos
expression and ERK phosphoryation in the CeA (Figure 3.5). Importantly, inhibition of
clathrin-mediated endocytosis reduced PACAP-induced hypersensitivity (Figure 3.5M 5N, bonferroni m.c. t(41)=2.57, p = 0.03). Neither PD98059 nor Pitstop 2 produced CeA
damage or cellular apoptosis (Suppl Figure 3.6) The efficacy of Pitstop 2 in blocking the
PACAP-mediated nociceptive responses appeared lower than that for MEK inhibition
which may reflect in part drug potency in vivo vs in vitro, and ERK activation via PAC1
receptor PKA or PKC mechanisms. Nevertheless, these studies in aggregate provide the
first in vivo evidence that GPCR PAC1 receptor internalization and downstream ERK
signaling can modulate CeA nociception responses.
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3.4. Discussion
The current studies establish roles for CeA PACAP signaling as an effector
conveying the behavioral and sensory consequences of chronic neuropathic pain. Among
several lines of evidence, CCI increased PACAP transcripts and neurons in the LPBn
which correlated with enhanced LPBn PACAP projection fiber immunoreactivity in the
CeLC and increased PACAP expression in the spino-parabrachioamygdaloid tract. In
good agreement with previous studies demonstrating the anxiety-related and nociceptive
hypersensitivity responses following CeA PACAP administration31, blockade of
endogenous PACAP signaling in CCI with PAC1 receptor antagonist PACAP(6-38)
attenuated the CCI neuropathic pain-induced heightened anxiety-like behavior in the
open field tests and nociceptive hypersensitivity in thermal assays. Importantly, both
CCI and PACAP stimulated CeA ERK activation and c-fos expression which were
diminished upon pretreatments with MEK or clathrin-mediated endocytosis inhibitors in
parallel with diminished PACAP-induced nociceptive hypersensitivity. These results
further our understandings of CNS PACAP mechanisms and functions, and how
maladaptions in PACAP signaling in intersecting stress-related and pain circuits may
negatively impact the course of psychopathologies.
Previous studies have shown PACAP neurophenotypic plasticity and
demonstrated that central and peripheral neuronal PACAP expression can be upregulated
in response to diverse homeostatic challenges. In a chronic stress paradigm, heightened
PACAP and PAC1 receptor transcript expression was observed in the BNST and
paraventricular nucleus of the hypothalamus28. In several nerve injury models, PACAP
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was elevated in sensory, autonomic and motor neurons 32,33,43. The recent availability of
the PACAP-EGFP mice illustrated that plasticity; whereas basal endogenous PACAP
levels appeared low in many neuronal systems, physiological challenges especially nerve
injury significantly induced PACAP expression. Consistent with previous results, CCI
increased DRG PACAP expression, which augmented dramatically PACAP levels in
both peripheral sensory fibers in the sciatic nerve and central DRG axons in the dorsal
horn and spinal pathways. Second order PACAP producing neurons were found in
lamina I/II of the dorsal horn but notably CCI also increased PACAP expression centrally
in the LPBn and CeA as a consequence of enhanced nociceptive signaling in the spinoparabrachioamygdaloid pathway. The injury mechanisms underlying the induction of
phenotypically plastic peptides, including PACAP, are not well understood but may
reflect inflammatory responses or cellular stress from diminished target tissue signaling.
The same mechanisms may underlie the PACAP induction in the few ventral horn motor
neurons in CCI; PACAP function in these neurons have not been studied but posited to
be regenerative or neuroprotective. Uniquely, these studies demonstrate PACAP
expression at all levels of the spino-parabrachio-amygdaloid pathway suggesting that
PACAP is a common mediator at all levels of the nociceptive circuit.
The second order dorsal horn neurons project to the brain bilaterally; hence
unilateral CCI produced bilateral increases in LPBn PACAP expression with
corresponding increases in CeA PACAP immunoreactivity and pERK activation.
However, when all data sets were analyzed with reference to tissues ipsilateral or
contralateral to injury site, PACAP and pERK immunoreactivity was preferentially
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heightened in the right CeA, irrespective of left or right sciatic nerve ligation. These
observations agreed with studies suggesting that the CeA displays a degree of lateralized
function with the right CeA displaying greater increases in pERK and synaptic
potentiation in response to pain34,35. Accordingly, the lateralization of CeA PACAP may
be consistent with the functional lateralization nociceptive processes in the CeA.
The evidence for PACAP functions as a nociceptive neurotransmitter is
substantive. PACAP was identified initially as a sensory peptide44 and in agreement with
current work, other studies have shown that the low basal expression levels of PACAP in
DRG neurons can be dramatically induced in sensory neurons and sciatic nerve fibers
after injury. Furthermore, heightened DRG PACAP is likely released from C-fibers in
the superficial layers of the dorsal horn, as capsaicin applications decreased dorsal horn
PACAP immunoreactivity and increased PACAP levels in cerebral spinal fluid perfusate
44,45

. PACAP knockout mice develop significantly less thermal and mechanical

hypersensitivity from both neuropathic and inflammatory pain models, and have
decreased somatic sensitivity in normal conditions 26. Consistent with these findings,
mice that lack PAC1 receptors display reduced mechanical hypersensitivity during the
late phase following formalin injection27. However, the nociception studies after PACAP
infusion have been more variable depending on the route of peptide administration. In
the periphery, direct PACAP injections into the hindpaw was largely anti-nociceptive
reducing thermal and mechanical sensitization in inflammatory pain46. However, in
parallel with our CeA studies, central and intrathecal PACAP administrations were pronociceptive capable of potentiating hypersensitivity under normal conditions, and the
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responses could be blocked with PACAP(6-38) 31,47,48. The reasons for the variable
results are unclear but may be related to PACAP regulation of many homeostatic
systems. In addition to expression and function in sensory systems, PACAP also
regulates autonomic and immune functions; the anti-inflammatory and
immunosuppressive attributes of PACAP for example, may be contributory to the
peripheral anti-nociceptive effects.
Following CCI, a two week postsurgical recovery period was established to allow
locomotor return from transient deficits, injury-induced PACAP expression and the
development of chronic pain hypersensitivity and stress-related behaviors for multiple
nociceptive and behavioral assessments. BNST PACAP expression was upregulated in a
seven day chronic variate stress paradigm but not following one day of acute stress29,30;
whether a similar time course is necessary for PACAP induction in chronic versus acute
pain and whether PACAP levels in the spino-parabrachioamygdaloind pathway increase
incrementally with chronic pain duration have not been established. As many weeks of
CCI have been shown to gradually cause anxiodepressive-like disorders 49 and PACAP
has been implicated in anxiety- and depression-related behaviors 15,29,50,51, the increase in
PACAP expression and signaling may be a mechanism underlying the development of
psychopathologies.
The current CCI paradigm produced anxiety-like responses in open field tests and
thermal hypersensitivity in the ipsilateral hindpaw. To evaluate whether continued CeA
PACAP signaling participates in these heightened pain and behavioral responses, the
PAC1/VPAC2 receptor antagonist PACAP(6-38) was infused into the CeA before
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testing. The infusion of PACAP(6-38) alone into sham control animals had no effects on
either pain or stress-related behaviors, suggesting that PACAP signaling under basal
conditions may be low not to significantly impact the normal course of CeA functions.
The ability for acute PACAP(6-38) treatments to mitigate anxiety-like behavior and
thermal hypersensitivity responses during chronic injury suggested that the increase in
CeA PACAP levels and signaling was sustained during the course of CCI to facilitate the
pain-related behavioral responses. The involvement of CeA PACAP only in a state of
persistent pain and/or stress and not under normal conditions is comparable to
observations for other CeA systems including CGRP, CRH and mGluR regulatedfunctions8,52-54. The mechanisms through which CCI-induced CeA PACAP may result in
anxiety-like behaviors is not clear but may involve the potentiation of basolateral
amygdala (BLA) excitatory postsynaptic transmission to the CeL 55. Similarly LPBn
PACAP projections to the BNST may not only have anxiogenic but hyperalgesic
attributes by interactions with CRH systems 38. Hence, CCI-induced LPBn PACAP
expression and release could heighten nociceptive hypersensitivity and anxiety-like
behaviors via multiple complementary mechanisms with projections facilitating BLA to
CeL neurotransmission, modulating descending inhibitory signals, altering BNST
function or enhancing CeLC nociceptive signals to the substantia innominata dorsalis for
anxiety, aversion and fear responding56.
Activation of the ERK pathway is a central means of nociceptive signaling in a
variety of pain models. PACAP potently activates ERK through PAC1 receptors which
may have contributed to the sustained levels of pERK in the CeLC during prolonged
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CCI. Both CCI and acute CeA PACAP infusion increased ERK phosphorylation and
levels of the neuronal activity marker c-fos. The increase in pERK and c-fos were
colocalized to the same CeA neurons, and as c-fos stimulation could be abrogated
concomitantly with pERK levels with MEK inhibitors, the increase in c-fos appeared
downstream of PACAP signaling. This was supported by the observation that the
majority of the pERK neurons was found to be in close apposition to PACAPergic fibers.
Further, the ability for MEK inhibition to attenuate CeA PACAP-stimulated pERK and cfos in parallel with blockade of PACAP-induced thermal sensitivity demonstrated that
PACAP/PAC1 receptor-mediated ERK signaling is requisite for CeA nociceptive
hypersensitivity responses. There are several routes of PAC1 receptor-mediated
activation of MEK including adenylyl cyclase/cAMP and PLC/PKC. While these plasma
membrane initiated cascades may be relatively short lived, the recent observations that
PAC1 receptor endocytosis and recruitment of scaffolding proteins for endosomal MEK
signaling may represent a key mechanism for prolonged intracellular ERK activation. As
with MEK inhibitors, Pitstop 2, an inhibitor of clathrin mediated endocytosis also
blocked PACAP-mediated CeA pERK and c-fos levels and attenuated PACAP-mediated
nociceptive hypersensitivity responses. The internalization of several GPCR systems
have been described to participate intracellular signaling; these results may be one
demonstration of how GPCR internalization and endosomal signaling may relevant in a
physiological mechanisms and in particular nociceptive mechanisms.
In summary, our results demonstrate that spino-parabrachioamygdaloid PACAP
expression and signaling are augmented in neuropathic pain and that this heightened
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expression may contribute to adverse pain- and stress-related behaviors. While clinical
data have placed considerable emphasis on the dysregulation of inhibitory pathways as
mechanisms underlying pain-associated psychopathologies, the maladaptations from
ascending activating pathways including neurophenotypically plastic PACAPergic
system may be contributory to that process. CeA PAC1 receptor antagonism or inhibition
of downstream endosomal ERK signaling can blunt PACAP- and CCI-induced
nociceptive hypersensitivity and associated anxiety-like responses. As PACAP receptor
antagonism during CCI advancement can still ameliorate the adverse neuropathic pain
and behavioral responses, these observations suggest that interventions in PACAP
signaling during the progression of pain and associated behavioral responses may have
therapeutic utility in improving disorder outcomes.

3.5. Methods
Animals
Adult male Sprague-Dawley rats were from Charles River Laboratories,
Wilmington, MA. PACAP promoter-dependent EGFP BAC transgenic mice, generated
by the GENSTAT (Gene Expression Nervous System Atlas) project were obtained from
James Waschek (UCLA, Los Angeles, CA). All animals were housed under a 12-hour
light/dark cycle (lights on 0700 h) with food and water available ad libitum, and
habituated to the animal facility for at least one week prior to any experiments. All
procedures were approved by the Institutional Animal Care and Use Committee at the
University of Vermont.
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Neuropathic pain model
Chronic constriction injury (CCI) of the sciatic nerve was performed in rats as
described previously57. Rats were anesthetized with isoflurane and four loose ties (4-0
chromic gut sutures, Ethicon) were placed proximal to the trifurcation of the sciatic
nerve. In sham surgeries, the sciatic nerve was briefly exposed before incision closing
with wound clips. In some experiments with intra-amygdalar infusions, the stereotactic
surgery for cannula implantation was performed concurrently with CCI. Only animals
that developed thermal hypersensitivity in Hargreave’s assay were used for testing and
analyses. In PACAP-EGFP mice, the same CCI procedure was followed except only
three chromic gut sutures were used.

Intra-amygdalar infusion
Rats were prepared as described previously29,31 and two stainless steel cannulae
(22GA, PlasticsONe, Roanoke, VA) were placed targeting the CeA using the coordinates
(from bregma in mm) AP: -2.6, ML: ± 4.5, DV: -7.2. For CeA drug administration, rats
were lightly restrained with a towel and infused with drug or vehicle (0.5 µl/min, Harvard
Apparatus, Holliston, MA) through an internal cannula with a 1 mm projection beyond
the end of the guide cannulae. Infused compounds included PACAP(6-38) (0.3 µg/0.5
µl), Pitstop 2 (30 µM/0.5 µl) and PD98059 (20 µM/0.5 µl).
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Immunohistochemistry
Anesthetized rats were perfused transcardially with 4% paraformaldehyde and the
brains were postfixed for 24 h, washed and equilibrated in 30% sucrose before
embedding in OCT compound (ThermoFisher Scientfic, Waltham, MA) for
cryosectioning (30 µm). The sections were mounted onto subbed slides, permabilized
with 0.3% Triton X-100, blocked with 1% BSA and incubated in primary antibody.
Immunocytochemical staining for PACAP (1:10, 48 h at 4 C, Jens Hannibal, Bisperg
Hospital, Copenhagen, Denmark) was enhanced by tyramide signal amplification (Perkin
Elmer, Waltham, MA) for visualization with Cy3-conjugated streptavidin (1:200, 2 h;
Jackson Immunoresearch, West Grove, PA) as previously described31. Detection for
phosphorylated ERK (1:1000, #4370 Cell Signaling Technology, Danvers, MA) and cfos (1:300, sc-52 Santa Cruz Biotechnology, Dallas, TX) were performed using species
specific AlexaFluor 488 or Cy3-conjugated secondary antibodies. Antibodies to vGlut1
(1:1000, AB5905), vGlut2 (1:1000, AB2251) and GAD (1:300, AB1511) were all from
Millipore Billerica, MA.

Image Analysis
Micrographs were obtained using a Nikon E800 point scanning confocal
microscope, except in analyses of PACAP immunoreactivity levels in which the images
were captured using an Olympus fluorescence microscope captured using identical
parameters. For quantification of CeA PACAP fiber immunoreactivity, the
corresponding CeA fields in the different brains were identified using the hippocampus
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and optic tracts as reference points; area of threshold was used as an indicator of relative
fluorescence from same sized fields. For enumeration of CeA pERK-, c-fos-, and
PACAP-EGFP+ cells in fixed areas, a semi-autonomous cell counting method was
performed in ImageJ. All data represent mean values ± SEM.

Behavioral Assessments
Open Field
Behavioral testing was performed 0.5 h following infusions. Rats were
individually placed into the corner of a 75 cm x 75 cm opaque black open arena with 50
cm walls (United States Plastics Corp., Lima, OH) illuminated at 20 lux using a red bulb.
Rat arena center entries and total distance traveled over 5 min test sessions were digitally
captured with a ceiling mounted camera for analyses using EthoVision XT version
6.1.326 (Noldus Information Technology, The Netherlands).

Thermal Sensitivity Assessment
A Hargreave’s apparatus (Plantar Analgesia Meter, IITC Life Science, Inc.,
Woodland Hills, CA). was used to assess thermal stimuli responses. Following
habituation in the acrylic testing chambers (30 min each day for 2 days), the rats were
placed in the apparatus chamber with the glass floor maintained at 30 C with an internal
heating element. A low intensity guide light (8% active intensity) was used to target the
plantar surface of the each hindpaw from beneath the glass floor before a beam of
focused radiant light (4 x 6 mm, 25% active intensity) was switched on. Upon animal
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awareness of the heat stimulus, indicated by a withdrawal response or licking of the
hindpaw, the heat source was terminated and the reaction time automatically recorded.
An automated 30 sec cut-off was used to prevent tissue damage. The hindpaws were
randomly selected at trial initiation and 3 trials separated by 5 min inter-trial intervals
were performed on each of the left and right hindpaws .

Transcript analysis
Quantitative PCR (QPCR) was performed in the same manner as previously
described28,29 . Following brief isoflurane anesthesia and rapid decapitation, rat brains
were quickly frozen in OCT compound (ThermoFisher Scientfic, Waltham, MA); 300
µm cryosections were prepared and 740 µm micropunches from each region were
harvested. Total RNA extraction was performed using STAT-60 RNA/mRNA isolation
reagent (Tel-Test “B”, Friendswood, TX). Each set of brain regions was reverse
transcribed simultaneously using random hexamer primers using SuperScript II
Preamplification System (Invitrogen, Carlsbad, CA). The cDNA templates were diluted
10-fold and assayed on an ABI Prism 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA) using SYBR Green I JumpStart Taq ReadyMix (Sigma, St.
Louis, MO) containing 5.0 mM MgCl2, 200 µM dATP, dGTP, dCTP and dTTP, 0.64 U
Taq DNA polymerase and 300 nM of each primer in a 25 µl reaction volume.
Oligonucleotide primers were as follows: PACAP (S) 5’CATGTGTAGCGGAGCAAGGTT-3’ (AS) 5’-GTCTTGCAGCGGGTTTCC-3', PAC1
(S) 5’ -AACGACCTGATGGGACTAAAC-3' (AS) 5’131

CGGAAGCGGCACAAGATGACC-3'. Following amplification, melting profiles of
amplicons were used to verify unique product generation. A standard curve constructed
by amplification of serially 10-fold diluted plasmids containing the target sequence was
used for analysis. Increase in SYBR Green I fluorescence intensity(ΔRn) was plotted as a
function of cycle number and threshold cycle (CT) was determined using software as the
amplification cycle at which the ΔRn intersects the established baseline. Transcript
levels were calculated from the CT by interpolation from the standard curve. For each
target sequence, all sample from the same brain region were amplified simultaneously.
All data was normalized to 18s RNA and calculated as a fold change from control.

Statistics
All statistical tests were performed in SPSS (version 22) and GraphPad PRISM
(version 6). Two-way analysis of variance (ANOVA) was performed to examine main
effects and interactions, and Bonferrroni’s multiple comparisons tests were used to
compare different groups for all experiments, except for those indicated. A multifactorial
ANOVA was used to examine PACAP6-38 treatment with CCI condition across side and
day in tests of thermal sensitivity. Students T tests were performed to compare changes in
average weight gain and post surgery weight loss.
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Figure 3.1. CCI increases LPBn and CeA PACAP levels. Control sham surgery (A) or
CCI (B) were performed on transgenic PACAP-EGFP mice and native EGFP
fluorescence was examined in LPBn tissues 2 weeks following surgery. The number of
LPBn PACAP-EGFP cells was increased bilaterally in CCI compared to sham with a
main effect of condition (C; sham ipsilatera/contralateral = 31.0 ± 7.1 cells/26.3 ± 3.5
cells vs CCI ipsilateral/contralateral = 52.5 ± 9.2 cells/50.8 ± 9.7 cells; F(1,22) = 7.99,
p = 0.01, n = 6-7 per group, 3 sections enumerated per side per animal). CeA PACAP
immunoreactivity was also increased after CCI (E) compared to sham controls (D). From
image analyses with thresholded area, there was a main effect of CCI (F; sham
ipsilatera/contralateral = 21.7 ± 2.0 units/20.6 ± 1.3 units vs CCI ipsilateral/contralateral
= 27.3 ± 0.4 units/ 30.6 ± 1.1, F(1,28) = 14.74, p = 0.0006; n = 8 per group) but no main
effect (F(1,28)=0.32, p=0.6) or interaction (F(1,28) = 1.17, p = 0.3) with respect to side.
Data represent mean cells/unit area or fluorescence units/unit area ± SEM; scp, superior
cerebellar peduncle; IL, ipsilateral; CL, contralateral; Scale bar = 200 µm.
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Figure 3.2. Sensory pathway PACAP expression is enhanced by CCI. Compared to
sham surgery controls (A), unilateral partial sciatic nerve CCI (B) induced PACAP EGFP expression in the ipsilateral L4 dorsal root ganglion (DRG) sensory neurons (C;
sham ipsilateral/contralateral = 1.3 ± 0.9 cells/2.0 ± 1.0 cells vs CCI
ipsilateral/contralateral = 96.0 ± 9.6 cells/1.3 ± 0.3 cells, condition*side F(1,8) = 95.78,
p<0.0001), *p = 0.0001 Bonferroni’s m.c; n = 3 per group). L4 DRG represents the
major contributor to mouse sciatic nerve; similar PACAP-EGFP inductions were
observed in L3 and L5 DRGs (Suppl Figure 3.3). The increase in CCI induced DRG
PACAP expression was also reflected in peripheral and central DRG axons. The
ipsilateral sciatic nerve fibers proximal to the ligation demonstrated pronounced PACAPEGFP fluorescence (E) compared to sham (D) or contralateral control tissues (F; sham
ipsilateral/contralateral = 0.8 ± 0.5 units/0.9 ± 0.4 units vs CCI ipsilateral/contralateral
= 54.7 ± 6.1 units/0.2 ± 0.1 units; interaction side*condition F(1,10)=57.22, p<0.0001;
n = 3 - 4). The CCI-induced PACAP-EGFP fluorescence in the central DRG axons were
observed in the dorsal horn with prominent projections in the dorsal while matter tracts
(G). Few PACAP-EGFP neurons were also observed in laminae I of the dorsal horn but
there were no apparent differences between ipsilateral and contralateral dorsal horn
PACAP neuronal number after sciatic nerve injury. CCI also induced PACAP-EGFP
expression in the ipsilateral ventral horn motor neurons. Data represent mean cells/unit
area or fluorescence units/unit area ± SEM; DH, dorsal horn; VH, ventral horn; GF,
gracile fasciculus. Scale bars = 200 µm
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Figure 3.3. Blocking CeA PACAP signaling attenuates CCI-mediated anxiety-like
behavior and thermal nociceptive hypersensitivity. CCI and CeA cannulations were
performed concurrently in rats for behavior and nociception studies in the experimental
timeline shown (A). The CCI-mediated pain- and stress-related responses were associated
with attenuated weight gain compared to sham control animals during the post-surgical
recovery period (B). There was decreased weight gain in the CCI operated animals
compared to sham, (main effect of CCI, F(10,280) = 80.80, p < 0.0001, n =8 per group)..
The pain- and stress-related behavior in CCI was also reflected in decreased center
entries in open field tests compared to sham controls (C; open bars). CeA infusions in
sham operated animals with the PACAP receptor antagonist PACAP(6-38) had no effects
on center field entries over the 5 min test period (sham-vehicle = 7.5 ± 0.7 vs shamPACAP(6-38) = 6.75 ± 1.4, Bonferroni’s m.c. t(22) = 0.47, p = 0.9) but blocked the
stress- and anxiety-like open field responses in CCI (CCI-vehicle = 3.7 ± 0.8 vs CCIPACAP(6-38) = 9.0 ± 1.3, Bonferroni’s m.c. t(22) = 3.12, p = 0.03; condition*treatment
F(1,22) = 6.78, p = 0.02, n = 5 - 8 per group). (D), Representative movement tracks in
open field area for the 4 groups. There were no significant differences in total distance
traveled for either condition or treatment. Data represent mean open field entry ± SEM.
In Hargreave’s thermal nociception assays, CCI increased thermal sensitivity as reflected
by decreased baseline latency times in the ipsilateral hindpaw compared to the
contralateral leg or in sham animals (F(1,21) = 14.13, p = 0.001). PACAP(6-38) infusions
into the CeA attenuated the CCI-induced thermal hypersensitivity compared to baseline
(E); simple effect of day in CCI-PACAP(6-38) on IL side (baseline: 5.3 ± 0.6s vs. 30
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min: 7.2 ± 0.7s, F(1,21) = 12.21, p = 0.002) and interaction of condition*treatment*day
(F(1,21) = 7.83, p = 0.009, n = 5 - 8 animals per group) and within group PACAP(6-38)
ameliorated the nociceptive sensitivity. The effects were amplified when the responses of
each animal were normalized to their own baseline measures prior to antagonist treatment
(G; CCI-Vehicle: -3.4 ± 7.2% vs. CCI-PACAP(6-38): 36.2 ± 6.6%, simple effect of
treatment F(1,21) = 16.40, p = 0.001, interaction of condition*treatment F(1,21) = 15.49,
p = 0.001. (H); There were no effects of PACAP(6-38) on thermal latency in the
contralateral leg (F).
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Figure 3.4. PACAPergic fibers contact CeA activated ERK cells in CCI.
CCI produced a bilateral increase in the number CeLC activated pERK+ neurons (Cy3,
red) compared to that in the sham condition (A - C; sham ipsilateral/contralateral = 32.1 ±
4.5 cells/30.6 ± 2.8 cells vs CCI ipsilateral/contralateral = 53.4 ± 12.6 cells/56.6 ± 11.9
cells, F(1,26)=7.62, p = 0.01, n = 7 - 8 animals per group). When the same sections were
dually processed for PACAP immunoreactivity (AlexaFluor 488, green), a majority of
the CeLC pERK+ neurons were found in apposition to PACAP-immunoreactive fibers
and varicosities (D - E). Data represent mean cells/unit area ± SEM; IL, ipsilateral; CL,
contralateral. Scales bar = 50 µm
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Figure 3.5. PACAP receptor internalization and ERK activation participate in
CeA-mediate nociceptive hypersensitivity. Compared to vehicle (A), CeA PACAP
infusion increased the number of activated phosphorylated ERK neurons (D, Cy3 red)
which coincided with the increase in neuronal activity marker c-fos (G, J, blue).
Pretreatments with MEK inhibitor PD98059 (B, E, H) or clathrin-mediated endocytosis
inhibitor Pitstop 2 (C, F, I) blocked the ability of PACAP to induce ERK
phosphorylation or c-fos in CeA neurons. K, The increase in PACAP-stimulated ERK
activation was attenuated approximately 60 - 70% by PD98059 (vehicle + PACAP =
149.0 ± 33.1 cells vs PD98059 + PACAP = 41.9 ± 15.9 ± 6.7 cells, (bonferroni’s m.c.
t(40) = 4.49, p = 0.0001) and Pitstop 2 (veh + PACAP = 149.0 ± 33.1 cells vs Pitstop2
+ PACAP = 62.7 ± 14.2 cells, bonferroni’s m.c. t(40) = 3.50, p = 0.002),
pretreatment*treatment(F2,40) = 4.67, p = 0.02. L, Similarly, the increase in PACAPstimulated c-fos levels activation was attenuated approximately 50 - 60% by PD98059
(cells/unit area, vehicle + PACAP = 148.5 ± 32.3 cells vs. PD98059 + PACAP = 59.8 ±
18.7 cells, bonferroni’s m.c. t(40) = 3.62, p = 0.002) and Pitstop 2 (vehicle + PACAP =
148.5 ± 32.3 cells vs. Pitstop2 + PACAP = 74.4 ± 15.8 cells, t(40) = 2.92, p = 0.02)
pretreatment*treatment (F(2,40) = 3.46, p = 0.04). Scale bar: 100 µm. Data represent
mean cell number ± SEM; n = 7 - 8 per group. Commensurate with ERK activation,
CeA PACAP injection induced nociceptive hypersensitivity in decreasing thermal
latency; both MEK and endocytosis inhibition blocked the PACAP-induced thermal
sensitivity (M; latency in sec, Veh + PACAP = 7.1 ± 0.6 sec vs PD98059 + PACAP =
11.2 ± 0.8, bonferroni’s m.c. t(41) = 5.05, p < 0.0001; Veh + PACAP = 7.1 ± 0.6 vs
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Pitstop2 + PACAP = 9.8 ± 0.4, bonferroni’s m.c. t(41) = 3.31, p = 0.004)
(pretreatment*treatment F(2,41) = 6.64, p = 0.003). Expressed as percent change from
baseline measures of each animal before drug administration, both MEK inhibition (%
latency change from vehicle control; PACAP = -37.8 ± 5.9% vs. PD98059 + PACAP =
2.6 ± 4.8%, bonferroni’s m.c. t(41) = 5.58, p=0.0001) and endocytosis inhibitor Pitstop
2 (PACAP = -37.8 ± 5.9% vs Pitstop + PACAP = -13.5 ± 4.9%, bonferroni’s m.c. t(40)
= 3.36, p = 0.003) attenuated nociceptive hypersensitivity. Data represent mean ±
SEM, n = 7 - 8 per group.
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Supplementary Figure 3.1. CCI increases PACAP transcript in the LPBn.
Adult male rats underwent either CCI or sham surgery as described in text and 14 days
following the indicated brain regions were harvested for quantitative PCR analysis.
Tissue samples for each region were reverse transcribed and normalized against 18s
RNA. In the LPBn was a significant increase in PACAP transcript (1.47 ± 0.1) fold
change SEM) compared to tissues from sham animals ((1.00 ± 0.2), t(12) = 2.36, p =
0.036). Demonstrating that this effect may be specific to the LPBn, there were no
significant changes in PACAP transcript in the CeA (CCI: 0.96 ± 0.2 vs. sham: 1.00 ±
0.3, t(12) = 0.12, p = 0.9), anterolateral BNST (CCI:1.06 ± 0.2 vs. sham: 1.00 ± 0.2, t(13)
= 0.21, p = 0.8), or the solitary nucleus (NTS)(CCI: 1.00 ± 0.2 vs. sham: 0.90 ± 0.3, t(14)
= 0.29, p = 0.8). There were no significant changes in PAC1 R transcript in the LPBn
(CCI:1.15 ± 0.1 vs. Sham 1.00 ± 0.1, t(12) = 1.09, p = 0.3) or CeA (CCI:1.03 ± 0.1 vs.
Sham: 1.00 ± 0.1, t(12) = 0.45, p = 0.7). n = 6-8 per group, dependent on viability of
tissue sample during processing. Data represent fold change normalized to 18s; ± SEM.
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Supplementary Figure 3.2. The CeA demonstrates lateralization in CCI-induced
increases in PACAP and pERK immunoreactivity. CCI (14 days) preferentially
increased PACAP immunoreactivity and pERK+ cells in the right CeA. When
thresholded PACAP immunoreactivity from Figure 3.2 was analyzed with respect to right
or left CeA, there was a significant main effect of side (A; F(1,28) = 4.87, *p = 0.04), but
no interaction between side and condition (F(1,28) = 1.63, p = 0.2), with greater PACAP
immunoreactivity in the right CeA. There was a significant main effect of CCI for
increased PACAP immunoreactivity (F(1,28) = 17.24, p = 0.0003). There was a similar
bias in pERK+ cells in the right CeA with a trend for the effect of side (B; F(1,26) = 3.15,
p = 0.09). There was also a main effect of CCI for increased pERK+ cells (F(1,26) =
8.85, p = 0.006). These results appear consistent with the lateralization of CeA pERK
shown previously in persistent pain, and implicate PACAP in the lateralization of the
nociceptive process.
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Supplementary Figure 3.3. CCI increases PACAP-EGFP expressing L3 and L5
DRG neurons. Similar to the L4 DRG (Figure 3.2), unilateral CCI increased the
number of L3 and L5 DRG PACAP-EGFP+ neurons 14 days postsurgery (B, E)
compared to sham controls (A, D). L3 - L5 DRG peripheral sensory axons travel in the
sciatic nerve with major contributions from L4. The increase in CCI-induced PACAPEGFP+ neuron expression in L3 DRG (C; sham ipsilateral = 5.0 ± 2.1 cells vs CCI
ipsilateral = 36.3 ± 4.3 cells, *p = 0.0002, n = 3 per group) and L5 DRG (F; sham
ipsilateral = 4.5 ± 1.5 cells vs CCI ipsilateral = 37.5 ± 10.5 cells, n = 2 per group) was
not as robust as that in L4 DRG. Data represent mean cells/unit area ± SEM.
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Supplementary Figure 3.4. CeA and BNST PACAP fibers colocalize
predominantly with vGlut2 immunoreactivity. CeA (A) and BNST (D) tissues were
dually processed for PACAP (Alexa Fluor 488, green) and vGlut2 (Cy3, red) to help
establish neuronal transmitter identity. CeA and BNST PACAP colocalized with
glutaminergic marker vGlut2 as shown in their respective isolated merged signals (B, E;
yellow). From quantitative image analyses, there was minimal overlap between PACAP
and vGlut1 or GAD (C, F; see Suppl. Figure 3.5). Scale bar = 25 µm
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Supplementary Figure 3.5. PACAPergic fibers contact BNST pERK+ neurons in
CCI. As in the CeLC, CCI increased bilaterally the number of pERK+ neurons in the
anterolateral BNST compared to sham controls (A - C). The BNST pERK+ cells (Cy3,
red) were in close contact with PACAP fibers (D,E; Alexa Fluor 488, green), implicating
PACAP as a potential mechanism of CCI-induced nociceptive ERK signaling. There is
a main effect of CCI (C; F(1,8) = 15.3 p = 0.005, n = 3 per group). Scale bar = 50µm.
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Supplementary Figure 3.6. CeA and BNST PACAP immunoreactivity does not
colocalize with vGlut1 or GAD. CeA (A, B) and BNST (E, G) tissues were dually
processed for PACAP (Alexa Fluor 488, green) and vGlut (Cy3, red) or GAD (Cy3,
red). Unlike vGlut2 (Supplementary Figure 3.4), there was little overlap with the
glutamatergic marker vGlut1 or GABAergic marker GAD in both regions as shown by
the paucity of merged signals (B, D, F and H; yellow). Quantitative analyses in Suppl.
Figure 3.4. Scale bar = 25 µm

152

Supplementary Figure 3.7. Acute CeA infusions with inhibitors does not induce
apoptosis. To verify that the CeA infusions with drugs to block MEK (PD98059) or
endocytic mechanisms (Pitstop 2) did not cause overt neurotoxicity and apoptosis to
impact results, the treated tissues were also processed for nuclear Hoechst staining (A C) and apoptotic marker cleaved caspase-3 immunoreactivity (D - F). Hoechst nuclear
staining confirmed there were no apparent signs of substantial cell loss in any of the
treatment conditions; further, there were no signs of any ongoing apoptosis in the CeA.
Cleaved caspase 3+ cells were found sporadically throughout the brain; G, an example of
a cleaved caspase 3+ hippocampal neuron at the same magnification. Scale bar = 50µm
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Chapter 4.
General Discussion

The studies in this dissertation were aimed to investigate the role of CeA PACAP
signaling in mediating the emotional components of pain. Severe emotional
dysregulation often co-exists in patients with chronic pain, as evidenced by the high rates
of comorbid affective disorders including post-traumatic stress disorder (PTSD),
generalized anxiety disorder (GAD), and panic disorder (PD). Chronic pain carries an
enormous personal, societal, and economic burden and in the presence of comorbid
affective disorders, the degree of disability and suffering in these individuals becomes
greatly amplified. Moreover, the presence of an affective disorder may not only
exacerbate pain, but may also act to reinforce the underlying mechanistic processes of
chronic pain in a self-perpetuating cycle. As these mechanisms are not well understood,
studies elucidating the key signaling molecules and neural circuits in this system may
offer insights to the pathogenesis of these disorders and provide therapeutic approaches to
break the cycle of chronic pain and affective disorders. To this end, the studies in this
dissertation find evidence that PACAP signaling within the parabrachio-amygdaloid tract
may be a key mediator of the emotional components of pain.
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4.1. Insights into PACAP neurocircuits and plasticity
PACAP expression in the spino-parabrachioamygdaloid tract
In the course of ongoing investigation, our laboratory found dense PACAP fiber
immunoreactivity in the CeLC and CeL regions of the central amygdala (CeA). From in
situ hybridization data, there appeared to be little endogenous PACAP expression within
the CeA, indicating that the observed immunoreactivity reflected axonal fiber projections
of undetermined external origins (Piggins et al., 1996). Using anterograde tracing with
10 kDa BDA and excitotoxic lesion studies, we showed that the vast majority CeA
PACAP immunoreactivity originated from the LPBn (ure 2.3, 2.4). This finding is of
particular interest because sensory input converges on the LPBn before projecting to the
CeLC. Nociceptive information from the entire body and face are relayed by the spinal
cord and sensory trigeminal system, respectively, via second order sensory afferents onto
LPBn neurons. Additionally, the LPBn also receives visceral input from the vagal nerve
via relays from the NTS. Given the involvement of the LPBn in sensory systems, the
expression of PACAP in the LPBn is suggestive of a role in the processing of nociceptive
stimuli.
The LPBn has major projections to the CeLC, anterolateral BNST (BNSTal), and
the VMH. Interestingly, LPBn-BNST projections are either direct or via collaterals from
axons ultimately projecting to the CeLC (Sarhan et al., 2005). We found that lesioning
the LPBn resulted in a substantial loss (~70%) of PACAP expression within the
ipsilateral BNST, similar to the findings within the CeA (Figure 2.4). Although the
source of the remaining BNST PACAP (~30%) was not investigated, the residual
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PACAP could have originated from the PVH or dorsal vagal complex, or represented
endogenous BNST expression (Hammack et al., 2009; Kozicz et al. 1998). Although not
examined directly in this work, PACAP in the VMH was previously found to originate
from the LPBn (Resch et al., 2013). In projecting to the CeLC, BNST and VMH, the
population of LPBn PACAP neurons may be components of a much enlarged network
and behave as a sensory distribution hub, relaying discrete information to these three
regions to coordinate the behavioral and physiological responses to aversive sensory
input. Along this line, the effect of PACAP signaling in each of these regions has now
been investigated. PACAP infusion directly into the VMH resulted in hypophagia and
increased thermogenesis (Resch et al., 2011). BNST PACAP infusion produces anxietylike behaviors, hypophagia, weight loss, and HPA axis activation (Hammack et al., 2009;
Roman et al. 2014; Kocho-Schellenberg et al., 2014; Lezak et al., 2014). Whereas, CeA
PACAP was demonstrated in the current studies to produce nociceptive hypersensitivity
and anxiety-like behavior, CeA PACAP signaling has also recently been reported to
produce a delayed hypophagia and weight loss (Figure 2.6; Iemolo et al., 2015).
Interestingly, PACAP signaling in CeA, BNST, and VMH appear to initiate various
combinations of hypophagia, anxiety-like behavior, and nociceptive hypersensitivity.
Hence, these responses may represent a behavioral and physiological phenotype that is
characteristic of sustained or enhanced LPBn activity, as might occur following
prolonged nociceptive input with chronic pain.
Further, PACAP expression in nociceptive pathways is not restricted to LPBnCeLC projections, as it is found all along the spino-parabrachio-amygdaloid pathway
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(Figure 4.1). PACAP is found within peripheral afferent terminals and within a subset of
peptidergic DRG cells that also express CGRP and the precursor of substance P (Mulder
et al., 1994; Usoskin et al., 2015). PACAPergic fibers from these DRGs project to the
dorsal horn, and dense PACAP immunoreactivity is found in lamina I/II of the spinal
cord (Vizzard, 2000). At the next step of this pathway, neurons in lamina I/II have been
reported to express PACAP, and although yet to be established, these neurons may
represent the second-order spinal projection neurons that relay nociceptive information to
the LPBn (Pettersson et al., 2004). In our experiments utilizing PACAP-EGFP mice, we
confirmed PACAP-EGFP expression in a subset of DRG neurons and consistently found
PACAP-EGFP expressing cells within lamina I/II of the spinal cord (Figure 3.2). Our
findings are in agreement with prior work and demonstrate that PACAP is expressed at
all levels of the spino-parabrachio-amygdaloid pathway. These PACAP expression
patterns raise the possibility of PACAP-expressing neurons synapsing onto other PACAP
neurons (PACAP to PACAP projections) all along the spino-parabrachio-amygdaloid
tract. Mechanistically this system would appear plausible, as PACAP signaling was
found to exhibit positive autoregulation in the sympathetic system, with PACAP receptor
activation driving more PACAP expression (Braas et al., 2007). Additionally, the
existence of PACAPergic fibers synapsing on PACAPergic neurons has been suggested
in the enteric nervous system (Nagahama et al., 1998). Further, infusion of PACAP
appears pro-nociceptive at several levels of the spino-parabrachio-amygdaloid pathway
(Table 4.1). Potentially this system could also involve visceral sensory input, as there is
a substantial population of PACAP neurons within the NTS, corresponding to the
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location of the primary relay of visceral information to the LPBn. The possibility of
PACAP expression at every level of the spino-parabrachio-amygdaloid pathway is
significant, as it would identify a signaling molecule used along an entire pathway.
Further, it might indicate that PACAP expression could mark a set of neural circuits
within the CNS that integrate aversive sensory information with emotional salience.
Intriguingly, PACAP is the mostly highly conserved peptide in its family and appears to
be present along one of the more phylogenetically ancient spino-parabrachial nociceptive
pathway, in comparison to the more evolutionarily recent neospinothalamic pathway
(Almeida et al., 2004; Sherwood et al., 2000). Given what is known about its function,
PACAP-expressing neural circuits may function in the generation of a primitive, wholebody response to particularly averse and long-lasting challenges, such as prolonged pain.

CEA PACAP is coexpressed with CGRP
In addition to PACAP, the CeA also expresses diverse neuropeptides and
markers, including somatostatin (SST), CRH, parvalbumin (PV), cholecystokinin (CCK),
calbindin, calretinin and VIP, all of which display characteristic unique or overlapping
expression patterns (Ehrlich et al., 2009; Kemppainen & Pitkanen, 2000). The CeA
PACAP fiber immunoreactivity is confined to the CeLC and CeL, and the PACAP
terminals form perisomatic basket-type innervations of amygdala neurons. We found no
overlap between PACAP and somatostatin or CRH immunoreactivity in the CeA; the
distribution of each peptide appeared to display non-overlapping, but intermingled
expression patterns (Figure 2.1). However, co-labeling with CGRP and PACAP resulted
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in fairly extensive colocalization in the CeA (Figure 2.2). CGRP expression in the CeLC
has been previously shown to originate from the LPBn; thus PACAP and CGRP appear
to demonstrate high levels of coexpression within LPBn-CeLC projections (Dobolyi et
al., 2005). Similarly, within the BNSTal, there is a substantial overlap of PACAP and
CGRP immunoreactivity, suggesting that this too is part of the LPBn projections. This
latter finding was confirmed, as LPBn lesions produced a concomitant loss of CGRP
immunoreactivity with PACAP in both the BNST and CeLC (Figure 2.2).
CGRP signaling could play a similar or complementary role to PACAP in the
generation of stress-related behavioral responses in the limbic system. CGRP signaling
can promote unconditioned fear, as CGRP infusions into the amygdala produced an
unconditioned freezing response before any aversive stimulus was presented
(Kocorowski & Helmstetter, 2001). Further, pretreatment with the CGRP receptor
antagonist, CGRP(8-37) in the amygdala disrupted cued but not contextual fear
conditioning. In the BNST, infusion of CGRP induced anxiety-like responses on the
elevated plus maze and produced a dose-dependent enhancement of startle (Kelly et al.,
2011). This effect appeared to be dependent on CRH signaling, since either pretreatment
with CRHR1 antagonist or virally-mediated siRNA knockdown of CRH expression,
blocked the ability of BNST CGRP to enhance startle (Sink et al., 2013). CGRP is well
known as a peripheral modulator of nociceptive transmission and this role may hold true
within the brain. Application of CGRP to amygdala sections increases excitatory
postsynaptic currents (EPSCs) on PBn-CeLC synapses, increasing amplitude but not the
frequency of miniature EPSCs (Han et al., 2010). Further, CeA administration of CGRP
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into awake rats was found to increase audible and ultrasonic vocalizations and produce
mechanical hypersensitivity. CeA CGRP may also play a role in feeding behavior.
Using optogenetic and pharmacogenetic manipulation of CGRP-expressing PBn-CeLC
projections, activation of these projections strongly suppressed appetite. Conversely,
inhibition of CGRP LPBn-CeLC projections increased food intake in situations when
mice normally do not eat, and prevented starvation after agouti-related peptide (AgRP)
neuronal ablation, implicating CGRP LPBn-CeLC signaling may be connected to the
principal feeding circuits within the hypothalamus (Carter et al., 2013). Interestingly,
activation of CGRP LPBn neurons was sufficient to induce conditioned taste aversion in
the absence of an anorexigenic substance, and inhibition of these same neurons
attenuated conditioned taste aversion to lithium chloride (Carter et al., 2015). From these
studies, CGRP LPBn-CeLC projections are thought to encode a type of visceral malaise
signal. In sum, the effects of CGRP in the CeA bare some striking similarities to those of
PACAP, inducing anxiety-like behaviors, nociceptive hypersensitivity, and hypophagia.
Given the overlap in expression and functional similarities of PACAP and CGRP
in the CeLC, these two peptides might play complementary roles. In mammalian brains
it has been found that generally when two or more neuropeptides are coexpressed within
the same neuronal population, they are also co-stored within the same large dense core
vesicles (Merighi, 2002). Co-storage would have functional implications; first, it would
necessitate co-release of both neuropeptides, allowing for interactions between the
different peptides, and second, it would suggest that regulation of these systems would be
most readily accomplished through altering rates of synthesis. Neuropeptides can often
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work in a synergistic manner. One of the best-known examples of this is the potentiation
of CRH by vasopressin in the pituitary gland, where the effect of vasopressin greatly
increases the amount of adreno-corticotropin releasing hormone (ACTH) that is released
by CRH binding (Merighi, 2002). Studies of the ophthalmic artery, suggest the
possibility of a synergistic interaction between PACAP and CGRP. In the porcine
ophthalmic artery, both PACAP and CGRP each induced a concentration dependent
vasorelaxation, but when both peptides where administered together the amount of
relaxation substantially increased, beyond what would be predicted individually (Elsas &
White, 1997).

Pain-related plasticity of PACAPergic neural circuits
To examine if there is increased PACAP signaling during persistent pain, we
performed a set of experiments using a CCI model of neuropathic pain. At 14 days
following CCI surgery, PACAP transcript was increased in the LPBn (Figure s3.1). This
effect appeared to be specific to the LPBn, as no other CNS regions examined had
significant alterations in expression. Increased PACAP transcript levels at 14 days
corresponded to an increase in PACAP immunoreactivity in the CeA, indicating
increased PBn PACAP biosynthesis and increased axonal transport of PACAP peptide to
CeA terminals (Figure 3.1). Complementary to these studies, tissue from transgenic
PACAP-EGFP mice was analyzed following CCI. In agreement, 14 days following CCI
there was a bilateral increase number of PACAP-EGFP+ cells in the LPBn, compared to
sham surgery (Figure 3.1). These results provide strong evidence that CCI increases
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PACAP signaling in LPBn-CeLC circuits and support PACAP involvement in chronic
pain-related plasticity.
In addition to the LPBn-CeLC, CCI induced PACAP expression along multiple
neural sites within the spino-parabrachial amygdaloid pathway. Following CCI, PACAPEGFP mice displayed marked PACAP-EGFP expression within the proximal sciatic
nerve and in L3-L5 DRG ipsilateral to the injury (Figure 3.2). This is consistent with a
number of previous studies reporting enhanced PACAP expression in peripheral nerve
and DRG following injuries including axotomy, injection of complete Freund’s adjuvant,
L5 nerve transection, or capsaicin treatment (Jongsma et al., 2000; Mabuchi et al., 2004;
Mulder et al., 1999; Nemeth et al., 2006; Pettersson et al., 2004). In the spinal cord, we
identified prominent PACAP-EGFP fibers in the dorsal columns/medial lemnisicus tract
that give off collaterals into lamina III-V (Figure 3.2). This pathway likely corresponds
to Aβ fibers conveying non-noxious sensory information to the gracile nucleus. The
presence of PACAP within this pathway may be a consequence of its role as a
prosurvival/injury response factor. Interestingly, it has been proposed that during
neuropathic pain, the sprouting of these collateral Aβ fibers from lamina III-V into
lamina I-II may explain the presence of allodynia (Mannion et al., 1996; Woolf et al.,
1992). In this model, as a consequence of pain-related sprouting, lamina I neurons would
now receive non-noxious sensory input, and result in innocuous sensory stimuli leading
to the perception of pain to normally non-noxious stimuli. However, this interpretation
has been questioned because of the development of new more precise techniques, raising
questions about peripheral sprouting of Aβ lamina III-V fibers as a mechanism of
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sensitization (Hughes et al., 2003; Zhang et al., 2015). In our studies, the lack of
PACAP-EGFP fibers in lamina I in either normal conditions or following CCI is
surprising and might suggest a specific role in non-noxious sensory transmission in the
periphery. However, under normal conditions PACAP immunoreactivity has been
repeatedly found primarily within lamina I and not in lamina III-V (Hannibal, 2002;
Vizzard, 2000). The lack of PACAP within lamina I could simply be a result of native
EGFP detection limits or differences in cellular mechanisms between different sized
neuronal fibers and causing EGFP to be found only in larger neuronal fibers. The
increased expression of PACAP-EGFP along multiple levels of the spino-parabrachioamygdaloid pathway suggests PACAP signaling might contribute to pain-related neural
transmission and plasticity within distinct nociceptive pathways.
All experiments that examined alterations in PACAP expression were performed
at 14 days following CCI surgery to allow comparisons across different experiments.
There were several factors in the determination of this time point. The first is that it
allowed sufficient time for recovery from surgery, such that the cutaneous incision would
be healed, and motor deficits could be largely resolved. This time point also corresponds
to a time following CCI when hypersensitivity behaviors are fully developed. Finally,
given the nature of stress stimuli required in our previous studies, several days of
persistent pain may be required for the regulation of PACAP in this system.
Upregulation of PACAP and PAC1R transcript in the BNST was found following 7 days
of stress, but no change following one acute stressor exposure (Hammack et al., 2009;
Lezak et al., 2014). Further, although PAC1R deficient mice have normal stress response
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to acute restraint stress, longer periods of stress (14-21 days) resulted in a significant
attenuation of HPA axis activation and stress-induced hypophagia (Mustafa et al., 2015).
Thus, the induction of PACAP expression and signaling might occur at later time points
and require a prolonged stimulus. Future characterization at different time points is
necessary to determine whether longer durations of pain are required to induce PACAP
expression in the PBn-CeLC. Interestingly, the development of anxiodepressive
behaviors in rats with CCI follows a very gradual timeline, appearing over the course of a
number of days, in comparison to hypersensitivity which has more immediate
development in the hours following surgery (Alba-Delgado et al., 2013). The biological
mechanisms that could be governing these changes occurring in the timeframe of several
days and weeks following initial onset are not well understood. Given the delayed onset
of many pharmacological antidepressant treatments (Lam, 2012), the factors that mediate
neural circuit plasticity over longer time courses might be those most valuable for
treating psychiatric disease.

4.2. The role of PACAP in emotional behaviors
PACAP as a regulator of anxiety-like behaviors
The amygdala plays a principal role in assigning emotional salience to external
stimuli and coordinating the behavioral and physiological responses to these triggers. As
PACAP expression corresponds to a direct nociceptive input into the amygdala, this
suggests that CeA PACAP could have a role in modifying the attachment of emotional
salience to nociceptive stimuli. In agreement with this idea, we found CeA PACAP
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infusion produced an aversive emotional response, as reflected by an increase in anxietylike behaviors on the elevated plus maze (Figure 2.6). These findings are consistent with
two prior studies suggesting CeA PACAP signaling can produce negative/defensive
emotional behaviors. In the shock-probe fear/defensive burying task, rats are placed in
an arena with an electrified probe and allowed to explore freely. After freely
encountering the probe and receiving an electric shock, the resulting behavioral responses
are recorded and classified into stereotypical categories. CeA PACAP infusion created a
shift towards passive coping strategies characterized by increased immobility time and
avoidance, in contrast to active behavioral strategies like burying the probe with bedding
(Legradi et al., 2007). Another study, found that CeA PACAP signaling may also
regulate feeding behavior. Infusion of PACAP in the CeA produced a dose-dependent
decrease in food intake and resulted in weight loss through mechanisms that required
melanocortin and TrkB signaling (Iemolo et al., 2015). In aggregate, these data suggest
that CeA PACAP signaling appears produce an emotional state characterized by
increased passive behaviors, decreased exploratory behaviors, and hypophagia.
The role of CeA PACAP signaling should be interpreted in the context of the
neural circuitry of the larger extended amygdala complex that includes the BLA, CeA,
BNST, and other less studied regions, such as the substantia innominate. While the terms
fear and anxiety are often used interchangeably, on the basis of neural circuitry there may
be rationale for the separation of these into two distinct entities (Davis et al., 2010;
Walker et al., 2009). Within the extended amygdala, the CeA is thought to a have a
greater role in fear responses, which are short phasic responses, and likely best
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recapitulated in cued fear conditioning and fear-potentiated startle paradigms. On the
other hand, the BNST is thought to mediate responses primarily to longer-duration,
diffuse, or unpredictable threats, and which are more akin to anxiety. Paradigms such as
light or CRH-enhanced startle, and learned helplessness were found to be dependent on
BNST activity (Hammack et al., 2004; Davis et al., 2010; Walker et al., 2009). With this
interpretation it might suggest that the emotional responses found following CeA PACAP
might be related to ongoing fear behaviors or a decreased threshold in the generation of
the fear response. Detailed analysis of the behaviors of CeA PACAP on elevated plus
maze revealed that total locomotor activity was reduced; however this was not the result
of increased spontaneous freezing responses (a fear response), but rather a selective
decrease in the choice to enter the open arms. The traditional extended amygdala model
is complicated by the fact that previous studies have relied largely on lesion techniques,
where often the entire CeA was lesioned. In phasic fear responses, the CeM appears
critical as an output to brainstem targets to drive fear responses. The role CeLC and CeL
is less straightforward, although both areas have prominent projections to the CeM which
are thought to be important in the release of inhibitory signals on the CeM, to allow the
expression of fear behaviors through CeM to brainstem projections (Ciocchi et al., 2010;
Haubensak et al., 2010). Additionally prominent projections of the CeL and CeLC to the
BNST have been postulated to be important in the transition from phasic to sustained fear
(Walker et al., 2009). A population of CRH neurons within the CeL is the source of the
majority of CRH fiber immunoreactivity within the BNSTal, and CeA-BNST CRH
signaling within is thought to be a mediator of conditioned anxiety-like behaviors. As
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such, CeA PACAP could produce anxiety-like responses through enhanced neuronal
activation or CRH release in the BNST (Beckerman et al., 2013). Previous studies within
the PVH demonstrate that PACAP can drive CRH expression (Agarwal et al., 2005). In
the future, determining which neurons are being activated in the CeLC and CeL by
PACAP, and defining their projections will be crucial to understanding the role of
PACAP within these neural circuits and the extended amygdala.
One intriguing possibility is that CeA PACAP signaling could lead to plasticity
within fear circuitry that conveys the unconditioned stimulus (US). Compared to the
BLA, the contribution of the PBn in fear conditioning has been relatively unexplored;
however it has been recently found that following fear conditioning, there is a synaptic
potentiation of both BLA-CeLC and LPBn-CeLC pathways (Watabe et al., 2013). This
appears to be accomplished by both pre- and postsynaptic mechanisms. In addition, there
was a correlation between BLA-CeLC and LPBn-CeLC synaptic potentiation suggesting
a heterosynaptic interaction between these two pathways. In a follow up study,
inactivation of the LPBn during acquisition of fear conditioning decreased freezing to the
conditioned stimulus (CS) during testing. Further, optogenetic activation of LPBn-CeLC
projections could be paired with a tone and resulted in increased freezing to the
presentation upon presentation of the tone, suggesting that LPBn-CeLC activation could
effectively act as a US (Sato et al., 2015).
Given the presence of PACAP within LPBn-BNST projections, BNST PACAP
signaling might also have a role in the emotional components of pain, similar to CeA
PACAP. Our previous work has extensively characterized BNST PACAP as it relates to
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the behavioral and physiological consequences to chronic stress (Hammack et al. 2009;
Roman et al., 2014; Kocho-Schellengberg et al., 2014, Lezak et al., 2014). Situations of
chronic stress can potentiate pain experience, such as in stress-induced hyperalgesia
(McEwen & Kalia, 2010). Thus, during chronic stress the BNST might enhance pain
experience through direct or indirect influences on descending pathways to modulate
pain. Further, the existence of the ascending LPBn-BNST projections and that some of
these projections as collaterals of nociceptive LPBn-CeLC projections, suggests a
possible role for the BNST in ascending nociceptive modulation. Unlike the LPBn-CeA
projections, there have been sparse investigations into the contribution of LPBn-BNST
projections as they relate to nociception. An electrophysiological study of anesthetized
rats found that over a quarter of BNST neurons were excited by noxious stimulation, and
that this afferent pathway was not a result of indirect input from the amygdala (Casada &
Dafny, 1992).

PACAP signaling in pain-related behaviors
Since neuropathic pain increased PACAP expression in the CeLC, we wanted to
determine if this heightened PACAP signaling in the CeLC contributed to pain-related
behaviors. To examine this, the PACAP receptor antagonist PACAP6-38, a PAC1 and
VPAC2 receptor antagonist, was injected into the CeA following CCI to examine its
abilities to attenuate pain-induced hypersensitivity or emotional behaviors. The CCI
model has been shown to heighten anxio-depressive behaviors including anxiety-like
behaviors on the elevated plus maze and increased depressive behaviors in open field and
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forced swim tests (Roeska et al., 2008; Zeng et al., 2008). Fourteen days following
surgery, CeA infusion of PACAP6-38 was able to block heightened anxiety-like
behaviors in the open field in the CCI condition (Figure 3.3). There was no effect of
PACAP6-38 alone on rats with sham surgery, suggesting that ongoing CeA PACAP
signaling has a role in modulating behavior in the setting of pain, but does not modulate
behaviors under normal conditions. Similarly, CeA infusion of PACAP6-38 resulted in
an attenuation of thermal hypersensitivity in the CCI afflicted hindpaw, but did not alter
response latency for either the contralateral hindpaw, or for either hindpaws in the sham
condition (Figure 3.3). A lack of thermal sensitivity in either condition implies that CeA
PACAP signaling may modulate sensitivity in situations of persistent pain, but may not
alter thresholds under normal conditions. The selective involvement of PACAP in states
of persistent pain mimics the involvement of several neurotransmitter systems in the CeA
that selectively contribute to increased CeA activity during pain. Arthritic pain increased
expression of metabotropic glutamate receptor 1 (mGluR1) in the CeA; a selective
mGluR1 antagonist reduced synaptic transmission in the CeA from arthritic animals but
had no effect in the CeA of control animals (Neugebauer et al., 2003). Blockade of the
CGRP1 receptor in the CeA attenuated enhanced synaptic transmission from arthritic
animals, reducing EPSC amplitude and spike frequency, as well as attenuating
heightened spinal reflexes and ultrasonic vocalizations, but had no effect in control
animals (Han, et al., 2005). Thus, enhanced PACAP signaling might be one of a
collection of molecular and synaptic changes in the CeA during pain that influences painrelated behaviors.
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A mechanism of CeA PACAP signaling via ERK
Among intracellular signaling cascades, enhanced ERK signaling within the
CeLC appears to have prominent roles in pain-related plasticity. At 4 hours following
formalin injection into the hindpaw or 2 hours following acid-induced muscle pain, an
induction of pERK+ cells was found in the CeLC (Carrasquillo & Gereau, 2007; Cheng
et al., 2011). Consistent with these observations we found an increase in pERK+ cells in
the CeLC 14 days following CCI surgery (Figure 3.4). The induction of CeLC ERK
signaling in several different pain models signifies that ERK signaling is likely a pain
signature, and not a response to any one model. Additionally, the presence of increased
ERK signaling at 14 days following CCI would suggest that ongoing ERK signaling in
the CeA may be a component of persistent pain, rather than just part of the initial
plasticity.
Further, we found evidence that PACAP signaling may mediate CeLC ERK
activation. In cell culture, PACAP signaling in primary neuronal or HEK EGFP-PAC1R
cells results in potent and sustained ERK activation (May et al., 2010; May et al., 2014).
In examining the CeA from CCI rats, a majority of pERK+ cells were immediately
apposed to PACAP-immunoreactive fibers. CeA PACAP administration resulted in a
robust induction of pERK+ cells, demonstrating that CeA PACAP signaling activates
ERK in the amygdala neurons (Figure 3.5). Further, ERK activation was found to be
necessary for CeA PACAP to alter nociception, as pretreatment with a MEK inhibitor
abolished PACAP-induced thermal hypersensitivity. One remaining question is whether
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PACAP signaling is the sole mediator of pain-related activation of ERK. This appears
unlikely as several other candidates, including signaling through NMDA, mGluR, and
reactive oxygen species (ROS) have been found to contribute to ERK activation in the
CeLC (Cheng et al., 2011; Li, Ji, & Neugebauer, 2011). In this view, ERK signaling
appears to be a site of convergence for multiple signaling systems in the CeLC to allow
for diverse modulation and the dynamic regulation of amygdalar circuits.
One prominent mechanism through which PACAP may activate ERK is through
the internalization of PACAP receptors. Internalization of G-protein coupled receptors
(GPCRs) was once thought to be primarily a means of receptor desensitization; however,
more recent studies have suggested GPCR internalization may play a role in receptor
resensitization and even act as an alternative form of intracellular signaling (Ferguson,
2001; Sorkin & von Zastrow, 2009). The most common form of GPCR internalization of
signaling endosomes is dependent on the binding of β-arrestin scaffolds and the
formation of clathrin-coated pits, to result in a signaling endosome (Ferguson, 2001;
Sorkin & von Zastrow, 2009). Using an EGFP-PAC1 receptor cell line, PACAP/PAC1
receptor binding and signaling was shown to induce PAC1 receptor internalization, which
was inhibited by blocking either clathrin (Pitstop) or dynamin I/II (Dynasore) (Merriam
et al., 2013). Blocking internalization of the PAC1 receptor was found to strongly reduce
PACAP-mediated ERK activation. However, the induction of ERK signaling was not
completely blocked by inhibiting internalization, as a further reduction of ERK signaling
was affected by blocking phospholipase C/diacylglycerol/protein kinase C signaling.
These results demonstrate that PAC1 receptor-mediated ERK activation is accomplished
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via multiple mechanisms through both internalization/cytosolic signaling and plasma
membrane signaling (May et al., 2014). The current work extends these findings in vivo
and suggests that receptor internalization may occur with CeLC PACAP nociceptive
signaling. Blocking endocytosis by using the clathrin inhibitor, Pitstop, attenuated the
ability of PACAP to activate ERK in the CeA in parallel with a reduction in CeA
PACAP- induced thermal hypersensitivity (Figure 3.5). This is the first piece of evidence
to suggest that PACAP receptors may internalize in vivo and demonstrates a possible
functional role of this process. However, an important limitation in this line of studies is
that Pitstop is not selective to the PAC1 receptor and results in the global inhibition of
clarthrin-mediated endocytosis. However, as there were no changes between vehicle and
Pitstop-treated control animals that did not receive PACAP, it can be reasonably
concluded that clathrin-mediated endocytosis is required for CeA PACAP signaling to
fully induce pERK and behavioral hypersensitivity. To determine conclusively if this
was a direct effect of the PAC1 receptor would likely require the genetic modification to
generate a PAC1 receptor incapable of internalization. One possible role for PAC1
receptor internalization is that it may provide a mechanism to allow sustained ERK
activation. This would be consistent with the findings that in comparison to some other
neuropeptides, PACAP mediated effects have a more gradual onset but are much longer
in duration (Shimizu et al 2004) . As such, PACAP released in the CeA during chronic
pain might result in a prolonged excitability and heightened plasticity of CeA neurons
and lead to the strengthening of amygdalar nociceptive and emotional-salience circuits.
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One fundamental remaining question is whether CeA PACAP signaling is specific
to nociception. Recent experiments utilizing genetic circuit manipulations have resulted
in the hypothesis that specific subsets of amygdala neurons and their connections may not
encode specific modalities but rather encode a positive or negative emotional valence
(Namburi et al., 2015; Redondo et al., 2014). In this view, CeA PACAP signaling would
likely be a circuit carrying negative emotional valence, and nociceptive stimuli would be
one of numerous stimuli that result in PACAP release. Given that the vast majority of
CeA PACAP originates from the LPBn, the decisive factor would be determining the
modality of stimuli that activates the LPBn. Prior studies which suggest the existence of
amygdalar circuits for positive and negative valence have been focused on the BLA, a
region which receives highly polymodal and processed nociceptive information (Namburi
et al., 2015; Neugebauer et al., 2004; Redondo et al., 2014). The LPBn, in contrast,
receives direct nociceptive information from lamina I of the spinal cord and visceral
inputs from the NTS. The contrast between the input of BLA compared to the LPBn is
illustrated by its role in fear conditioning. The BLA is thought to receive afferents related
to both the US (electric shock) in combination with a host of other environmental sensory
information (light, tone, etc.). The PBn-CeLC projection is only thought to convey the
only the US (electric shock), likely due to aversive/nociceptive nature (Paré et al., 2004;
Sato et al., 2015). However, a recent study found that the CGRP expressing LPBn-CeLC
projections (which overlap with PACAP projections) can convey a visceral malaise
signal to strongly inhibit feeding behavior, such as those induced by lithium chloride
(Carter et al., 2015). Even though these results were argued not to reflect nociceptive
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activation, this was not tested directly (Carter et al., 2013). Regardless, CGRP LPBnCeLC activation can be regarded as a highly aversive interoceptive stimulus. Further, it
remains to be determined if inflammatory factors could also result in the activation of
LPBn-CeA circuits via the NTS. Although much remains to be determined, CeA PACAP
signaling may be encoding a negative valence that is associated with a subset of highly
aversive sensory stimuli.

4.3. Summary
PACAP has been well established as neuropeptide that regulates homeostatic
function. Several recent lines of research have demonstrated that PACAP signaling
potently activates both physiological and behavioral responses to stressors and that these
responses are likely due to PACAP signaling in limbic regions. Additionally, it had been
previously established that PACAP might have important roles in nociceptive
transmission and sensitization in peripheral systems. In this work, the role of PACAP in
nociceptive processes was found to extend centrally into limbic regions via the spinoparabrachio-amgydaloid pathway. Through this pathway, PACAP functions to potentiate
many of the emotional components of pain.
This work has several key limitations. The PBn was found to be a substantial
source of CeA PACAP, thus the effects of infusions of PACAP or PACAP(6-38) on both
pain and anxiety-related behaviors were attributed to nociceptive PBn-CeA projections.
However, it cannot be ruled out that PACAP signaling from sources other than the PBn
or locally within the amygdala could be contributing to these effects. Additionally, all
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infusions were performed bilaterally; however our results and others have suggested that
there may be a lateralization of the CeA in pain processing. Thus, comparisons of
injections into the left and right CeA could be performed to explore this area. A second
limitation comes from the use of hypersensitivity assessments to measure pain-related
behaviors. While hypersensitivity assessments may provide a well-used indicator of
evoked pain-responses, often a larger problem in chronic pain sufferers is the presence of
spontaneous pain. However, spontaneous pain often been particularily difficult to model
in rodents; hence careful design of experiments assessing spotaneous pain behaviors may
be needed to address these questions. Finally, while the Pitstop experiments suggest that
receptor internalization may be required for CeA PACAP-induced thermal
hypersentivity, the studies did not specifically address whether PAC1 receptor
internalization was the primary driver of the nociceptive effects or whether the response
was a consequence of other interacting receptor systems. Future experiments that
directly interfere with PAC1 receptor internalization would address this possibility.
The results of this work raise a number of important new questions. Heightened
levels of PACAP expression were observed 14 days following CCI in the LPBn-CeLC
pathway. The time course of induction and the exact nature of the challenge, whether it
is specific to pain or aversive stimuli, all remain to be determined. We found that the use
of PACAP-EGFP mice could offer a powerful tool for investigating these questions. The
recent creation of PACAP-Cre mice allows for a whole new set of investigations
examining circuit specific functions using optogenetic and pharmacogenetic
manipulations. The behavioral and physiological role of PACAPergic projections from
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the LPBn to the CeLC, BNST, and VMH can now be individually stimulated and
inhibited to allow characterization. PACAPegeric PBn-CeA projections can be directly
examined by injecting a virus containing a floxed channelrhodopsin directly into the PBn
of PACAP-Cre mice. By optogentically stimulating the terminals of CeA fibers, the
effects of activating only PACAP containing PBn-CeA projections can be examined for
its effects on pain and anxiety-related behaviors. In a similar manner, by inhibiting these
same fibers in a model of chronic pain, the contributions of the PBn-CeA projections can
be determined in pain-related behavioral changes. The use of PACAP-specific viral
tracting will allow for the deciphering of PACAP pain and stress circuits with better
prescision and resolution in future functional studies.
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4.4. Figures
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Figure 4.1. Schematic of known pain-related plasticity of PACAP expression within
the spino-parabrachioamygdaloid pathway
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Region
Amygdala

Compound
PACAP

PACAP(6-38)

Spinal Cord

PACAP

PACAP(6-38)
Sensory
Afferent Fibers

PACAP

Behavioral / physiological result
Thermal sensitivity (Missig et al., 2014)
Anxiety-like behavior (Missig et al., 2014)
Food intake (Iemolo et al., 2015)
Passive-behavior responding (shock-probe)
(Legradi et al., 2007)
Pain-induced thermal hypersensitivity
(unpublished observations)
Pain-induced anxiety-like behavior
(unpublished observations
Thermal sensitivity (Ohsawa et al. 2002)
Aversive licking/scratching behavior (Ohsawa
et al. 2002)
NMDA-induced nocifensive responses
(Ohsawa et al., 2002)
Tail flick sensitivity (late phase) (Narita et al.,
1996)
Multireceptive cell excitability (Dickinson et
al. 1997)
NMDA currents (Ohsawa et al., 2002)
Nocifensive responses to formalin (Ohsawa et
al. 2002)
Nocifensive responses to formalin (Sandor et
al., 2009)
Heat-injury induced thermal sensitivity
(Sandor et al., 2009)
Acetic acid-induced writhing behaviors
(Sandor et al., 2009)
n.c.Thermal / mechanical sensitivity (baseline)
(Sandor et al. 2009)
Activity of knee joint (Sandor et al. 2009)
n.c.: no change

Table 4.1. Summary of site-specific actions of PACAP or PACAP(6-38)

184

Comprehensive Bibliography

Adwanikar, H., Ji, G., Li, W., Doods, H., Willis, W. D., & Neugebauer, V. (2007). Spinal
CGRP1 receptors contribute to supraspinally organized pain behavior and painrelated sensitization of amygdala neurons. Pain, 132(1-2), 53-66.
Agarwal, A., Halvorson, L. M., & Legradi, G. (2005). Pituitary adenylate cyclaseactivating polypeptide (PACAP) mimics neuroendocrine and behavioral
manifestations of stress: Evidence for PKA-mediated expression of the
corticotropin-releasing hormone (CRH) gene. Brain Res Mol Brain Res, 138(1),
45-57. 	
  
Al-Khater, K. M., & Todd, A. J. (2009). Collateral projections of neurons in laminae I,
III, and IV of rat spinal cord to thalamus, periaqueductal gray matter, and lateral
parabrachial area. J Comp Neurol, 515(6), 629-646.
Alba-Delgado, C., Llorca-Torralba, M., Horrillo, I., Ortega, J. E., Mico, J. A., SanchezBlazquez, P., . . . Berrocoso, E. (2013). Chronic pain leads to concomitant
noradrenergic impairment and mood disorders. Biol Psychiatry, 73(1), 54-62.
Almli, L.M., Mercer, K.B., Kerley, K., Feng, H., Bradley, B., Conneely, K.N., Ressler,
K.J. (2013). ADCYAP1R1 genotype associates with post-traumatic stress
symptoms in highly traumatized African-American females. Am. J. Med. Genet. B
Neuro- psychiatr. Genet. 162B, 262-272.
Alheid, G. F. (2003). Extended amygdala and basal forebrain. Ann N Y Acad Sci, 985,
185-205.
Almeida, T. F., Roizenblatt, S., & Tufik, S. (2004). Afferent pain pathways: a
neuroanatomical review. Brain Research(1000), 40-56.
Apkarian, A. V., Bushnell, M. C., Treede, R. D., & Zubieta, J. K. (2005). Human brain
mechanisms of pain perception and regulation in health and disease. Eur J Pain,
9(4), 463-484.
Asmundson, G. J. G., & Katz, J. (2009). Understanding the co-occurrence of anxiety
disorders and chronic pain: state-of-the-art. Depress Anxiety., 26(10), 888-901.

185

Barrie, A. P., Clohessy, A. M., Buensuceso, C. S., Rogers, M. V., & Allen, J. M. (1997).
Pituitary adenylyl cyclase-activating peptide stimulates extracellular signalregulated kinase 1 or 2 (ERK1/2) activity in a Ras-independent, mitogen-activated
protein Kinase/ERK kinase 1 or 2-dependent manner in PC12 cells. J Biol Chem,
272(32), 19666-19671.
Basbaum, A. I., Bautista, D. M., Scherrer, G., & Julius, D. (2009). Cellular and
Molecular Mechanisms of Pain. Cell, 139(2), 267-284.
Beaudet, M. M., Braas, K. M., & May, V. (1998). Pituitary adenylate cyclase activating
polypeptide (PACAP) expression in sympathetic preganglionic projection neurons
to the superior cervical ganglion. J Neurobiol, 36(3), 325-336.
Beckerman, M. A., Van Kempen, T. A., Justice, N. J., Milner, T. A., & Glass, M. J.
(2013). Corticotropin-releasing factor in the mouse central nucleus of the
amygdala: ultrastructural distribution in NMDA-NR1 receptor subunit expressing
neurons as well as projection neurons to the bed nucleus of the stria terminalis.
Exp Neurol, 239, 120-132.
Bennett, G. J., & Xie, Y. K. (1988). A peripheral mononeuropathy in rat that produces
disorders of pain sensation like those seen in man. Pain, 33(1), 87-107.
Bernard, J. F., Bester, H., & Besson, J. M. (1996). Involvement of the spino-parabrachio amygdaloid and -hypothalamic pathways in the autonomic and affective
emotional aspects of pain. Prog Brain Res, 107, 243-255.
Bernard, J. F., Huang, G. F., & Besson, J. M. (1992). Nucleus centralis of the amygdala
and the globus pallidus ventralis: electrophysiological evidence for an
involvement in pain processes. J Neurophysiol, 68(2), 551-569.
Bird, G. C., Lash, L. L., Han, J. S., & Zou, X. (2005). Protein kinase A-dependent
enhanced NMDA receptor function in pain-related synaptic plasticity in rat
amygdala neurones. J Physiol, 564(3), 907-921.
Blechman, J., & Levkowitz, G. (2013). Alternative Splicing of the Pituitary Adenylate
Cyclase-Activating Polypeptide Receptor PAC1: Mechanisms of Fine Tuning of
Brain Activity. Front Endocrinol (Lausanne), 4, 55.
Bon, K., Lantéri-Minet, M., Michiels, J. F., & Menétrey, D. (1998). Cyclophosphamide
cystitis as a model of visceral pain in rats: a c-fos and Krox-24 study at
telencephalic levels, with a note on pituitary adenylate cyclase activating
polypeptide (PACAP). Experimental Brain Research, 122(2), 165-174.

186

Bonaz, B., Baciu, M., Papillon, E., Bost, R., Gueddah, N., Le Bas, J. F., . . . Segebarth, C.
(2002). Central processing of rectal pain in patients with irritable bowel
syndrome: an fMRI study. Am J Gastroenterol, 97(3), 654-661.
Bornhovd, K. (2002). Painful stimuli evoke different stimulus-response functions in the
amygdala, prefrontal, insula and somatosensory cortex: a single-trial fMRI study.
Brain, 125(6), 1326-1336.
Botz, B., Imreh, A., Sándor, K., Elekes, K., Szolcsányi, J., Reglodi, D., . . . Helyes, Z.
(2013). Role of Pituitary Adenylate-Cyclase Activating Polypeptide and Tac1
gene derived tachykinins in sensory, motor and vascular functions under normal
and neuropathic conditions. Peptides, 43, 105-112.
Bourgeais, L., Gauriau, C., & Bernard, J. F. (2001). Projections from the nociceptive area
of the central nucleus of the amygdala to the forebrain: a PHA-L study in the rat.
Eur J Neurosci, 14(2), 229-255.
Bouschet, T., Perez, V., Fernandez, C., Bockaert, J., Eychene, A., & Journot, L. (2003).
Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant
activation of Ras, protein kinase C, and protein kinase A in neuronal cells. J Biol
Chem, 278(7), 4778-4785.
Braas, K.M., May, V. (1999). Pituitary adenylate cyclase-activating polypeptides directly
stimulate sympathetic neuron NPY release through PAC1 receptor isoform
activation of specific intracellular signaling pathways. J. Biol. Chem. 274, 2770227710.
Braas, K. M., Schutz, K. C., Bond, J. P., Vizzard, M. A., & Girard, B. M. (2007).
Microarray analyses of pituitary adenylate cyclase activating polypeptide
(PACAP)-regulated gene targets in sympathetic neurons. Peptides.
Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006). Survey of
chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J
Pain, 10(4), 287-333.
Butler, R. K., & Finn, D. P. (2009). Stress-induced analgesia. Prog Neurobiol., 88(3),
184-202.
Carrasquillo, Y., & Gereau, R. W. (2007). Activation of the extracellular signal-regulated
kinase in the amygdala modulates pain perception. J Neurosci, 27(7), 1543-1551.
Carrasquillo, Y. & Gereau, R. W. (2008) Hemispheric lateralization of a molecular
signal for pain modulation in the amygdala. Mol Pain., 4, 24.
187

Carter, M. E., Han, S., & Palmiter, R. D. (2015). Parabrachial calcitonin gene-related
peptide neurons mediate conditioned taste aversion. J Neurosci, 35(11), 45824586.
Carter, M. E., Soden, M. E., Zweifel, L. S., & Palmiter, R. D. (2013). Genetic
identification of a neural circuit that suppresses appetite. Nature, 503(7474), 111114.
Casada, J. H., & Dafny, N. (1992). Evidence for two different afferent pathways carrying
stress-related information (noxious and amygdala stimulation) to the bed nucleus
of the stria terminalis. Brain Res, 579(1), 93-98.
Cassell, M.D., Gray, T.S., Kiss, J.Z. (1986). Neuronal architecture in the rat central
nucleus of the amygdala: a cytological, hodological, and immunocytochemical
study. J. Comp. Neurol., 246, 478-499.
Chen, W., Boutaoui, N., Brehm, J.M., Han, Y.Y., Schmitz, C., Cressley, A., AcostaPerez, E., Alvarez, M., Colon-Semidey, A., Baccarelli, A.A., Weeks, D.E., Kolls,
J.K., Canino, G., Celedo_n, J.C. (2013). ADCYAP1R1 and asthma in Puerto
Rican children. Am. J. Respir. Crit. Care Med., 187, 584-588.
Cheng, S.-J., Chen, C.-C., Yang, H.-W., Chang, Y.-T., Bai, S.-W., Chen, C.-C., . . . Min,
M.-Y. (2011). Role of extracellular signal-regulated kinase in synaptic
transmission and plasticity of a nociceptive input on capsular central amygdaloid
neurons in normal and acid-induced muscle pain mice. J Neurosci, 31(6), 22582270.
Cho, J.H., Zushida, K., Shumyatsky, G.P., Carlezon, W.A.J., Meloni, E.G., Bolshakov,
V.Y. (2012). Pituitary adenylate cyclase-activating polypeptide in- duces
postsynaptically expressed potentiation in the intra-amygdala circuit. J. Neurosci.
32, 14165-14177.
Chowdhury, D., Marco, S., Brooks, I. M., Zandueta, A., Rao, Y., Haucke, V., . . . PerezOtano, I. (2013). Tyrosine phosphorylation regulates the endocytosis and surface
expression of GluN3A-containing NMDA receptors. J Neurosci, 33(9), 41514164.
Ciocchi, S., Herry, C., Grenier, F., Wolff, S. B. E., Letzkus, J. J., Vlachos, I., . . . Lüthi,
A. (2010). Encoding of conditioned fear in central amygdala inhibitory circuits.
Nature, 468(7321), 277-282.
Coste, B., Mathur, J., Schmidt, M., Earley, T. J., Ranade, S., Petrus, M. J., . . .
Patapoutian, A. (2010). Piezo1 and Piezo2 are essential components of distinct
mechanically activated cation channels. Science, 330(6000), 55-60.
188

Cox, J. J., Reimann, F., Nicholas, A. K., Thornton, G., Roberts, E., Springell, K., . . .
Woods, C. G. (2006). An SCN9A channelopathy causes congenital inability to
experience pain. Nature, 444(7121), 894-898.
Cui, X.Y., Lundeberg, T., Yu, L.C. (2004). Role of corticotropin-releasing factor and its
receptor in nociceptive modulation in the central nucleus of amygdala in rats.
Brain Res. 995, 23-28.
Das, M., Vihlen, C.S., Legradi, G. (2007). Hypothalamic and brainstem sources of pituitary adenylate cyclase-activating polypeptide nerve fibers innervating the
hypothalamic paraventricular nucleus in the rat. J. Comp. Neurol., 500, 761-776.
Davis-Taber, R., Baker, S., Lehto, S. G., Zhong, C., Surowy, C. S., Faltynek, C. R., . . .
Honore, P. (2008). Central Pituitary Adenylate Cyclase 1 Receptors Modulate
Nociceptive Behaviors in Both Inflammatory and Neuropathic Pain States. J
Pain., 9(5), 449-456.
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010). Phasic vs sustained fear in rats
and humans: role of the extended amygdala in fear vs anxiety.
Neuropsychopharmacology, 35(1), 105-135.
Defrin, R., Ginzburg, K., Solomon, Z., Polad, E., Bloch, M., Govezensky, M., &
Schreiber, S. (2008). Quantitative testing of pain perception in subjects with
PTSD – Implications for the mechanism of the coexistence between PTSD and
chronic pain. Pain, 138(2), 450-459.
Delgado, M., Pozo, D., & Ganea, D. (2004). The significance of vasoactive intestinal
peptide in immunomodulation. Pharmacol Rev, 56(2), 249-290.
Demyttenaere, K., Bruffaerts, R., Lee, S., Posada-Villa, J., Kovess, V., Angermeyer, M.
C., . . . Von Korff, M. (2007). Mental disorders among persons with chronic back
or neck pain: Results from the world mental health surveys. Pain, 129(3), 332342.
Dickinson, T., & Fleetwood-Walker, S. M. (1999). VIP and PACAP: very important in
pain? Trends Pharmacol Sci., 20(8), 324-329.
Dickinson, T., Fleetwood-Walker, S. M., Mitchell, R., & Lutz, E. M. (1997). Evidence
for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase
activating polypeptide (PACAP) receptors in modulating the responses of rat
dorsal horn neurons to sensory inputs. Neuropeptides, 31(2), 175-185.

189

Dickinson, T., Mitchell, R., Robberecht, P., Fleetwood-Walker, S.M. (1999). The role of
VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an
experimental peripheral mononeuropathy. Neuropharmacology, 38, 167-180.
Dobner, P.R., 2006. Neurotensin and pain modulation. Peptides 27, 2405-2414.
Dobolyi, A., Irwin, S., Makara, G., Usdin, T. B., & Palkovits, M. (2005). Calcitonin
gene-related peptide-containing pathways in the rat forebrain. J Comp Neurol,
489(1), 92-119.
Dong, H. W., Petrovich, G. D., & Swanson, L. W. (2001). Topography of projections
from amygdala to bed nuclei of the stria terminalis. Brain Res Brain Res Rev,
38(1-2), 192-246.
Duvarci, S., & Pare, D. (2014). Amygdala microcircuits controlling learned fear. Neuron,
82(5), 966-980.
Ehrlich, I., Humeau, Y., Grenier, F., Ciocchi, S., Herry, C., & Lüthi, A. (2009).
Amygdala inhibitory circuits and the control of fear memory. Neuron, 62(6), 757771.
Engelund, A., Fahrenkrug, J., Harrison, A., & Hannibal, J. (2010). Vesicular glutamate
transporter 2 (VGLUT2) is co-stored with PACAP in projections from the rat
melanopsin-containing retinal ganglion cells. Cell Tissue Res, 340(2), 243-255.
Elsas, T., & White, L. R. (1997). Evidence for a possible synergism between pituitary
adenylate cyclase activating polypeptide and calcitonin gene-related peptide in
porcine ophthalmic artery. Acta Ophthalmol Scand, 75(2), 159-161.
Ferguson, S. S. (2001). Evolving concepts in G protein-coupled receptor endocytosis: the
role in receptor desensitization and signaling. Pharmacol Rev, 53(1), 1-24.
Flor, H., Fydrich, T., & Turk, D. C. (1992). Efficacy of multidisciplinary pain treatment
centers: a meta-analytic review. Pain, 49(2), 221-230.
Fu, Y. & Neugebauer, V. Differential mechanisms of CRF1 and CRF2 receptor functions
in the amygdala in pain-related synaptic facilitation and behavior (2008). J
Neurosci. 28, 3861-3876.
Fulwiler, C. E., & Saper, C. B. (1984). Subnuclear organization of the efferent
connections of the parabrachial nucleus in the rat. Brain Res, 319(3), 229-259.
Gaskin, D. J., & Richard, P. (2012). The economic costs of pain in the United States. J
Pain., 13(8), 715-724.
190

Gauriau, C., Bernard, J.F., (2002). Pain pathways and parabrachial circuits in the rat. Exp.
Physiol. 87, 251-258.
Gauriau, C., & Bernard, J.-F. (2004). Posterior triangular thalamic neurons convey
nociceptive messages to the secondary somatosensory and insular cortices in the
rat. J Neurosci, 24(3), 752-761.
Geuze, E., Westenberg, H. G. M., Jochims, A., de Kloet, C. S., Bohus, M., Vermetten, E.,
& Schmahl, C. (2007). Altered Pain Processing in Veterans With Posttraumatic
Stress Disorder. Arch Genl Psychiatry., 64(1), 76-85.
Girard, B. A., Lelievre, V., Braas, K. M., Razinia, T., Vizzard, M. A., Ioffe, Y., . . .
Victor, M. (2006). Noncompensation in peptide/receptor gene expression and
distinct behavioral phenotypes in VIP- and PACAP-deficient mice. J Neurochem.,
99(2), 499-513.
Goncalves, L., Silva, R., Pinto-Ribeiro, F., Pego, J. M., Bessa, J. M., Pertovaara, A., . . .
Almeida, A. (2008). Neuropathic pain is associated with depressive behaviour and
induces neuroplasticity in the amygdala of the rat. Exp Neurol, 213(1), 48-56.
Guo, Z., Zhao, C., Huang, M., Huang, T., Fan, M., Xie, Z., . . . Cheng, L. (2012). Tlx1/3
and Ptf1a Control the Expression of Distinct Sets of Transmitter and Peptide
Receptor Genes in the Developing Dorsal Spinal Cord. J Neurosci, 32(25), 85098520.
Hammack, S. E., Cheung, J., Rhodes, K. M., Schutz, K. C., Falls, W. A., Braas, K. M., &
May, V. (2009). Chronic stress increases pituitary adenylate cyclase-activating
peptide (PACAP) and brain-derived neurotrophic factor (BDNF) mRNA
expression in the bed nucleus of the stria terminalis (BNST): roles for PACAP in
anxiety-like behavior. Psychoneuroendocrinology, 34(6), 833-843.
Hammack,	
  S.	
  E.	
  &	
  May,	
  V.	
  (2015)	
  Pituitary	
  adenylate	
  cyclase	
  activating	
  polypeptide	
  
in	
  stress-‐related	
  disorders:	
  data	
  convergence	
  from	
  animal	
  and	
  human	
  
studies.	
  Biol	
  Psychiatry,	
  78(3):	
  167-‐177.	
  	
  
	
  
Hammack, S. E., Richey, K. J., Watkins, L. R., & Maier S. F. (2004). Chemical lesion of
the bed nucleus of the stria terminalis blocks the behavioral consequences of
uncontrollable stress. Behav Neurosci, 118(2), 443-448.
Han, J. S., Adwanikar, H., Li, Z., Ji, G., & Neugebauer, V. (2010). Facilitation of
synaptic transmission and pain responses by CGRP in the amygdala of normal
rats. Mol Pain, 6, 10.
191

Han, J. S., Li, W., & Neugebauer, V. (2005). Critical Role of Calcitonin Gene-Related
Peptide 1 Receptors in the Amygdala in Synaptic Plasticity and Pain Behavior. J.
Neurosci., 25(46), 10717-10728.
Hannibal, J. (2002). Pituitary adenylate cyclase-activating peptide in the rat central
nervous system: An immunohistochemical and in situ hybridization study. J
Comp Neurol., 453(4), 389-417.
Hannibal, J., Mikkelsen, J. D., Fahrenkrug, J., & Larsen, P. J. (1995). Pituitary adenylate
cyclase-activating peptide gene expression in corticotropin-releasing factorcontaining parvicellular neurons of the rat hypothalamic paraventricular nucleus
is induced by colchicine, but not by adrenalectomy, acute osmotic, ether, or
restraint stress. Endocrinology, 136(9), 4116-4124.
Hannibal, J., Moller, M., Ottersen, O. P., & Fahrenkrug, J. (2000). PACAP and glutamate
are co-stored in the retinohypothalamic tract. J Comp Neurol, 418(2), 147-155.
Harmar, A.J., Fahrenkrug, J., Gozes, I., Laburthe, M., May, V., Pisegna, J.R., Vaudry, D.,
Vaudry, H., Waschek, J.A., Said, S.I. (2012). Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclaseactivating polypeptide: IUPHAR review 1. Br. J. Pharmacol., 166, 4-17.
Hashimoto, H. (2006). New Insights into the Central PACAPergic System from the
Phenotypes in PACAP- and PACAP Receptor-Knockout Mice. Annal N Y Acad
Sci., 1070(1), 75-89.
Hashimoto, H., Shintani, N., Tanaka, K., Mori, W., Hirose, M., Matsuda, T., . . . Baba, A.
(2001). Altered psychomotor behaviors in mice lacking pituitary adenylate
cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci U S A., 98(23),
13355-13360.
Hattori, S., Takao, K., Tanda, K., Toyama, K., Shintani, N., Baba, A., . . . Miyakawa, T.
(2012). Comprehensive behavioral analysis of pituitary adenylate cyclaseactivating polypeptide (PACAP) knockout mice. Front Behav Neurosci, 6, 58.
Hawke, Z., Ivanov, T.R., Bechtold, D.A., Dhillon, H., Lowell, B.B., Luckman, S.M.
(2009). PACAP neurons in the hypothalamic ventromedial nucleus are targets of
central leptin signaling. J. Neurosci., 29, 14828-14835.
Haubensak, W., Kunwar, P. S., Cai, H., Ciocchi, S., Wall, N. R., Ponnusamy, R., . . .
Anderson, D. J. (2010). Genetic dissection of an amygdala microcircuit that gates
conditioned fear. Nature, 468(7321), 270-276.

192

Huang, G. F., Besson, J. M., & Bernard, J. F. (1993). Morphine depresses the
transmission of noxious messages in the spino(trigemino)-ponto-amygdaloid
pathway. Eur J Pharmacol, 230(3), 279-284.
Hughes, D. I., Scott, D. T., Todd, A. J., & Riddell, J. S. (2003). Lack of evidence for
sprouting of Abeta afferents into the superficial laminas of the spinal cord dorsal
horn after nerve section. J Neurosci, 23(29), 9491-9499.
Iemolo, A., Ferragud, A., Cottone, P., & Sabino, V. (2015). Pituitary Adenylate CyclaseActivating Peptide in the Central Amygdala Causes Anorexia and Body Weight
Loss via the Melanocortin and the TrkB Systems. Neuropsychopharmacology,
40(8), 1846-1855.
Ikeda, R., Takahashi, Y., Inoue, K., & Kato, F. (2007). NMDA receptor-independent
synaptic plasticity in the central amygdala in the rat model of neuropathic pain.
Pain, 127(1-2), 161-172.
Jasmin, L., Wang, H., Tarczy-Hornoch, K., Levine, J. D., & Basbaum, A. I. (1994).
Differential effects of morphine on noxious stimulus-evoked fos-like
immunoreactivity in subpopulations of spinoparabrachial neurons. J Neurosci,
14(12), 7252-7260.
Ji, G., Fu, Y., Adwanikar, H., Neugebauer, V. (2013). Non-pain-related CRF1 activation
in the amygdala facilitates synaptic transmission and pain responses. Mol. Pain 9, 2.
Ji, G., Neugebauer, V. (2009). Hemispheric lateralization of pain processing by amygdala
neurons. J. Neurophysiol., 102, 2253-2264.
Ji, R. R., Gereau IV, R. W., Malcangio, M., & Strichartz, G. R. (2009). MAP kinase and
pain. Brain Res Rev., 60(1), 135-148.
Ji, R. R., Baba, H., Brenner, G. J., & Woolf, C. J. (1999). Nociceptive-specific activation
of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci,
2(12), 1114-1119.
Jin, W.Y., Liu, Z., Liu, D., Yu, L.C. (2010). Antinociceptive effects of galanin in the
central nucleus of amygdala of rats, an involvement of opioid receptors. Brain Res.,
1320, 16-21.
Jongsma, H., Danielsen, N., Sundler, F., & Kanje, M. (2000). Alteration of PACAP
distribution and PACAP receptor binding in the rat sensory nervous system
following sciatic nerve transection. Brain Research, 853(2), 186-196.

193

Jongsma, H., Pettersson, L. M., Zhang, Y., Reimer, M. K., Kanje, M., Waldenström,
A., . . . Danielsen, N. (2001). Markedly reduced chronic nociceptive response in
mice lacking the PAC1 receptor. Neuroreport, 12(10), 2215-2219.
Jongsma Wallin, H., Pettersson, L. M., Verge, V. M., & Danielsen, N. (2003). Effect of
anti-nerve growth factor treatment on pituitary adenylate cyclase activating
polypeptide expression in adult sensory neurons exposed to adjuvant induced
inflammation. Neuroscience, 120(2), 325-331.
Jovanovic,	
  T.	
  et	
  al.	
  PAC1	
  receptor	
  (ADCYAP1R1)	
  genotype	
  is	
  associated	
  with	
  dark-‐
enhanced	
  startle	
  in	
  children	
  (2013).	
  Mol	
  Psychiatry,	
  18,	
  742-‐743.
Kammermeier, P. J. (2008). Endogenous homer proteins regulate metabotropic glutamate
receptor signaling in neurons. J Neurosci, 28(34), 8560-8567.
Kemppainen, S., & Pitkanen, A. (2000). Distribution of parvalbumin, calretinin, and
calbindin-D(28k) immunoreactivity in the rat amygdaloid complex and
colocalization with gamma-aminobutyric acid. J Comp Neurol, 426(3), 441-467.
Klüver, H, Bucy, P.C. (1937). "Psychic blindness" and other symptoms following
bilateral temporal lobectomy in rhesus monkeys. Am. J. Physiol., 119, 352-353.
Kocho-Schellenberg, M., Lezak, K. R., Harris, O. M., Roelke, E., Gick, N., Choi, I., . . .
Hammack, S. E. (2014). Pituitary Adenylate Cyclase Activating Peptide
(PACAP) in the Bed Nucleus of the Stria Terminalis (BNST) Produces Anorexia
and Weight Loss in Male and Female Rats. Neuropsychopharmacology, 39, 16141623.
Kocorowski, L. H., & Helmstetter, F. J. (2001). Calcitonin gene-related peptide released
within the amygdala is involved in Pavlovian auditory fear conditioning.
Neurobiology of Learning and Memory, 75(2), 149-163.
Koob, G.F., Heinrichs, S.C. (1999). A role for corticotropin releasing factor and urocortin
in behavioral responses to stressors. Brain Res., 848, 141-152.
Kozicz, T., Vigh, S., & Arimura, A. (1998). The source of origin of PACAP- and VIPimmunoreactive fibers in the laterodorsal division of the bed nucleus of the stria
terminalis in the rat. Brain Research, 810(1-2), 211-219.
Kroenke, K., & Price, R. K. (1993). Symptoms in the community. Prevalence,
classification, and psychiatric comorbidity. Arch Intern Med, 153(21), 2474-2480.

194

Kulkarni, B., Bentley, D. E., Elliott, R., Julyan, P. J., Boger, E., Watson, A., . . . Jones, A.
K. (2007). Arthritic pain is processed in brain areas concerned with emotions and
fear. Arthritis Rheum., 56(4), 1345-1354.
Lam, R. W. (2012). Onset, time course and trajectories of improvement with
antidepressants. Eur Neuropsychopharmacol, 22 Suppl 3, S492-498.
Latremoliere, A., & Woolf, C. J. (2009). Central sensitization: a generator of pain
hypersensitivity by central neural plasticity. J Pain., 10(9), 895-926.
Lee, Y., Davis, M. (1997). Role of the hippocampus, the bed nucleus of the stria terminalis, and the amygdala in the excitatory effect of corticotropin-releasing
hormone on the acoustic startle reflex. J. Neurosci., 17, 6434-6446.
Ledoux, J. E., (2000). Emotion circuits in the brain. Annu. Rev. Neurosci., 23, 155-184.
Lehmann, M. L., Mustafa, T., Eiden, A. M., Herkenham, M. & Eiden, L. E. PACAPdeficient mice show attenuated corticosterone secretion and fail to develop
depressive behavior during chronic social defeat stress (2013)
Psychoneuroendocrinology, 38, 702-715.
Legradi, G., Das, M., Giunta, B., Hirani, K., Mitchell, E. A., & Diamond, D. M. (2007).
Microinfusion of pituitary adenylate cyclase-activating polypeptide into the
central nucleus of amygdala of the rat produces a shift from an active to passive
mode of coping in the shock-probe fear/defensive burying test. Neural plasticity,
2007, 79102.
Lezak, K. R., Roelke, E., Harris, O. M., Choi, I., Edwards, S., Gick, N., . . . Hammack, S.
E. (2014). Pituitary adenylate cyclase-activating polypeptide (PACAP) in the bed
nucleus of the stria terminalis (BNST) increases corticosterone in male and
female rats. Psychoneuroendocrinology, 45, 11-20.
Lezak, K. R., Roman, C. W., Braas, K. M., Schutz, K. C., Falls, W. A., Schulkin, J., . . .
Hammack, S. E. (2014). Regulation of Bed Nucleus of the Stria Terminalis
PACAP Expression by Stress and Corticosterone. J Mol Neurosci., 54(3), 477484.
Li, J., Hou, B., Tumova, S., Muraki, K., Bruns, A., Ludlow, M. J., . . . Beech, D. J.
(2014). Piezo1 integration of vascular architecture with physiological force.
Nature, 515(7526), 279-282.

195

Li, Z., Ji, G., & Neugebauer, V. (2011). Mitochondrial reactive oxygen species are
activated by mGluR5 through IP3 and activate ERK and PKA to increase
excitability of amygdala neurons and pain behavior. J Neurosci, 31(3), 11141127.
Lu, Y. C., Chen, Y. Z., Wei, Y. Y., He, X. T., Li, X., Hu, W., . . . Dong, Y. L. (2015).
Neurochemical properties of the synapses between the parabrachial nucleusderived CGRP-positive axonal terminals and the GABAergic neurons in the
lateral capsular division of central nucleus of amygdala. Mol Neurobiol, 51(1),
105-118.
Mabuchi, T., Shintani, N., & Matsumura, S. (2004). Pituitary adenylate cyclaseactivating polypeptide is required for the development of spinal sensitization and
induction of neuropathic pain. J Neurosci., 24(33), 7283-7291.
Macdonald, D. S., Weerapura, M., Beazely, M. A., Martin, L., Czerwinski, W., Roder, J.
C., . . . MacDonald, J. F. (2005). Modulation of NMDA receptors by pituitary
adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein
kinase C, and activation of Src. J Neurosci, 25(49), 11374-11384.
Makino, S., Shibasaki, T., Yamauchi, N., Nishioka, T., Mimoto, T., Wakabayashi, I.,
Gold, P.W., Hashimoto, K. (1999). Psychological stress increased corticotropinreleasing hormone mRNA and content in the central nucleus of the amygdala but
not in the hypothalamic paraventricular nucleus in the rat. Brain Res., 850, 136143.
Mannion, R. J., Doubell, T. P., Coggeshall, R. E., & Woolf, C. J. (1996). Collateral
sprouting of uninjured primary afferent A-fibers into the superficial dorsal horn of
the adult rat spinal cord after topical capsaicin treatment to the sciatic nerve. J
Neurosci, 16(16), 5189-5195.
Martin, M., Otto, C., Santamarta, M. T., Torrecilla, M., Pineda, J., Schutz, G., &
Maldonado, R. (2003). Morphine withdrawal is modified in pituitary adenylate
cyclase-activating polypeptide type I-receptor-deficient mice. Brain Res Mol
Brain Res, 110(1), 109-118.
May, V., Beaudet, M. M., Parsons, R. L., Hardwick, J. C., Gauthier, E. A., Durda, J. P.,
& Braas, K. M. (1998). Mechanisms of pituitary adenylate cyclase activating
polypeptide (PACAP)-induced depolarization of sympathetic superior cervical
ganglion (SCG) neurons. Ann N Y Acad Sci., 865, 164-175.

196

May, V., Buttolph, T. R., Girard, B. M., Clason, T. A., & Parsons, R. L. (2014). PACAPinduced ERK activation in HEK cells expressing PAC1 receptors involves both
receptor internalization and PKC signaling. Am J Physiol Cell Physiol, 306(11),
C1068-C1079.
May, V., Lutz, E., MacKenzie, C., Schutz, K. C., Dozark, K., & Braas, K. M. (2010).
Pituitary adenylate cyclase-activating polypeptide (PACAP)/PAC1HOP1 receptor
activation coordinates multiple neurotrophic signaling pathways: Akt activation
through phosphatidylinositol 3-kinase gamma and vesicle endocytosis for
neuronal survival. J Biol Chem, 285(13), 9749-9761.
May, V., & Vizzard, M. A. (2010). Bladder dysfunction and altered somatic sensitivity in
PACAP-/- mice. J Urol., 183(2), 772-779.
McEwen, B. S., & Kalia, M. (2010). The role of corticosteroids and stress in chronic pain
conditions. Metabolism, 59, S9-S15.
McCoy, E. S., Taylor-Blake, B., Street, S. E., Pribisko, A. L., Zheng, J., & Zylka, M. J.
(2013). Peptidergic CGRPα primary sensory neurons encode heat and itch and
tonically suppress sensitivity to cold. Neuron, 78(1), 138-151.
McWilliams, L. A., Cox, B. J., & Enns, M. W. (2003). Mood and anxiety disorders
associated with chronic pain: an examination in a nationally representative
sample. Pain, 106(1-2), 127-133.
McWilliams, L. A., Goodwin, R. D., & Cox, B. J. (2004). Depression and anxiety
associated with three pain conditions: results from a nationally representative
sample. Pain, 111(1-2), 77-83.
Merighi, A. (2002). Costorage and coexistence of neuropeptides in the mammalian CNS.
Prog Neurobiol, 66(3), 161-190.
Merriam, L. A., Baran, C. N., Girard, B. M., Hardwick, J. C., May, V., & Parsons, R. L.
(2013). Pituitary Adenylate Cyclase 1 Receptor Internalization and Endosomal
Signaling Mediate the Pituitary Adenylate Cyclase Activating PolypeptideInduced Increase in Guinea Pig Cardiac Neuron Excitability. J Neurosci., 33(10),
4614-4622.
Missig, G., Roman, C. W., Vizzard, M. A., Braas, K. M., Hammack, S. E., & May, V.
(2014). Parabrachial nucleus (PBn) pituitary adenylate cyclase activating
polypeptide (PACAP) signaling in the amygdala: implication for the sensory and
behavioral effects of pain. Neuropharmacology, 86, 38-48.

197

Miyata, A., Arimura, A., Dahl, R. R., Minamino, N., Uehara, A., Jiang, L., . . . Coy, D.
H. (1989). Isolation of a novel 38 residue-hypothalamic polypeptide which
stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun.,
164(1), 567-574.
Moller, K., Reimer M., Ekblad, E., Hannibal J., Fahrenkrug, J., Kanje M., Sundler, F.
(1997) The effects of axotomy and preganglionic denervation on the expression of
pituitary adenylate cyclase activating peptide (PACAP), galanin and PACAP type
1 receptors in the rat superior cervical ganglion. Brain Res., 775(1-2), 166-182.
Moller, K., Zhang, Y. Z., Hakanson, R., Luts, A., Sjolund, B., Uddman, R., & Sundler, F.
(1993). Pituitary adenylate cyclase activating peptide is a sensory neuropeptide:
immunocytochemical and immunochemical evidence. Neuroscience, 57(3), 725732.
Morano, T.J., Bailey, N.J., Cahill, C.M., Dumont, E.C. (2008). Nuclei- and conditionspecific responses to pain in the bed nucleus of the stria terminalis. Prog. NeuroPsychopharmacol. Biol. Psychiatry, 32, 643-650.
Mulder, H., Jongsma, H., Zhang, Y., Gebre-Medhin, S., Sundler, F., & Danielsen, N.
(1999). Pituitary adenylate cyclase-activating polypeptide and islet amyloid
polypeptide in primary sensory neurons. Mol. Neurobio., 19(3), 229-253.
Mulder, H., Uddman, R., Moller, K., Zhang, Y. Z., Ekblad, E., Alumets, J., & Sundler, F.
(1994). Pituitary adenylate cyclase activating polypeptide expression in sensory
neurons. Neuroscience, 63(1), 307-312.
Mustafa, T., Jiang, S. Z., Eiden, A. M., Weihe, E., Thistlethwaite, I., & Eiden, L. E.
(2015). Impact of PACAP and PAC1 receptor deficiency on the neurochemical
and behavioral effects of acute and chronic restraint stress in male C57BL/6 mice.
Stress, 1-11.
Nagahama, M., Tsuzuki, M., Mochizuki, T., Iguchi, K., & Kuwahara, A. (1998). Light
and electron microscopic studies of pituitary adenylate cyclase-activating peptide
(PACAP)--immunoreactive neurons in the enteric nervous system of rat small and
large intestine. Anat Embryol (Berl), 198(5), 341-352.
Nakagawa, T., Katsuya, A., Tanimoto, S., Yamamoto, J., Yamauchi, Y., Minami, M., &
Satoh, M. (2003). Differential patterns of c-fos mRNA expression in the
amygdaloid nuclei induced by chemical somatic and visceral noxious stimuli in
rats. Neurosci Lett, 344(3), 197-200.
198

Namburi, P., Beyeler, A., Yorozu, S., Calhoon, G. G., Halbert, S. A., Wichmann, R., . . .
Tye, K. M. (2015). A circuit mechanism for differentiating positive and negative
associations. Nature, 520(7549), 675-678.
Narita, M., Dun, S. L., Dun, N. J., & Tseng, L. F. (1996). Hyperalgesia induced by
pituitary adenylate cyclase-activating polypeptide in the mouse spinal cord. Eur J
Pharmacol., 311(2-3), 121-126.
Nemeth, J., Reglodi, D., Pozsgai, G., Szabo, A., Elekes, K., Pinter, E., . . . Helyes, Z.
(2006). Effect of pituitary adenylate cyclase activating polypeptide-38 on sensory
neuropeptide release and neurogenic inflammation in rats and mice.
Neuroscience, 143(1), 223-230.
Neugebauer, V., & Li, W. (2002). Processing of nociceptive mechanical and thermal
information in central amygdala neurons with knee-joint input. J Neurophysiol.,
87(1), 103-112.
Neugebauer, V., Li, W., (2003). Differential sensitization of amygdala neurons to afferent
inputs in a model of arthritic pain. J. Neurophysiol., 89, 716-727.
Neugebauer, V., Li, W., Bird, G. C., Bhave, G., & Gereau, R. W. (2003). Synaptic
Plasticity in the Amygdala in a Model of Arthritic Pain: Differential Roles of
Metabotropic Glutamate Receptors 1 and 5. J Neurosci., 23(1), 52-63.
Neugebauer, V., Li, W., Bird, G. C., & Han, J. S. (2004). The Amygdala and Persistent
Pain. Neuroscientist, 10(3), 221-234.
Norman, S. B., Stein, M. B., & Dimsdale, J. E. (2008). Pain in the aftermath of trauma is
a risk factor for post-traumatic stress disorder. Psychol Med., 38(4), 533-542.
Obata, K., Yamanaka, H., Dai, Y., Tachibana, T., Fukuoka, T., Tokunaga, A., . . .
Noguchi, K. (2003). Differential activation of extracellular signal-regulated
protein kinase in primary afferent neurons regulates brain-derived neurotrophic
factor expression after peripheral inflammation and nerve injury. J Neurosci,
23(10), 4117-4126.
Ohsawa, M., Brailoiu, G. C., Shiraki, M., Dun, N. J., Paul, K., & Tseng, L. F. (2002).
Modulation of nociceptive transmission by pituitary adenylate cyclase activating
polypeptide in the spinal cord of the mouse. Pain, 100(1-2), 27-34.
Paré, D., Quirk, G. J., & Ledoux, J. E. (2004). New vistas on amygdala networks in
conditioned fear. Journal of Neurophysiology, 92(1), 1-9.

199

Petrovic, P., Ingvar, M., Stone-Elander, S., Petersson, K. M., & Hansson, P. (1999). A
PET activation study of dynamic mechanical allodynia in patients with
mononeuropathy. Pain, 83(3), 459-470.
Petrovich, G. D., & Swanson, L. W. (1997). Projections from the lateral part of the
central amygdalar nucleus to the postulated fear conditioning circuit. Brain Res.,
763(2), 247-254.
Pettersson, L. M., Dahlin, L. B., & Danielsen, N. (2004). Changes in expression of
PACAP in rat sensory neurons in response to sciatic nerve compression. Eur J
Neurosci, 20(7), 1838-1848.
Pettersson, L. M. E., Heine, T., Verge, V. M. K., Sundler, F., & Danielsen, N. (2004).
PACAP mRNA is expressed in rat spinal cord neurons. J Comp Neurol, 471(1),
85-96.
Phifer, J., Skelton, K., Weiss, T., Schwartz, A. C., & Wingo, A. (2011). Pain
symptomatology and pain medication use in civilian PTSD. Pain, 152(10), 22332240.
Piggins, H. D., Stamp, J. A., Burns, J., Rusak, B., & Semba, K. (1996). Distribution of
pituitary adenylate cyclase activating polypeptide (PACAP) immunoreactivity in
the hypothalamus and extended amygdala of the rat. J Comp Neurol, 376(2), 278294.
Pohlack, S. T., Nees, F., Ruttorf, M., Cacciaglia, R., Winkelmann, T., Schad, L. R., . . .
Flor, H. (2015). Neural Mechanism of a Sex-Specific Risk Variant for
Posttraumatic Stress Disorder in the Type I Receptor of the Pituitary Adenylate
Cyclase Activating Polypeptide. Biol Psychiatry. doi:
10.1016/j.biopsych.2014.12.018
Ranade, S. S., Woo, S. H., Dubin, A. E., Moshourab, R. A., Wetzel, C., Petrus, M., . . .
Patapoutian, A. (2014). Piezo2 is the major transducer of mechanical forces for
touch sensation in mice. Nature, 516(7529), 121-125.
Redondo, R. L., Kim, J., Arons, A. L., Ramirez, S., Liu, X., & Tonegawa, S. (2014).
Bidirectional switch of the valence associated with a hippocampal contextual
memory engram. Nature, 513(7518), 426-430.
Ren, W. & Neugebauer, V. (2010). Pain-related increase of excitatory transmission and
decrease of inhibitory transmission in the central nucleus of the amygdala are
mediated by mGluR1. Mol Pain., 6, 93.

200

Resch, J. M., Boisvert, J. P., Hourigan, A. E., Mueller, C. R., Yi, S. S., & Choi, S. (2011).
Stimulation of the hypothalamic ventromedial nuclei by pituitary adenylate
cyclase-activating polypeptide induces hypophagia and thermogenesis. Am J
Physiol Regul Integr Comp Physiol, 301(6), R1625-1634.
Resch, J. M., Maunze, B., Gerhardt, A. K., Magnuson, S. K., Phillips, K. A., & Choi, S.
(2013). Intrahypothalamic pituitary adenylate cyclase-activating polypeptide
regulates energy balance via site-specific actions on feeding and metabolism.
American journal of physiology. Endocrinology and metabolism, 305(12), E14521463.
Ressler, K. J., Mercer, K. B., Bradley, B., Jovanovic, T., Mahan, A., Kerley, K., . . . May,
V. (2011). Post-traumatic stress disorder is associated with PACAP and the PAC1
receptor. Nature, 470(7335), 492-497.
Robinson, D.A., Wei, F., Wang, G.D., Li, P., Kim, S.J., Vogt, S.K., Muglia, L.J., Zhuo,
M. (2002). Oxytocin mediates stress-induced analgesia in adult mice. J. Physiol.,
540, 593-606.
Roeska, K., Doods, H., Arndt, K., Treede, R.-D., & Ceci, A. (2008). Anxiety-like
behaviour in rats with mononeuropathy is reduced by the analgesic drugs
morphine and gabapentin. Pain, 139(2), 349-357.
Roman, C. W., Lezak, K. R., Hartsock, M. J., Falls, W. A., Braas, K. M., Howard, A.
B., . . . May, V. (2014). PAC1 receptor antagonism in the bed nucleus of the stria
terminalis (BNST) attenuates the endocrine and behavioral consequences of
chronic stress. Psychoneuroendocrinology, 47, 151-165.
Rouwette, T., Vanelderen, P., de Reus, M., Loohuis, N. O., Giele, J., van Egmond, J., . . .
Kozicz, T. (2012). Experimental neuropathy increases limbic forebrain CRF. Eur
J Pain, 16(1), 61-71.
Sah, P., Faber, E. S. L., Armentia, M. L. D., & Power, J. (2003). The Amygdaloid
Complex: Anatomy and Physiology. Physiol Rev., 83(3), 803-834.
Sakashita, Y., Kurihara, T., Uchida, D., Tatsuno, I., & Yamamoto, T. (2001).
Involvement of PACAP receptor in primary afferent fibre-evoked responses of
ventral roots in the neonatal rat spinal cord. Br J Pharmacol, 132(8), 1769-1776.
Sándor, K., Bölcskei, K., McDougall, J. J., Schuelert, N., Reglodi, D., Elekes, K., . . .
Helyes, Z. (2009). Divergent peripheral effects of pituitary adenylate cyclaseactivating polypeptide-38 on nociception in rats and mice. Pain, 141(1-2), 143150.
201

Sándor, K., Kormos, V., Botz, B., Imreh, A., Bölcskei, K., Gaszner, B., . . . Helyes, Z.
(2010). Impaired nocifensive behaviours and mechanical hyperalgesia, but
enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide
deficient mice. Neuropeptides, 44(5), 363-371.
Saper, C. B., Romanovsky, A. A., & Scammell, T. E. (2012). Neural circuitry engaged by
prostaglandins during the sickness syndrome. Nat Neurosci, 15(8), 1088-1095.
Sarhan, M., Freund-Mercier, M.-J., & Veinante, P. (2005). Branching patterns of
parabrachial neurons projecting to the central extended amgydala: single axonal
reconstructions. J Comp Neurol, 491(4), 418-442.
Sato, M., Ito, M., Nagase, M., Sugimura, Y. K., Takahashi, Y., Watabe, A. M., & Kato,
F. (2015). The lateral parabrachial nucleus is actively involved in the acquisition
of fear memory in mice. Mol Brain, 8(1), 22.
Schmidt, S. D., Myskiw, J. C., Furini, C. R., Schmidt, B. E., Cavalcante, L. E., &
Izquierdo, I. (2015). PACAP modulates the consolidation and extinction of the
contextual fear conditioning through NMDA receptors. Neurobiol Learn Mem,
118, 120-124.
Schneider, C.A., Rasband, W.S., Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years
of image analysis. Nat. Methods, 9, 671-675.
Scioli-Salter, E. R., Forman, D. E., Otis, J. D., Gregor, K., Valovski, I., & Rasmusson, A.
M. (2015). The shared neuroanatomy and neurobiology of comorbid chronic pain
and PTSD: therapeutic implications. Clin J Pain, 31(4), 363-374.
Sherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000). The origin and function of the
pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon
superfamily. Endocr Rev., 21(6), 619-670.
Shi, C., & Davis, M. (1999). Pain pathways involved in fear conditioning measured with
fear-potentiated startle: lesion studies. J Neurosci., 19(1), 420-430.
Shimizu, T., Katahira, M., Sugawara, H., Inoue, K., & Miyata, A. (2004). Diverse effects
of intrathecal pituitary adenylate cyclase-activating polypeptide on nociceptive
transmission in mice spinal cord. Regulatory Peptides, 123(1-3), 117-122.
Simons, L. E., Moulton, E. A., Linnman, C., Carpino, E., Becerra, L., & Borsook, D.
(2014). The human amygdala and pain: Evidence from neuroimaging. Hum Brain
Mapp., 35(2), 527-538.
Sink, K. S., Chung, A., Ressler, K. J., Davis, M., & Walker, D. L. (2013). Anxiogenic
202

effects of CGRP within the BNST may be mediated by CRF acting at BNST
CRFR1 receptors. Behavioural Brain Research, 243, 286-293.
Sink, K. S., Walker, D. L., Yang, Y., & Davis, M. (2011). Calcitonin gene-related peptide
in the bed nucleus of the stria terminalis produces an anxiety-like pattern of
behavior and increases neural activation in anxiety-related structures. J Neurosci,
31(5), 1802-1810.
Sorkin, A., & von Zastrow, M. (2009). Endocytosis and signalling: intertwining
molecular networks. Nat Rev Mol Cell Biol, 10(9), 609-622.
Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P.H.,
Journot, L. (1993). Differential signal transduction by five splice variants of the
PACAP receptor. Nature, 365, 170-175.
Spike, R. C., Puskar, Z., Andrew, D., & Todd, A. J. (2003). A quantitative and
morphological study of projection neurons in lamina I of the rat lumbar spinal
cord. Eur J Neurosci, 18(9), 2433-2448.
Stroth, N., & Eiden, L. E. (2010). Stress hormone synthesis in mouse hypothalamus and
adrenal gland triggered by restraint is dependent on pituitary adenylate cyclaseactivating polypeptide signaling. Neuroscience, 165(4), 1025-1030.
Suwanprathes, P., Ngu, M., Ing, A., Hunt, G., & Seow, F. (2003). c-fos immunoreactivity
in the brain after esophageal acid stimulation. Am J Med, 115 Suppl 3A, 31S-38S.
Todd, A. J. (2010). Neuronal circuitry for pain processing in the dorsal horn. Nat Rev
Neurosci., 11(12), 823-836.
Tovote, P., Fadok, J. P., & Lüthi A. (2015). Neuronal circuits for fear and anxiety. Nat
Neurosci., 16, 317-331.
Tracey, I., & Mantyh, P. W. (2007). The cerebral signature for pain perception and its
modulation. Neuron, 55(3), 377-391.
Tran, L., Wiskur, B., Greenwood-Van Meerveld, B. (2012). The role of the anteriolateral bed nucleus of the stria terminalis in stress-induced nociception. Am. J.
Physiol. Gastrointest. Liver Physiol., 302, G1301-G1309.
Trepanier, C. H., Jackson, M. F., & MacDonald, J. F. (2012). Regulation of NMDA
receptors by the tyrosine kinase Fyn. FEBS J, 279(1), 12-19.

203

Tsukiyama, N., Saida, Y., Kakuda, M., Shintani, N., Hayata, A., Morita, Y., . . . Baba, A.
(2011). PACAP centrally mediates emotional stress-induced corticosterone
responses in mice. Stress (Amsterdam, Netherlands), 14(4), 368-375.
Turk, D. C. (2002). Clinical effectiveness and cost-effectiveness of treatments for
patients with chronic pain. Clin J Pain, 18(6), 355-365.
Uddin, M., Chang, S.C., Zhang, C., Ressler, K., Mercer, K.B., Galea, S., Keyes, K.M.,
McLaughlin, K.A., Wildman, D.E., Aiello, A.E., Koenen, K.C. (2013).
Adcyap1r1 genotype, posttraumatic stress disorder, and depression among women
exposed to childhood maltreatment. Depress Anxiety, 30, 251-258.
Ulrich-Lai, Y. M., Xie, W., Meij, J. T. A., Dolgas, C. M., Yu, L., & Herman, J. P. (2006).
Limbic and HPA axis function in an animal model of chronic neuropathic pain.
Physiol Behav., 88(1-2), 67-76.
Usoskin, D., Furlan, A., Islam, S., Abdo, H., Lonnerberg, P., Lou, D., . . . Ernfors, P.
(2015). Unbiased classification of sensory neuron types by large-scale single-cell
RNA sequencing. Nat Neurosci, 18(1), 145-153.
Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., . . .
Vaudry, H. (2009). Pituitary adenylate cyclase-activating polypeptide and its
receptors: 20 years after the discovery. Pharmacol Rev., 61(3), 283-357.
Veinante, P., Yalcin, I., Barrot, M. (2013). The amygdala between sensation and affect: a
role in pain. J. Mol. Psychiatry, 1, 9.
Vizzard, M. A. (2000). Up-regulation of pituitary adenylate cyclase-activating
polypeptide in urinary bladder pathways after chronic cystitis. J Comp Neurol,
420(3), 335-348.
Walker, D. L., Miles, L. A., & Davis, M. (2009). Selective participation of the bed
nucleus of the stria terminalis and CRF in sustained anxiety-like versus phasic
fear-like responses. Progress in Neuro-Psychopharmacology & Biological
Psychiatry, 33(8), 1291-1308.
Watabe, A. M., Ochiai, T., Nagase, M., Takahashi, Y., Sato, M., & Kato, F. (2013).
Synaptic potentiation in the nociceptive amygdala following fear learning in mice.
Mol Brain, 6, 11.
Xu, W., Lundeberg, T., Wang, Y.T., Li, Y., Yu, L.C. (2003). Antinociceptive effect of
calcitonin gene-related peptide in the central nucleus of amygdala: activating
opioid receptors through amygdala-periaqueductal gray pathway. Neuroscience,
118, 1015-1022.
204

Xu, X. J., & Wiesenfeld-Hallin, Z. (1996). Intrathecal pituitary adenylate cyclase
activating polypeptide facilitates the spinal nociceptive flexor reflex in the rat.
Neuroscience, 72(3), 801-804.
Yalcin, I., Barthas, F., & Barrot, M. (2014). Emotional consequences of neuropathic pain:
insight from preclinical studies. Neurosci Biobehav Rev., 47, 154-164.
Yamamoto, T., & Tatsuno, I. (1995). Antinociceptive effect of intrathecally administered
pituitary adenylate cyclase activating polypeptide (PACAP) on the rat formalin
test. Neurosci Lett., 184(1), 32-35.
Woolf, C. J., Shortland, P., & Coggeshall, R. E. (1992). Peripheral nerve injury triggers
central sprouting of myelinated afferents. Nature, 355(6355), 75-78.
Zeng, Q., Wang, S., Lim, G., Yang, L., Mao, J., Sung, B., . . . Mao, J. (2008).
Exacerbated mechanical allodynia in rats with depression-like behavior. Brain
Res, 1200, 27-38.
Zhang, Q., Shi, T.-J., Ji, R.-R., Zhang, Y.-t., Sundler, F., Hannibal, J., . . . Hökfelt, T.
(1995). Expression of pituitary adenylate cyclase-activating polypeptide in dorsal
root ganglia following axotomy: time course and coexistence. Brain Res., 705(12), 149-158.
Zhang, Y., Chen, Y., Liedtke, W., & Wang, F. (2015). Lack of evidence for ectopic
sprouting of genetically labeled Abeta touch afferents in inflammatory and
neuropathic trigeminal pain. Mol Pain, 11, 18.
Zhang, Y., Danielsen, N., Sundler, F., & Mulder, H. (1998). Pituitary adenylate cyclaseactivating peptide is upregulated in sensory neurons by inflammation.
Neuroreport, 9(12), 2833-2836.
Zhang, Y., Malmberg, A. B., Sjölund, B., & Yaksh, T. L. (1996). The effect of pituitary
adenylate cyclase activating peptide (PACAP) on the nociceptive formalin test.
Neurosci Lett, 207(3), 187-190.
Zhang, Y. Z., Hannibal, J., Zhao, Q., Moller, K., Danielsen, N., Fahrenkrug, J., &
Sundler, F. (1996). Pituitary adenylate cyclase activating peptide expression in the
rat dorsal root ganglia: up-regulation after peripheral nerve injury. Neuroscience,
74(4), 1099-1110.

205

Zhang, Y. Z., Sjolund, B., Moller, K., Hakanson, R., & Sundler, F. (1993). Pituitary
adenylate cyclase activating peptide produces a marked and long-lasting
depression of a C-fibre-evoked flexion reflex. Neuroscience, 57(3), 733-737.

206

